0001213900-15-005930.txt : 20150811 0001213900-15-005930.hdr.sgml : 20150811 20150811161103 ACCESSION NUMBER: 0001213900-15-005930 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20150630 FILED AS OF DATE: 20150811 DATE AS OF CHANGE: 20150811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OptimizeRx Corp CENTRAL INDEX KEY: 0001448431 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 261265381 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53605 FILM NUMBER: 151044025 BUSINESS ADDRESS: STREET 1: 400 WATER ST., STE. 200 CITY: ROCHESTER STATE: MI ZIP: 48307 BUSINESS PHONE: 248-651-6558 MAIL ADDRESS: STREET 1: 400 WATER ST., STE. 200 CITY: ROCHESTER STATE: MI ZIP: 48307 10-Q 1 f10q0615_optimizerx.htm QUARTERLY REPORT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

☒  Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the quarterly period ended June 30, 2015

 

☐  Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934

 

For the transition period from  __________ to __________

 

Commission File Number:  000-53605

 

OptimizeRx Corporation

(Exact name of registrant as specified in its charter)

 

Nevada   26-1265381
(State or other jurisdiction of
incorporation or organization)		   (IRS Employer
Identification No.)

 

400 Water Street, Suite 200

Rochester, MI, 48307

(Address of principal executive offices)

 

248-651-6568
(Registrant's telephone number)

 

 

 

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days ☒ Yes   ☐ No


Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒    No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.

 

☐ Large accelerated filer ☐ Accelerated filer
☐ Non-accelerated filer ☒ Smaller reporting company

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐    No ☒

 

State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 22,949,819 common shares as of August 11, 2015.

 

 

 

 
 

 

TABLE OF CONTENTS

 

    Page
     

PART I – FINANCIAL INFORMATION

 
Item 1: Financial Statements 1
Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations 2
Item 3: Quantitative and Qualitative Disclosures About Market Risk 6
Item 4: Controls and Procedures 6
     

PART II – OTHER INFORMATION

 
Item 1: Legal Proceedings 6
Item 1A: Risk Factors 7
Item 2: Unregistered Sales of Equity Securities and Use of Proceeds 7
Item 3: Defaults Upon Senior Securities 7
Item 4: Mine Safety Disclosure 7
Item 5: Other Information 7
Item 6: Exhibits 8

 

 
 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

Our consolidated financial statements included in this Form 10-Q are as follows:

 

F-1  Condensed consolidated Balance Sheets as of June 30, 2015 and December 31, 2014 (unaudited);
F-2 Condensed consolidated Statements of Operations for the three and six months ended June 30, 2015 and 2014 (unaudited);
F-3 Condensed consolidated Statements of Cash Flow for the six months ended June 30, 2015 and 2014 (unaudited);
F-4 Notes to condensed consolidated financial statements.

 

These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the SEC instructions to Form 10-Q. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the interim period ended June 30, 2015 are not necessarily indicative of the results that can be expected for the full year.

 

1
 

 

OPTIMIZERx CORPORATION

 CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

AS OF JUNE 30, 2015 AND DECEMBER 31, 2014

 

   June 30,
2015		   December 31,
2014		 
ASSETS        
Current Assets        
Cash and cash equivalents  $3,645,878   $3,446,973 
Accounts receivable   1,918,419    2,100,381 
Prepaid expenses   76,376    28,093 
Total Current Assets   5,640,673    5,575,447 
Property and equipment, net   10,674    12,813 
Other Assets          
Patent rights, net   901,491    930,854 
Web development costs, net   424,075    504,643 
Security deposit   5,049    5,049 
Total Other Assets   1,330,615    1,440,546 
TOTAL ASSETS  $6,981,962   $7,028,806 
           
LIABILITIES AND STOCKHOLDERS' EQUITY          
Current Liabilities          
Accounts payable - trade  $172,183   $200,372 
Accounts payable - related party   570,000    570,000 
Accrued expenses   9,851    25,459 
Revenue share payable   1,190,995    1,502,761 
Deferred revenue   336,213    120,130 
Total Liabilities   2,279,242    2,418,722 
Stockholders' Equity          
Common stock, $.001 par value, 500,000,000 shares authorized, 22,949,819 and 22,867,319 shares issued and outstanding, respectively   22,950    22,867 
Preferred stock, $.001 par value, 10,000,000 shares authorized, no shares issued and outstanding   -    - 
Stock warrants   2,153,295    2,153,295 
Additional paid-in-capital   27,806,253    27,595,609 
Stock payable   1,132,148    963,063 
Deferred stock compensation   (18,750)   - 
Accumulated deficit   (26,393,176)   (26,124,750)
Total Stockholders' Equity   4,702,720    4,610,084 
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY  $6,981,962   $7,028,806 

 

The accompanying notes are an integral part of these financial statements. 

 

F-1
 

 

OPTIMIZERx CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2015 AND 2014

 

   For the Three Months Ended   For the Six Months Ended 
   June 30   June 30 
   2015   Restated
2014		   2015   Restated
2014		 
                 
NET REVENUE   $1,705,457   $1,426,808   $3,193,010   $2,716,236 
                     
REVENUE SHARE EXPENSE   882,327    730,140    1,638,768    1,291,551 
                     
GROSS MARGIN   823,130    696,668    1,554,242    1,424,685 
                     
OPERATING EXPENSES   980,659    896,529    1,823,269    2,386,747 
                     
INCOME (LOSS) FROM OPERATIONS   (157,529)   (199,861)   (269,027)   (962,062)
                     
OTHER INCOME (EXPENSE)                    
Interest income   304    223    601    329 
                     
TOTAL OTHER INCOME (EXPENSE)   304    223    601    329 
                     
INCOME (LOSS) BEFORE PROVISION                    
FOR INCOME TAXES   (157,225)   (199,638)   (268,426)   (961,733)
                     
PROVISION FOR INCOME TAXES   -    -    -    - 
                     
NET INCOME (LOSS)   $(157,225)  $(199,638)  $(268,426)  $(961,733)
                     
WEIGHTED AVERGE NUMBER OF SHARES OUTSTANDING                    
BASIC   22,924,819    23,241,707    22,917,678    20,355,651 
DILUTED    N/A    N/A     N/A     N/A 
                     
NET INCOME (LOSS) PER SHARE                    
BASIC  $(0.01)  $(0.01)  $(0.01)  $(0.05)
DILUTED     N/A   $N/A     N/A     N/A 

 

The accompanying notes are an integral part of these financial statements.

 

F-2
 

 

OPTIMIZERx CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

FOR THE SIX MONTHS ENDED JUNE 30, 2015 AND 2014

 

   For the six months Ended
June 30		 
   2015   Restated
2014		 
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net loss for the period  $(268,426)  $(961,733)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:          
Depreciation and amortization   159,337    115,828 
Stock and options issued for services   361,062    627,354 
Changes in:          
Accounts receivable   181,962    302,202 
Prepaid expenses   (48,283)   (30,198)
Accounts payable   (28,189)   203,714 
Revenue share payable   (311,766)   (414,563)
Accrued expenses   (15,608)   (12,000)
Deferred revenue   216,083    19,651 
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES   246,172    (149,745)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchase of property and equipment   -    (1.592)
Patent rights   (4,517)   (92.624)
Website site development costs   (42,750)   (119,616)
NET CASH USED IN INVESTING ACTIVITIES   (47,267)   (213,832)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
        Issuance of common stock   -    10,000,000 
        Equity issuance costs   -    (1,204,968)
        Purchase of common and preferred stock and warrants   -    (6,000,000)
NET CASH PROVIDED BY FINANCING ACTIVITIES   -    2,795,032 
NET INCREASE IN CASH AND CASH EQUIVALENTS   198,905    2,431,455 
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD   3,446,973    1,118,243 
CASH AND CASH EQUIVALENTS - END OF PERIOD  $3,645,878   $3,549,698 
           
SUPPLEMENTAL CASH FLOW INFORMATION:          
Cash paid for interest  $-   $- 
Cash paid for income taxes  $-   $ - 

 

The accompanying notes are an integral part of these financial statements. 

 

F-3
 

 

OPTIMIZERx CORPORATION

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

JUNE 30, 2015

 

NOTE 1 – NATURE OF BUSINESS AND BASIS OF PRESENTATION

 

OptimizeRx Corporation is a technology solution company focused on the health care industry. Its objective is to bring better access to better care by leveraging its proprietary technology to provide on demand savings and support within physicians and patients web based platforms, including Electronic Health Records and Patient Portals. Initially defined as a marketing and advertising company through its consumer website, OptimizeRx.com, the Company has matured as a technology solutions provider through its direct to physician solution, SampleMD. SampleMD allows physicians to automatically display and distribute sample vouchers and/or co-pay coupons electronically within the ePrescription platform to pharmacies on behalf of their patients. The SampleMD solution is integrated into the ePrescribing or Electronic Medical Records applications, but can also sit on a prescriber’s desktop.

 

OptimizeRx solutions provide health care institutions with an alternative option to the traditional hassles and issues associated with storing and managing physical drug samples and pre-printed coupons and it provides better access and affordability to patients to improve affordability, adherence and outcomes. In turn, OptimizeRx provides pharmaceutical manufacturers with both direct to consumer and direct to physician channels for more efficiently communicating and promoting their products and savings.

 

The consolidated financial statements for the three and six month periods ended June 30, 2015 and 2014 have been prepared by us without audit pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of management, all adjustments necessary to present fairly our financial position, results of operations, and cash flows as of June 30, 2015 and 2014, and for the periods then ended, have been made. Those adjustments consist of normal and recurring adjustments. The consolidated balance sheet as of December 31, 2014, has been derived from the audited consolidated balance sheet as of that date.

 

Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014, as filed with the Securities and Exchange Commission.

 

The results of operations for the three and six month periods ended June 30, 2015, are not necessarily indicative of the results to be expected for the full year. Certain reclassifications have been made in the prior period’s consolidated financial statements to conform to the current period’s presentation.

 

NOTE 2 – STOCKHOLDERS EQUITY

 

In January 2015, we issued 12,500 shares of common stock to outside Directors in connection with our Director Compensation plan, which calls for issuance of 6,250 shares per quarter for each Director. Those shares were recorded as stock payable at December 31, 2014. In addition, we recorded an additional 12,500 shares, valued at $16,375 as stock payable at March 31, 2015 for shares to be issued in April 2015 and 12,500 shares, valued at $13,375 were issued in June 2015 for the second quarter payment.

 

In February 2015, we entered into a capital markets advisory agreement covering a one year period, which called for 90,000 shares of common stock to be issued as compensation. These shares were valued at $112,500 and are being amortized to expense over the period of service. 45,000 of these shares were issued in March 2015, with the balance to be issued in August 2015. The agreement was terminated in July 2015, effective in August, and the remaining 45,000 shares will not be issued. The total expense to be recognized will be $56,250 and is being amortized over the period the agreement is in effect.

 

F-4
 

 

OPTIMIZERx CORPORATION

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

JUNE 30, 2015

 

NOTE 2 – STOCKHOLDERS EQUITY (CONTINUED)

 

In March 2014, we entered into a securities purchase agreement, pursuant to which we sold 8,333,333 shares of our common stock for $1.20 per share, or gross proceeds of $10,000,000.

 

Placement agents in the offering received commissions equal to approximately 9.7% of gross proceeds, for an aggregate commission of approximately $970,000, including reimbursements for their reasonable out of pocket expenses. Placement agents also received warrants to purchase up to 804,139 shares of our common stock with an exercise price of $1.20 per share and a term of 5 years. The warrants were valued at $1,110,211, have been recorded as equity issuance costs, and were registered on a registration statement that went effective May 28, 2014. In addition to the warrants to placement agents, we also paid cash bonuses of $240,000 to three executive officers, agreed to issue 200,000 shares to three executive officers, and issued 150,000 shares to a consultant, in connection with the equity raise. The stock was valued based on the fair market value on the grant date, which was $630,000 in total. These amounts have been recorded as equity issuance costs, resulting in total equity issuance costs of $2.95 million. The 200,000 shares for the three executive officers have not been issued, but are recorded as stock payable and can be requested by the executive officers at any time.

 

We used the net proceeds of the offering to exercise the securities redemption option agreement, as amended, with Vicis Capital Master Fund that provided us with an option to purchase all of the outstanding shares and derivative securities held by Vicis for total payment of $6,000,000. The shares and derivative securities included the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Common Stock, and warrants to purchase shares of common stock held by Vicis in the Company. The balance of the net proceeds were used for working capital purposes.

 

In January 2014, an executive officer exercised 500,000 stock warrants using the cashless exercise feature included in the warrants. In exchange for the 500,000 warrants, 410,348 shares of common stock were issued.

 

In June 2015, we agreed to grant 197,605 fully vested shares of our common stock to two executive officers as bonuses. These shares have not been issued, but are recorded as stock payable and can be requested by the officers at any time.

 

In February 2014, we agreed to grant 337,500 shares of our common stock, half of which vested immediately and half of which vested in August 2014, to two executive officers as bonuses based on their efforts to recapitalize the company to secure approximately $3 million in working capital while reducing fully diluted shares by approximately 7 million shares. These shares have not been issued, but are recorded as stock payable and can be requested by the officers at any time.

 

F-5
 

 

OPTIMIZERx CORPORATION

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

JUNE 30, 2015

 

NOTE 3 – SHARE BASED PAYMENTS – OPTIONS

 

We use the fair value method to account for stock based compensation. We recorded $110,039 and $170,611 in compensation expense in the periods ended June 30, 2015 and 2014, respectively, related to options issued under our stock-based incentive compensation plan. This includes expense related to options issued in prior years for which the requisite service period for those options includes the current year, options granted in the current year and options repriced in the current year. The fair value of these instruments was calculated using the Black-Scholes option pricing model. Information related to the assumptions used in this model is set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014.

 

NOTE 4 – COMMITMENTS AND CONTINGENCIES

 

Litigation

 

The company is currently involved in the following legal proceedings.

 

In September 2014, we initiated litigation against Shadron Stastney, the Company’s previous CEO, in the U.S. District Court in the Eastern District of Michigan as a result of a dispute related to his separation agreement. Mr. Stastney alleged damages related to the non-registration of shares that he was granted as part of his separation agreement signed in September 2013. Under the terms of the contract we are not obligated to register the shares and we deny any obligation to do so. We have requested declarative relief from the court and also requested an injunction from the court preventing Mr. Stastney from continuing to pursue his claims. Mr. Stastney has filed a counterclaim requesting damages of $450,000 related to the nonregistration of his shares. The parties are currently in the discovery process.

 

In March 2015, we initiated litigation against LDM Group, LLC and PDR Network, LLC in the U.S. District Court in the Eastern District of Missouri related to the breach by LDM, and PDR as successor, of the settlement agreement signed February 28, 2014 related to previous litigation with LDM. LDM has failed to live up to its obligations under the settlement agreement including, but not limited to, not allowing us to distribute our eCoupon programs in the LDM network, not allowing us to distribute the LDM patient education programs, and not providing other information required under the settlement agreement. We are seeking enforcement of the settlement agreement and we are seeking damages in an amount at least equal to the amounts paid to date to LDM under the settlement agreement, which approximates $1.0 million, as well as damages for lost income and business value as a result of LDM’s breach of the agreement.

 

In March 2015, we also initiated litigation against PDR Network, LLC in the U.S. District Court in the District of New Jersey as a result of PDR’s breach of the Master Services Agreement between the parties requiring PDR to exclusively use our eCoupon solution. We assert that PDR’s acquisition of LDM and the use of the LDM network to distribute coupons by PDR violates the agreement between the parties and we are seeking damages in an amount at least equal the amounts paid to date by us to LDM under the settlement agreement, which approximates $1.0 million, as well as damages for lost income and business value as a result of PDR’s actions.

 

In May 2015, we filed an amended complaint in the Missouri case to consolidate the two cases and withdrew the case against PDR Networks in the U.S. District Court in the District of New Jersey, without prejudice.

 

In July, 2015, the U.S. District Court for the Eastern District of Missouri dismissed the case, citing lack of Federal jurisdiction in the matter. We are in the process of refiling the consolidated case against PDR Network and LDM group in State court in Missouri.

 

F-6
 

  

OPTIMIZERx CORPORATION

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

JUNE 30, 2015

  

 

NOTE 5 – RESTATEMENT

 

We restated our financial statements to correct the way we accounted for certain items related to stock based compensation, revenue share expense, and revenue recognition. The full impact of the restatement was reflected in the December 31, 2014 financial statements at the end of the year. The table below reflects the impact on the 2014 period reflected in this report.

 

The restated Consolidated Statement of Operations and Consolidated Statement of Cash Flows for the three and six months ended June 30, 2014, as applicable, is as follows:

 

Three months ended June 30, 2014      Previously 
Financial Statement  Line Item  Corrected   Stated 
Income statement  Revenue   1,426,808    1,454,214 
Income statement  Cost of Sales  $730,140   $540,048 
Income statement  Operating expenses   896,529    967,070 
Income statement  Loss from operations  $(199,861)  $(52,904)
Income statement  Loss before income taxes  $(199,638)  $(52,681)
Income statement  Net loss  $(199,638)  $(52,681)

  

Six months ended June 30, 2014      Previously  
Financial Statement  Line Item  Corrected   Stated 
Income statement  Revenue   2,716,236    2,771,560 
Income statement  Cost of Sales  $1,291,551   $1,038,858 
Income statement  Operating expenses   2,386,747    2,439,028 
Income statement  Loss from operations  $(962,062)  $(706,326)
Income statement  Loss before income taxes  $(961,733)  $(705,996)
Income statement  Net loss  $(961,733)  $(705,996)
Statement of cash flows  Net loss  $(961,733)  $(705,996)
Statement of cash flows  Stock and options issued for services  $627,344   $654,634 
Statement of cash flows  Increase in accounts payable  $203,714   $173,889 
Statement of cash flows  Decrease in revenue share payable  $(311,776)  $(686,760)
Statement of cash flows  Increase in deferred revenue  $19,651   $38,656 

  

F-7
 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Forward-Looking Statements

 

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.   These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions.  We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions.  Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain.  Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.  We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

 

Overview

 

Company Highlights through August, 2015

 

1)Our sales for the first six months of 2015 approached $3.2 million, an 18% increase over the same period in 2014.
2)Our sales for the second quarter of 2015 exceeded $1.7 million, an increase of 20% over the same period in 2014 and a 15% increase over the first quarter of 2015.
3)We generated positive cash flow from operations of approximately $250,000 during the six month period of 2015.
4)Our cash balance increased to in excess of $3.6 million.
5)Our balance sheet continued to improve with working capital of approximately $3.4 million and a working capital ratio of 2.5 to 1.
6)Excluding non-cash expenses, the first six months of 2015 generated operating income of $251,372.
7)We initially launched our SampleMD e-coupon solution in April 2015 within Practice Fusion’s EMR and we are now fully integrated. We also began running key campaigns through NextGen in August 2015. Additionally, we have actively engaged and advanced with other leading platforms to position and prioritize integration of services.
8)We signed an agreement with Allscripts to integrate our eCoupon functionality into their Touchworks platform, which serves many large health systems throughout the country, and to become their exclusive eCoupon provider in all of their platforms.
9)We sponsored the ePrescribe/EHR conference held in Philadelphia in March 2015, which generated significant leads for our sales force.
10)We continued to add new brands in 2015 at both existing customers such as AstraZenica and Lilly, as well as at new customers such as Otsuka and Shionogi. AstraZeneca extended their contract and budget for two years to promote 15 of their leading brands.
11)We continued to prove an outstanding return on investment on our pharmaceutical promotions through independent analytics firms.
12)We have made substantial progress toward completing major technical upgrades, including migration to a new Oracle database to allow for very robust growth and performance.

 

2
 

 

The company continues to make significant progress on growing both sides of our business, including expanding new brands and agreements with pharmaceutical companies looking for new ways to promote and reach doctors and patients at point of prescribe; as well as our networks with the dramatic announcement of Allscripts agreeing to exclusively work with OptimizeRx to manage their patient savings within all platforms that will soon include their largest platform Touchworks.

 

With the addition of Allscripts, we now are the EXCLUSIVE delivery platform of over 200 other EHRs—which represent two thirds of our network.

 

Simply put, OptimizeRx has now created the largest promotional network that engages more healthcare providers at point of prescribe than any other company, including promotion of our programs within over 350 leading EHRs and growing. This also provides a huge barrier to entry to any potential competitors.

 

All of these advancements will have meaningful consequences to further accelerate our growth in the second half of year and into 2016.

 

However, to further leverage this huge market opportunity of bringing savings and patient support right into physicians workflow, we are seeking top notch sales executives on both sides to help us:

 

Expand pharma sales account executives, just hired one who has strong specialty products knowledge and

10+ years of pharma experience. Initiating search for Regional VP of Sales

 

On the business development side of our channels, we will also be searching for additional support to grow our network, including a new operational manager to interact daily with key clients and assess performance, as well as an additional key business development executiveto work with the team.

 

We also will be expanding our Investor and Public Relations efforts in the 3rd quarter, including attendance at the Liolios Group's 2015 Gateway Conference in San Francisco, as well as hiring a Public Relations firm.

 

For our Board of Directors, we are interviewing proven seasoned executives to further add outside guidance and leadership, as well as additional governance.

 

We are also involved in many strategic partnership discussions with some of the largest healthcare companies in the world to look at new opportunities to leverage our proprietary technology and grow our business.
 

We generated positive cash flow from operations for the six months ended June 30, 2015, and we expect to continue to do so each quarter for the rest of the year. We expect to achieve profitability in future quarters based on the expected escalation of revenues, unless we make positive decisions to invest in development activities to expand our network reach or commit additional marketing resources to customer procurement activities. The outlay of these funds may negatively affect our profitability in the short term, but we are confident the investment will escalate our revenues in the long term and put us in a better position to attain and increase profitability.

 

We also generated positive income from operations, when excluding non-cash expenses, as set forth in the table below.

  

   Six Months Ended June 30 
   2015   2014 
         
Net Revenue  $3,193,010   $2,716,236 
Revenue Share Expense   1,638,768    1,291,551 
           
Gross Margin   1,554,242    1,424,685 
           
Total Operating Expenses   1,823,269    2,386,747 
Less Noncash operating expenses   520,399    743,182 
           
Cash operating Expenses   1,302,870    1,643,565 
           
Income (loss) from Operations excluding noncash expenses  $251,372   $(218,880)

 

Our success in acquiring, integrating and expanding into new promotional EHR/eRx platforms continues to grow as well. We launched our initial brands into Practice Fusion on a limited basis in April 2015 and we fully integrated the rollout at end of June 2015. We are also working extensively with our existing platforms to expand the reach of our eCoupon product to all of their providers, as well as increasing the utilization of the eCoupon functionality by their existing users.

 

With the growth of both our pharmaceutical products and our distribution network, we expect that our distribution of e-coupons will continue to increase throughout the year and over the levels of last year.

 

Operating Results

 

We finished the first six months of 2015 with a loss of approximately $268,000 a substantial reduction over the same period last year, and we generated positive cash flow from operations during 2015.

 

 

3
 

 

Results of Operations for the Three and Six Months Ended June 30, 2015 and 2014

 

Revenues

 

Our total revenue for the three months ended June 30, 2015 was approximately $1.7 million, an increase of 20% over the approximately $1.425 million from the same period in 2014. Our total revenue for the six months ended June 30, 2015 was approximately $3.2 million, an increase of 18% over the approximately $2.7 million from the same period in 2014. These increased revenues result from both increased pharmaceutical brands being promoted and expanded distribution channels. We expect continued quarter over quarter revenue increases for the balance of 2015.

 

Cost of Sales

 

Our cost of sales, comprised of revenue share expense, increased over the same period in 2014 as a result of both the revenue increases and the LDM settlement signed in February 2014. In addition, revenue share expense as a percentage of revenue in 2015 increased over the same period in 2014 as a result of the LDM settlement. In the three month period, revenue share expense increased slightly to approximately 51.7% of sales in 2015 from approximately 51.1% in the same period in 2014 as a result of product mix. In the six month period, revenue share expense increased to approximately 51.3% of sales in 2015 from approximately 47.5% in the same period in 2014 as a result of the LDM settlement.

 

As discussed, these increases in revenue share expense as a percentage of revenue result from a combination of factors, including product mix whereby a larger percentage of overall revenues are subject to revenue share, the LDM agreement which resulted in increased revenue share payments, and increased distributions at channel partners with financial incentives to increase distributions that result in higher payments per distribution. We expect revenue share expense as a percentage of revenue in future quarters to continue at levels similar to that of the quarter ended June 30, 2015 as revenues subject to revenue share expense continues to increase as a percentage of our overall revenues.

 

Operating Expenses

 

Operating expenses increased from approximately $900,000 for the three month period ended June 30, 2014 to approximately $980,000 for the same period in 2015, an increase of approximately 9%. Operating expenses decreased from approximately $2.4 million for the six month period ended June 30, 2014 to approximately $1.8 for the same period in 2015, a decrease of approximately 24%. The detail by major category is reflected in the table below.

 

   Three Months Ended
June 30,		   Six Months Ended
June 30,		 
   2015   2014   2015   2014 
                 
Salaries, Wages, & Benefits  $387,074   $374,180   $782,273   $723,276 
Professional Fees   81,405    119,403    154,825    180,020 
Board Compensation   12,500    -    25,000    - 
Investor Relations   6,991    20,809    32,953    52,745 
Consultants   8,698    16,905    29,813    32,719 
Advertising and Promotion   -    20,951    37,150    50,551 
Depreciation and Amortization   79,668    56,922    159,337    115,828 
Development and Maintenance   56,445    36,023    106,860    68,157 
Office, Facility, and other   32,233    32,884    71,290    66,360 
Travel   34,174    30,937    62,706    69,737 
                     
Subtotal   699,188    709,014    1,462,207    1,359,393 
                     
Stock-based compensation   281,471    187,515    361,062    627,354 
Lawsuit settlement   -    -    -    400,000 
                     
Total Operating Expense  $980,659   $896,529   $1,823,269   $2,386,747 
                     

The main reasons for the decrease in operating expenses in 2015 are the lawsuit settlement in 2014, which resulted in a $400,000 payment to the plaintiff, and the reduction in stock-based compensation from 2014 to 2015. Ignoring those two items, operating expenses increased approximately 8%, however the majority of those increases related to things implemented after the first quarter of 2014, as opposed to new items in 2015. This would include new hires, as well as the addition of outside Directors and related compensation.

We expect our operating expenses to continue to increase slightly as we further implement our business plan and expand our operations, however, we do not expect those increases to be significant in the near future unless we make the proactive decision to increase marketing dollars spent on customer procurement activities or spend more on development activities to increase our overall reach. We expect development expenditures to increase significantly in the fourth quarter based on planned initiatives. Professional fees are significantly affected by litigation, and we do have litigation in progress, causing those fees to fluctuate from quarter to quarter.

 

4
 

 

Net Loss

 

Our net loss for the three months ended June 30, 2015 was approximately $157,000 as compared to a loss of approximately $200,000 during the same period in 2014. Our net loss for the six months ended June 30, 2015 was approximately $268,000 as compared to a loss of approximately $962,000 during the same period in 2014. The reasons for specific components are discussed above. Overall, the decreased loss for the six month period is primarily explained by the decrease in operating expenses.

 

Liquidity and Capital Resources

 

As of June 30, 2015, we had total current assets of approximately $5.6 million, compared with current liabilities of approximately $2.3 million, resulting in working capital of approximately $3.4 million and a current ratio of approximately 2.5 to 1, similar to, but improved over, the working capital of approximately $3.2 million and current ratio of 2.3 to 1 at December 31, 2014. We are currently generating positive cash flow from operations and we expect our working capital balance to continue to improve in future quarters as we continue to generate positive cash flow from operations.

 

Our operating activities generated approximately $250,000 in cash flow during the six months ended June 30, 2015, compared with cash used in operating activities of approximately $150,000 in the same period in 2014. This increase is primarily the result of the reduced loss for the period.

 

We used approximately $50,000 in investing activities in the six months ended June 30, 2015 compared with approximately $215,000 in the same period in 2014. These investment activities relate to improvements being implemented in our SampleMD website, as well as protection and expansion of our patent portfolio. These items both represent important components of our business strategy moving forward.

 

There were no cash flows from financing activities in 2015, however financing activities provided approximately $2.8 million during the six months ended June 30, 2014. This resulted from a $10 million equity raise in March 2014, partially offset by costs of the raise and redemption of all the common stock, preferred stock, and warrants held by a major shareholder that significantly reduced the fully diluted shares count, even when considering the new equity issued. With the financing and cash on hand, we have sufficient cash to operate our business for more than the next twelve months and we do not anticipate the need to raise additional equity for operating purposes, however we may consider a strategic investments that would allow us to accelerate the growth of the business.

 

Off Balance Sheet Arrangements

 

As of June 30, 2015, there were no off balance sheet arrangements.

 

Critical Accounting Policies

 

In December 2001, the SEC requested that all registrants list their most “critical accounting polices” in the Management Discussion and Analysis. The SEC indicated that a “critical accounting policy” is one which is both important to the portrayal of a company’s financial condition and results, and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Our accounting policies are discussed in the footnotes to our financial statements included in our annual report on Form 10-K for the year ended December 31, 2014, however we consider our critical accounting policies to be those related to revenue recognition, revenue share expense, stock-based compensation, capitalization and related amortization of intangible assets, and impairment of assets.

 

Recently Issued Accounting Pronouncements

 

The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operation, financial position or cash flow.

 

5
 

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

A smaller reporting company is not required to provide the information required by this Item.

 

Item 4. Controls and Procedures

 

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of June 30, 2015. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of June 30, 2015, our disclosure controls and procedures are not completely effective due to the presence of material weaknesses in internal control over financial reporting.

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified the following material weaknesses which have caused management to conclude that, as of June 30, 2015, our disclosure controls and procedures were not effective: (i) inadequate segregation of duties; and (ii) inadequate information technology reporting systems to insure that accurate financial information is provided for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

 

Remediation Plan to Address the Material Weaknesses in Internal Control over Financial Reporting

 

As discussed in our Annual Report on Form 10-K we have taken steps to enhance and improve the design of our internal controls over financial reporting. We will continue to establish procedures to mitigate the segregation of duties issues, but it is not possible to completely remediate the issue without hiring additional personnel. We are continuing to upgrade our technical systems to increase the reliability of information provided.

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings

 

Aside from the following, we are not a party to any material pending legal proceeding. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.

 

In September 2014, we initiated litigation against Shadron Stastney, the Company’s previous CEO, in the U.S. District Court in the Eastern District of Michigan as a result of a dispute related to his separation agreement. Mr. Stastney alleged damages related to the non-registration of shares that he was granted as part of his separation agreement signed in September 2013. Under the terms of the contract we are not obligated to register the shares and we deny any obligation to do so. We have requested declarative relief from the court and also requested an injunction from the court preventing Mr. Stastney from continuing to pursue his claims. Mr. Stastney has filed a counterclaim requesting damages of $450,000 related to the nonregistration of his shares. The parties are currently in the discovery process.

 

In March 2015, we initiated litigation against LDM Group, LLC and PDR Network, LLC in the U.S. District Court in the Eastern District of Missouri related to the breach by LDM, and PDR as successor, of the settlement agreement signed February 28, 2014 related to previous litigation with LDM. LDM has failed to live up to its obligations under the settlement agreement including, but not limited to, not allowing us to distribute our eCoupon programs in the LDM network, not allowing us to distribute the LDM patient education programs, and not providing other information required under the settlement agreement. We are seeking enforcement of the settlement agreement and we are seeking damages in an amount at least equal to the amounts paid to date to LDM under the settlement agreement, which approximates $1.0 million, as well as damages for lost income and business value as a result of LDM’s breach of the agreement.

 

6
 

 

In March 2015, we also initiated litigation against PDR Network, LLC in the U.S. District Court in the District of New Jersey as a result of PDR’s breach of the Master Services Agreement between the parties requiring PDR to exclusively use our eCoupon solution. We assert that PDR’s acquisition of LDM and the use of the LDM network to distribute coupons by PDR violates the agreement between the parties and we are seeking damages in an amount at least equal the amounts paid to date by us to LDM under the settlement agreement, which approximates $1.0 million, as well as damages for lost income and business value as a result of PDR’s actions.

 

In May 2015, we filed an amended complaint in the Missouri case to consolidate the two cases and withdrew the case against PDR Networks in the U.S. District Court in the District of New Jersey, without prejudice.

 

In July, 2015, the U.S. District Court for the Eastern District of Missouri dismissed the case, citing lack of Federal jurisdiction in the matter. We are in the process of refiling the consolidated case against PDR Network and LDM group in State court in Missouri.

  

Item 1A: Risk Factors

 

See risk factors included in the Company’s Annual Report on form 10-K for 2014.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None

 

Item 3. Defaults upon Senior Securities

 

None

 

Item 4. Mine Safety Disclosure

 

N/A

 

Item 5. Other Information

 

None 

 

7
 

  

Item 6. Exhibits

 

Exhibit Number   Description of Exhibit
31.1   Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2   Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1   Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101**   The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015 formatted in Extensible Business Reporting Language (XBRL).

 

**Provided herewith

 

8
 

 

SIGNATURES

 

In accordance with the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  

  OptimizeRx Corporation  
       
Date: August 11, 2015  
     
By: /s/ David Harrell  
    David Harrell  
 

Title:

 Chief Executive Officer, Principal Executive Officer, and Director  

 

 

  OptimizeRx Corporation  
       
Date: August 11, 2015  
       
By: /s/ Douglas P. Baker  
    Douglas P. Baker  
 

Title:

 Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer  

 

 

 

 

9

 

 

 

 EX-31.1 2 f10q0615ex31i_optimizerx.htm CERTIFICATION

Exhibit 31.1

 

CERTIFICATIONS

 

I, David Harrell, certify that;

 

1.   I have reviewed this quarterly report on Form 10-Q for the quarter ended June 30, 2015 of OptimizeRx Corp (the “registrant”);

 

2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.   Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.   The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.   Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.   Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.   Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.   Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.   The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a.   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b.   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 11, 2015

 

/s/ David Harrell  
By:    David Harrell  
Title: Chief Executive Officer  

 

 EX-31.2 3 f10q0615ex31ii_optimizerx.htm CERTIFICATIONS

Exhibit 31.2

 

CERTIFICATIONS

 

I, Douglas Baker, certify that;

 

1.   I have reviewed this quarterly report on Form 10-Q for the quarter ended June 30, 2015 of OptimizeRx Corp (the “registrant”);

 

2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.   Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.   The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.   Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.   Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.   Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.   Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.   The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a.   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b.   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 11, 2015

 

/s/ Douglas Baker  
By:    Douglas Baker  
Title: Chief Financial Officer  

 

 EX-32.1 4 f10q0615ex32i_optimizerx.htm CERTIFICATION

Exhibit 32.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND

CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the quarterly Report of OptimizeRx Corp (the “Company”) on Form 10-Q for the quarter ended June 30, 2015 filed with the Securities and Exchange Commission (the “Report”), I, David Harrell, Chief Executive Officer and I, Douglas Baker, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1.The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

 

2.The information contained in the Report fairly presents, in all material respects, the consolidated financial condition of the Company as of the dates presented and the consolidated result of operations of the Company for the periods presented.

 

By: /s/ David Harrell  
Name: David Harrell  
Title: Principal Executive Officer, and Director  
Date: August 11, 2015  
     
By: /s/ Douglas Baker  
Name: Douglas Baker  
Title: Principal Financial Officer  
Date: August 11, 2015  

 

This certification has been furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 EX-101.INS 5 oprx-20150630.xml XBRL INSTANCE FILE 0001448431 2013-12-31 0001448431 us-gaap:OfficerMember 2014-01-31 0001448431 us-gaap:OfficerMember 2014-01-01 2014-01-31 0001448431 2014-02-28 0001448431 2014-02-01 2014-02-28 0001448431 oprx:SecuritiesPurchaseAgreementMember 2014-03-31 0001448431 oprx:PlacementAgentsMember 2014-03-31 0001448431 oprx:ThreeOfficerMember 2014-03-31 0001448431 oprx:ConsultantMember 2014-03-31 0001448431 oprx:SecuritiesPurchaseAgreementMember 2014-03-01 2014-03-31 0001448431 oprx:PlacementAgentsMember 2014-03-01 2014-03-31 0001448431 2014-04-01 2014-06-30 0001448431 us-gaap:ScenarioPreviouslyReportedMember 2014-04-01 2014-06-30 0001448431 2014-01-01 2014-06-30 0001448431 us-gaap:ScenarioPreviouslyReportedMember 2014-01-01 2014-06-30 0001448431 2014-09-30 0001448431 2014-12-31 0001448431 us-gaap:DirectorMember 2015-01-31 0001448431 us-gaap:DirectorMember 2015-01-01 2015-01-31 0001448431 us-gaap:CapitalSupportAgreementMember 2015-02-01 2015-02-28 0001448431 us-gaap:CapitalSupportAgreementMember 2015-03-31 0001448431 2015-04-01 2015-06-30 0001448431 us-gaap:DirectorMember 2015-04-01 2015-06-30 0001448431 2015-01-01 2015-06-30 0001448431 us-gaap:DirectorMember 2015-01-01 2015-06-30 0001448431 oprx:TwoOfficersMember 2015-01-01 2015-06-30 0001448431 2015-06-30 0001448431 oprx:VicisMember 2015-06-30 0001448431 us-gaap:SubsequentEventMember us-gaap:CapitalSupportAgreementMember 2015-07-01 2015-07-31 0001448431 2015-08-11 0001448431 2014-06-30 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure OptimizeRx Corp 0001448431 false --12-31 10-Q 2015-06-30 2015 Q2 Smaller Reporting Company 22949819 1118243 3446973 3645878 3549698 2100381 1918419 28093 76376 5575447 5640673 12813 10674 930854 901491 504643 424075 5049 5049 1440546 1330615 7028806 6981962 200372 172183 570000 570000 25459 9851 1502761 1190995 120130 336213 2418722 2279242 22867 22950 2153295 2153295 27595609 27806253 963063 1132148 18750 -26124750 -26393176 4610084 4702720 7028806 6981962 0.001 0.001 500000000 500000000 22867319 22949819 22867319 22949819 0.001 0.001 10000000 10000000 1426808 1454214 2716236 2771560 1705457 3193010 730140 540048 1291551 1038858 756440 696668 1424685 823130 1554242 896529 967070 2386747 2439028 980659 1823269 -199861 -52904 -962062 -706326 -157529 -269027 223 329 304 601 223 329 304 601 -199638 -52681 -961733 -705996 -157225 -268426 -199638 -52681 -961733 -705996 -157225 -268426 115828 159337 627354 654634 361062 -302202 -181962 30198 48283 203714 173889 -28189 414563 -686760 311766 -12000 -15608 19651 38656 216083 -149745 246172 92624 4517 119616 42750 -213832 -47267 10000000 1204968 -6000000 2795032 2431455 198905 <div> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">NOTE 1 &#8211; NATURE OF BUSINESS AND BASIS OF PRESENTATION</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">OptimizeRx Corporation is a technology solution company focused on the health care industry. Its objective is to bring better access to better care by leveraging its proprietary technology to provide on demand savings and support within physicians and patients web based platforms, including Electronic Health Records and Patient Portals. Initially defined as a marketing and advertising company through its consumer website, OptimizeRx.com, the Company has matured as a technology solutions provider through its direct to physician solution, SampleMD. SampleMD allows physicians to automatically display and distribute sample vouchers and/or co-pay coupons electronically within the ePrescription platform to pharmacies on behalf of their patients. The SampleMD solution is integrated into the ePrescribing or Electronic Medical Records applications, but can also sit on a prescriber&#8217;s desktop.</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">OptimizeRx solutions provide health care institutions with an alternative option to the traditional hassles and issues associated with storing and managing physical drug samples and pre-printed coupons and it provides better access and affordability to patients to improve affordability, adherence and outcomes. In turn, OptimizeRx provides pharmaceutical manufacturers with both direct to consumer and direct to physician channels for more efficiently communicating and promoting their products and savings.</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The consolidated financial statements for the three and six month periods ended June 30, 2015 and 2014 have been prepared by us without audit pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of management, all adjustments necessary to present fairly our financial position, results of operations, and cash flows as of June 30, 2015 and 2014, and for the periods then ended, have been made. Those adjustments consist of normal and recurring adjustments. The consolidated balance sheet as of December 31, 2014, has been derived from the audited consolidated balance sheet as of that date.</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014, as filed with the U.S. Securities and Exchange Commission.</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The results of operations for the three and six month periods ended June 30, 2015, are not necessarily indicative of the results to be expected for the full year. Certain reclassifications have been made in the prior period&#8217;s consolidated financial statements to conform to the current period&#8217;s presentation.</p> </div> <div> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="letter-spacing: -0.1pt;">NOTE 2 &#8211; STOCKHOLDERS EQUITY</font></p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="letter-spacing: -0.1pt;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="letter-spacing: -0.1pt;">In January 2015, we issued 12,500 shares of common stock to outside Directors in connection with our Director Compensation plan, which calls for issuance of 6,250 shares per quarter for each Director. Those shares were recorded as stock payable at December 31, 2014. In addition, we recorded an additional 12,500 shares, valued at $16,375 as stock payable at March 31, 2015 for shares to be issued in April 2015 and 12,500 shares, valued at $13,375 were issued in June 2015 for the second quarter payment.</font></p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="letter-spacing: -0.1pt;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="letter-spacing: -0.1pt;">In February 2015, we entered into a capital markets advisory agreement covering a one year period, which called for 90,000 shares of common stock to be issued as compensation. These shares were valued at $112,500 and are being amortized to expense over the period of service. 45,000 of these shares were issued in March 2015, with the balance to be issued in August 2015. The agreement was terminated in July 2015, effective in August, and the remaining 45,000 shares will not be issued. The total expense to be recognized will be $56,250 and is being amortized over the period the agreement is in effect.</font></p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="letter-spacing: -0.1pt;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In&#160;March 2014,&#160;we&#160;entered into a securities purchase agreement, pursuant to which&#160;we&#160;sold 8,333,333 shares of&#160;our common stock for $1.20 per share, or gross proceeds of $10,000,000.</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Placement agents in the offering received commissions equal to approximately 9.7% of gross proceeds, for an aggregate commission of approximately $970,000, including reimbursements for their reasonable out of pocket expenses. Placement agents also received warrants to purchase up to 804,139 shares of&#160;our common stock with an exercise price of $1.20 per share and a term of 5 years. The warrants were valued at $1,110,211, have been recorded as equity issuance costs, and were registered on a registration statement that went effective May 28, 2014. In addition to the warrants to placement agents, we also paid cash bonuses of $240,000 to three executive officers, agreed to issue 200,000 shares to three executive officers, and issued 150,000 shares to a consultant, in connection with the equity raise. The stock was valued based on the fair market value on the grant date, which was $630,000 in total. These amounts have been recorded as equity issuance costs, resulting in total equity issuance costs of $2.95 million. The 200,000 shares for the three executive officers have not been issued, but are recorded as stock payable and can be requested by the executive officers at any time.</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">We&#160;used the net proceeds of the offering to exercise the securities redemption option agreement, as amended, with Vicis Capital Master Fund that provided&#160;us&#160;with an option to purchase all of the outstanding shares and derivative securities held by Vicis for total payment of $6,000,000. The shares and derivative securities included the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Common Stock, and warrants to purchase shares of common stock held by Vicis in the Company. The balance of the net proceeds were used for working capital purposes.</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In January 2014, an executive officer exercised 500,000 stock warrants using the cashless exercise feature included in the warrants. In exchange for the 500,000 warrants, 410,348 shares of common stock were issued.</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In June 2015, we agreed to grant 197,605 fully vested shares of our common stock to two executive officers as bonuses. These shares have not been issued, but are recorded as stock payable and can be requested by the officers at any time.</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In February 2014, we agreed to grant 337,500 shares of our common stock, half of which vested immediately and half of which vested in August 2014, to two executive officers as bonuses based on their efforts to recapitalize the company to secure approximately $3 million in working capital while reducing fully diluted shares by approximately 7 million shares. These shares have not been issued, but are recorded as stock payable and can be requested by the officers at any time.</p> </div> <div> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="letter-spacing: -0.1pt;">NOTE 3 &#8211; SHARE BASED PAYMENTS &#8211; OPTIONS</font></p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="letter-spacing: -0.1pt;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">We use the fair value method to account for stock based compensation. We recorded $110,039 and $170,611 in compensation expense in the periods ended June 30, 2015 and 2014, respectively, related to options issued under our stock-based incentive compensation plan. This includes expense related to options issued in prior years for which the requisite service period for those options includes the current year, options granted in the current year and options repriced in the current year. The fair value of these instruments was calculated using the Black-Scholes option pricing model. Information related to the assumptions used in this model is set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014.</p> </div> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="letter-spacing: -0.1pt;">NOTE 4 &#8211; COMMITMENTS AND CONTINGENCIES</font></p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="letter-spacing: -0.1pt;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="letter-spacing: -0.1pt;"><i>Litigation</i></font></p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="letter-spacing: -0.1pt;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The company is currently involved in the following legal proceedings.</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In September 2014, we initiated litigation against Shadron Stastney, the Company&#8217;s previous CEO, in the U.S. District Court in the Eastern District of Michigan as a result of a dispute related to his separation agreement. Mr. Stastney alleged damages related to the non-registration of shares that he was granted as part of his separation agreement signed in September 2013. Under the terms of the contract we are not obligated to register the shares and we deny any obligation to do so. We have requested declarative relief from the court and also requested an injunction from the court preventing Mr. Stastney from continuing to pursue his claims. Mr. Stastney has filed a counterclaim requesting damages of $450,000 related to the nonregistration of his shares. The parties are currently in the discovery process.</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In March 2015, we initiated litigation against LDM Group, LLC and PDR Network, LLC in the U.S. District Court in the Eastern District of Missouri related to the breach by LDM, and PDR as successor, of the settlement agreement signed February 28, 2014 related to previous litigation with LDM. LDM has failed to live up to its obligations under the settlement agreement including, but not limited to, not allowing us to distribute our eCoupon programs in the LDM network, not allowing us to distribute the LDM patient education programs, and not providing other information required under the settlement agreement. We are seeking enforcement of the settlement agreement and we are seeking damages in an amount at least equal to the amounts paid to date to LDM under the settlement agreement, which approximates $1.0 million, as well as damages for lost income and business value as a result of LDM&#8217;s breach of the agreement.</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In March 2015, we also initiated litigation against PDR Network, LLC in the U.S. District Court in the District of New Jersey as a result of PDR&#8217;s breach of the Master Services Agreement between the parties requiring PDR to exclusively use our eCoupon solution. We assert that PDR&#8217;s acquisition of LDM and the use of the LDM network to distribute coupons by PDR violates the agreement between the parties and we are seeking damages in an amount at least equal the amounts paid to date by us to LDM under the settlement agreement, which approximates $1.0 million, as well as damages for lost income and business value as a result of PDR&#8217;s actions.</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In May 2015, we filed an amended complaint in the Missouri case to consolidate the two cases and withdrew the case against PDR Networks in the U.S. District Court in the District of New Jersey, without prejudice.</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="color: black;">In July, 2015, the U.S. District Court for the Eastern District of Missouri dismissed the case, citing lack of Federal jurisdiction in the matter. We are in the process of refiling the consolidated case against PDR Network and LDM group in State court in Missouri.</font></p> <div> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="letter-spacing: -0.1pt;">NOTE 5 &#8211; RESTATEMENT</font></p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">We restated our financial statements to correct the way we accounted for certain items related to stock based compensation, revenue share expense, and revenue recognition. The full impact of the restatement was reflected in the December 31, 2014 financial statements at the end of the year. The table below reflects the impact on the 2014 period reflected in this report.</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The restated Consolidated Statement of Operations and Consolidated Statement of Cash Flows for the three and six months ended June&#160;30, 2014, as applicable, is as follows:</p> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="padding: 0pt; text-align: center; text-indent: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3">Three months ended June 30, 2014</td> <td style="padding: 0pt; text-align: center; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: center; text-indent: 0pt;" colspan="2">&#160;</td> <td style="padding: 0pt; text-align: center; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: center; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: center; text-indent: 0pt;" colspan="2">Previously</td> <td style="padding: 0pt; text-align: center; text-indent: 0pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="padding: 0pt; text-align: center; text-indent: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Financial Statement</td> <td style="padding: 0pt; text-align: center; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: center; text-indent: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Line Item</td> <td style="padding: 0pt; text-align: center; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: center; text-indent: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Corrected</td> <td style="padding: 0pt; text-align: center; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: center; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: center; text-indent: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Stated</td> <td style="padding: 0pt; text-align: center; text-indent: 0pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="padding: 0pt; width: 543px; text-align: left; text-indent: 0pt;">Income statement</td> <td style="padding: 0pt; width: 18px; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; width: 543px; text-indent: 0pt;">Revenue</td> <td style="padding: 0pt; width: 18px; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; width: 18px; text-align: left; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; width: 175px; text-align: right; text-indent: 0pt;">1,426,808</td> <td style="padding: 0pt; width: 18px; text-align: left; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; width: 19px; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; width: 19px; text-align: left; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; width: 177px; text-align: right; text-indent: 0pt;">1,454,214</td> <td style="padding: 0pt; width: 19px; text-align: left; text-indent: 0pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">Income statement</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-indent: 0pt;">Cost of Sales</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">$</td> <td style="padding: 0pt; text-align: right; text-indent: 0pt;">730,140</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">$</td> <td style="padding: 0pt; text-align: right; text-indent: 0pt;">540,048</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">Income statement</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">Operating expenses</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: right; text-indent: 0pt;">896,529</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: right; text-indent: 0pt;">967,070</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="padding: 0pt; text-align: justify; text-indent: 0pt;">Income statement</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">Loss from operations</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">$</td> <td style="padding: 0pt; text-align: right; text-indent: 0pt;">(199,861</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">)</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">$</td> <td style="padding: 0pt; text-align: right; text-indent: 0pt;">(52,904</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">Income statement</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">Loss before income taxes</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">$</td> <td style="padding: 0pt; text-align: right; text-indent: 0pt;">(199,638</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">)</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">$</td> <td style="padding: 0pt; text-align: right; text-indent: 0pt;">(52,681</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">Income statement</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">Net loss</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">$</td> <td style="padding: 0pt; text-align: right; text-indent: 0pt;">(199,638</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">)</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">$</td> <td style="padding: 0pt; text-align: right; text-indent: 0pt;">(52,681</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">)</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', serif; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="letter-spacing: -0.1pt;"><b><i>&#160;</i></b>&#160;</font></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3">Six months ended June 30, 2014</td> <td style="text-align: center; padding-bottom: 1.5pt;">&#160;</td> <td style="text-align: center;" colspan="2">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt;">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt;">&#160;</td> <td style="text-align: center;" colspan="2">Previously</td> <td style="text-align: center; padding-bottom: 1.5pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Financial Statement</td> <td style="text-align: center; padding-bottom: 1.5pt;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Line Item</td> <td style="text-align: center; padding-bottom: 1.5pt;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Corrected</td> <td style="text-align: center; padding-bottom: 1.5pt;">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Stated</td> <td style="text-align: center; padding-bottom: 1.5pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 543px; text-align: left; text-indent: 0pt; padding-left: 0pt;">Income statement</td> <td style="width: 18px;">&#160;</td> <td style="width: 543px; text-indent: 0pt; padding-left: 0pt;">Revenue</td> <td style="width: 18px;">&#160;</td> <td style="width: 18px; text-align: left;">&#160;</td> <td style="width: 175px; text-align: right;">2,716,236</td> <td style="width: 18px; text-align: left;">&#160;</td> <td style="width: 19px;">&#160;</td> <td style="width: 19px; text-align: left;">&#160;</td> <td style="width: 177px; text-align: right;">2,771,560</td> <td style="width: 19px; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Income statement</td> <td>&#160;</td> <td style="text-indent: 0pt; padding-left: 0pt;">Cost of Sales</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">1,291,551</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">1,038,858</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Income statement</td> <td>&#160;</td> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Operating expenses</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,386,747</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,439,028</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt;">Income statement</td> <td>&#160;</td> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Loss from operations</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(962,062</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(706,326</td> <td style="text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Income statement</td> <td>&#160;</td> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Loss before income taxes</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(961,733</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(705,996</td> <td style="text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Income statement</td> <td>&#160;</td> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Net loss</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(961,733</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(705,996</td> <td style="text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Statement of cash flows</td> <td>&#160;</td> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Net loss</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(961,733</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(705,996</td> <td style="text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Statement of cash flows</td> <td>&#160;</td> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Stock and options issued for services</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">627,344</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">654,634</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Statement of cash flows</td> <td>&#160;</td> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Increase in accounts payable</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">203,714</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">173,889</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Statement of cash flows</td> <td>&#160;</td> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Decrease in revenue share payable</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(311,776</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(686,760</td> <td style="text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Statement of cash flows</td> <td>&#160;</td> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Increase in deferred revenue</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">19,651</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">38,656</td> <td style="text-align: left;">&#160;</td> </tr> </table> </div> <div> <p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="padding: 0pt; text-align: center; text-indent: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3">Three months ended June 30, 2014</td> <td style="padding: 0pt; text-align: center; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: center; text-indent: 0pt;" colspan="2">&#160;</td> <td style="padding: 0pt; text-align: center; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: center; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: center; text-indent: 0pt;" colspan="2">Previously</td> <td style="padding: 0pt; text-align: center; text-indent: 0pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="padding: 0pt; text-align: center; text-indent: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Financial Statement</td> <td style="padding: 0pt; text-align: center; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: center; text-indent: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Line Item</td> <td style="padding: 0pt; text-align: center; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: center; text-indent: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Corrected</td> <td style="padding: 0pt; text-align: center; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: center; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: center; text-indent: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Stated</td> <td style="padding: 0pt; text-align: center; text-indent: 0pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="padding: 0pt; width: 543px; text-align: left; text-indent: 0pt;">Income statement</td> <td style="padding: 0pt; width: 18px; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; width: 543px; text-indent: 0pt;">Revenue</td> <td style="padding: 0pt; width: 18px; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; width: 18px; text-align: left; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; width: 175px; text-align: right; text-indent: 0pt;">1,426,808</td> <td style="padding: 0pt; width: 18px; text-align: left; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; width: 19px; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; width: 19px; text-align: left; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; width: 177px; text-align: right; text-indent: 0pt;">1,454,214</td> <td style="padding: 0pt; width: 19px; text-align: left; text-indent: 0pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">Income statement</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-indent: 0pt;">Cost of Sales</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">$</td> <td style="padding: 0pt; text-align: right; text-indent: 0pt;">730,140</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">$</td> <td style="padding: 0pt; text-align: right; text-indent: 0pt;">540,048</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">Income statement</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">Operating expenses</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: right; text-indent: 0pt;">896,529</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: right; text-indent: 0pt;">967,070</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="padding: 0pt; text-align: justify; text-indent: 0pt;">Income statement</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">Loss from operations</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">$</td> <td style="padding: 0pt; text-align: right; text-indent: 0pt;">(199,861</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">)</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">$</td> <td style="padding: 0pt; text-align: right; text-indent: 0pt;">(52,904</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">Income statement</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">Loss before income taxes</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">$</td> <td style="padding: 0pt; text-align: right; text-indent: 0pt;">(199,638</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">)</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">$</td> <td style="padding: 0pt; text-align: right; text-indent: 0pt;">(52,681</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">Income statement</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">Net loss</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">$</td> <td style="padding: 0pt; text-align: right; text-indent: 0pt;">(199,638</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">)</td> <td style="padding: 0pt; text-indent: 0pt;">&#160;</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">$</td> <td style="padding: 0pt; text-align: right; text-indent: 0pt;">(52,681</td> <td style="padding: 0pt; text-align: left; text-indent: 0pt;">)</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', serif; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="letter-spacing: -0.1pt;"><b><i>&#160;</i></b>&#160;</font></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3">Six months ended June 30, 2014</td> <td style="text-align: center; padding-bottom: 1.5pt;">&#160;</td> <td style="text-align: center;" colspan="2">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt;">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt;">&#160;</td> <td style="text-align: center;" colspan="2">Previously</td> <td style="text-align: center; padding-bottom: 1.5pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Financial Statement</td> <td style="text-align: center; padding-bottom: 1.5pt;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Line Item</td> <td style="text-align: center; padding-bottom: 1.5pt;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Corrected</td> <td style="text-align: center; padding-bottom: 1.5pt;">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Stated</td> <td style="text-align: center; padding-bottom: 1.5pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 543px; text-align: left; text-indent: 0pt; padding-left: 0pt;">Income statement</td> <td style="width: 18px;">&#160;</td> <td style="width: 543px; text-indent: 0pt; padding-left: 0pt;">Revenue</td> <td style="width: 18px;">&#160;</td> <td style="width: 18px; text-align: left;">&#160;</td> <td style="width: 175px; text-align: right;">2,716,236</td> <td style="width: 18px; text-align: left;">&#160;</td> <td style="width: 19px;">&#160;</td> <td style="width: 19px; text-align: left;">&#160;</td> <td style="width: 177px; text-align: right;">2,771,560</td> <td style="width: 19px; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Income statement</td> <td>&#160;</td> <td style="text-indent: 0pt; padding-left: 0pt;">Cost of Sales</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">1,291,551</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">1,038,858</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Income statement</td> <td>&#160;</td> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Operating expenses</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,386,747</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,439,028</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt;">Income statement</td> <td>&#160;</td> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Loss from operations</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(962,062</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(706,326</td> <td style="text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Income statement</td> <td>&#160;</td> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Loss before income taxes</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(961,733</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(705,996</td> <td style="text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Income statement</td> <td>&#160;</td> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Net loss</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(961,733</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(705,996</td> <td style="text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Statement of cash flows</td> <td>&#160;</td> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Net loss</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(961,733</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(705,996</td> <td style="text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Statement of cash flows</td> <td>&#160;</td> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Stock and options issued for services</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">627,344</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">654,634</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Statement of cash flows</td> <td>&#160;</td> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Increase in accounts payable</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">203,714</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">173,889</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Statement of cash flows</td> <td>&#160;</td> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Decrease in revenue share payable</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(311,776</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(686,760</td> <td style="text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Statement of cash flows</td> <td>&#160;</td> <td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Increase in deferred revenue</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">19,651</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">38,656</td> <td style="text-align: left;">&#160;</td> </tr> </table> </div> 6250 90000 410348 200000 150000 12500 45000 8333333 10000000 P5Y 1.20 6000000 0.097 970000 804139 1110211 1.20 240000 112500 56250 12500 12500 16375 13375 630000 337500 197605 3000000 7000000 2950000 500000 170611 110039 450000 1000000 -961733 -705996 730140 1291551 882327 1638768 23241707 20355651 22924819 22917678 -0.01 -0.05 -0.01 -0.01 1592 45000 EX-101.SCH 6 oprx-20150630.xsd XBRL SCHEMA FILE 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - Nature of Business and Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Stockholders Equity link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Share Based Payments - Options link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Restatement link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Restatement (Tables) link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Stockholders Equity (Details) link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Share Based Payments - Options (Details) link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Restatement (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 oprx-20150630_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 oprx-20150630_def.xml XBRL DEFINITION FILE EX-101.LAB 9 oprx-20150630_lab.xml XBRL LABEL FILE EX-101.PRE 10 oprx-20150630_pre.xml XBRL PRESENTATION FILE EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`'N!"T?Y:$2P=`$``&`,```3````6T-O;G1E;G1?5'EP97-= M+GAM;,U7RV[",!#\%91K14QH2Q\"+J77%JG]`=?9$`N_M#8!_KYV@*J-4@0M MD7R)X\SNSMAKCY3Q^]:`[6VD4':2E,Z91T(L*T%2FVH#RB.%1DF=G^*"&,J6 M=`%D.!B,"-/*@7)]%VHDT_%K!8@\A][3#@BU)PDU1G!&'=>*5"IO5.WKHN`, MDSE/#E<>3WIRB>Z'2ER`;06I@]\S2@)/+$%J#0'-;`C@I4NNV`FP; M_PXY,,^@H"OASB+>[UV*(.H86W*SIWK>^"K6?YLD'K4G,303CRGC,C3-J,6/ MC##_XUH:FUA),4.ZY@V"JK,VA3&5E*NV5JTU+C^T7E[RF$!850YYWZ`/1,=; M3HD/GGO4$E_Z7]R'D\(TPDF$(;##2U%2A/S-H>]O^]WX'M"=CM#7^OVWIM>@ M)?70H4FQW8OG*\M"_V/Z'D4X$G1H>)% M]2-F`Q+M*;V"^GH`A3&^.R6:E((C-Z."N[_8_`)02P,$%`````@`>X$+1ZFB M.H@;`0``F@H``!H```!X;"]?"A@(X^K-K>ORZ*B#UM=(,T&!)9FO@V_ M.&M*BR<-L:-R_M&V#/V3AVB(SG?8.,7^./'A/]9 M;YJFK_!JJM<1M?M#(;\6"!D&96%0Q@+:AD%;%M`N#-JQ@/9AT)X%E(=!.0OH M$`8=6$#',.C(`CJ%02<6$*21,J8\I%BL>6H-D5P#3Z\A$FS@*39$D@T\S89( MM(&GVK#(-G7*8OWL;*];6EOS;7A4M.@VN<>`ZU/FJ5'#(M7.;T(Y7U?_W.>I MGQ#YZS?T\@%02P,$%`````@`>X$+1ZHW8^H-`@``,`8``!````!D;V-0&ULO55-C]HP$/TK5D[TL!N@I0?$1BH?4BNU753H]NQU)L3"L5// M@*"_ON,$TK`+NRV'KS]JN\7NY=%-)T&:=;M35<^DAY:8GU9MDA?FX9YTF<">Y MM"M(V]CGFTU0:;:KN92>TQ&6QIN09'SAVO:TK6W ME#H5+AT?EGP^C,2C1`CA7;257DM+D4#]BY?]J&Y;9ZO8E$@^^>'\&G,`PE'< M)*NPC6W'^EW2&U0(CDZ1<:,L.=AVHCMDEIH,X'TVEY[^DQ65IJ,1O4'44G\L M(:1-QSGAGT[CPM/ M+)3B0\SE/EB-XD;DW<6G_X_)+\!4$L#!!0` M```(`'N!"T=D^\DP/@$``&D#```1````9&]C4')O<',O8V]R92YX;6S-DTU/ MPS`,AO\*ZKU+LVD3BKH>`'%B$A)#(&XA\;:PYD.)IZ[_GBSK6L:X[,:MKOT^ M?ATGI7!,6`_/WCKPJ"#<['5M`A-NGFT0'2,DB`UH'D:QPL3DRGK-,89^31P7 M6[X&,BZ*&=&`7'+DY`#,74_,JE(*)CQPM+[#2]'CW<[7"28%@1HT&`R$CBC) MJE>S-;8Q)1GT51D=USS@PDJU4B#OVJ'L,A4[(W@=CG*0??OT]T\/*4.RKG(? M5%_5-,VHF:2Z.#`E[XNGEW0VN3(!N1$054$Q;!W,LU/GM\G]P_(QJ\8%G>;% M;4[IDLX8I6Q*/PZ3G?D;#.MNB'_K^&0P;1<5UG#E;I-&IN6FSP22$(17#I4U M5^$2YHA2O=KB`XO)ZYL;7U[3/V*SEY5]0U0 M2P,$%`````@`>X$+1YE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M3A^%$5B-;'EDD81_ MOTV23;J;/`0LZ?O.14?GZ#AY\^XN8NB&B)3R> +]O6N[!3+UES@6QHO(];JM-O= M5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!$U=!)KF(M/+Y;,7\ MVMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9KQ]'22(""R7V4!;I) M]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2BW`A(5M>5`TR``6'!VULS2`Y9>*?IU ME!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D`4.`#?$T4Q0?*]!MHK@PI+2 M7)#6SRFU4!H(FLB!]4>"(<7K;YH]5Z%82=J$^!!&&N*< M<^9ST6S[!Z5&T?95O-RCEU@5`9<8WS2J-2S%UGB5P/&MG#P=$Q+-E`L&08:7 M)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9-AIRM1:!MG&IA&!: M$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+D!&_'H8X2IKMHG%8 M!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T!Z.:60F]A%9JGZJ' M-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+`.7\N?<^E[[GT/:'2 MMSAD6R4)RU3393>*$IY"&V[I4_5*E=?E MK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y"M-2D&_#^>G%>!KB M.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#0X=Y>U^89Y7&4#04 M;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O&`RN0HGQ,C$7H<.>77%_C MT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55ORL+YJ/;053L_^6:W( MGPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SCYL=Q3E.X$G:V#P(R MN;LYJ7IE,6>F\M\M#`DL6XA9$N)-7>W5YYNTB42%(JP#`4A%W+C[^^3:G>,U_HL M@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF8$O#>FZ=+2?_VU[4 M/;07/4;SHYG@'K.'YA,L0Z1^P7V*BH`1 MJV*^NJ]/^26<.[1[\8$@F_S6VZ3VW>`,?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1? MCQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!U4#E/]O4#6CV#30< MD05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_`5!+`P04````"`![@0M'2HZ50$<" M``#@"0``#0```'AL+W-T>6QE@%T\^9TY__?3BV$D@2YMUI?ZBTZ.[YQZ=Y+/C!M:#`-PUD@"),X MC64KY@(:E*M60H(O!PCY^%M5T`0_GG_\U2JX^8#\>/;I["Q\O+C9Q\_=P@5& MGN-;D>!H=H6#YY-.PO`PL5W<(Y^]D/QOW'O4UY8ZZ`N4QJ628YVFV`-IW#RA M%>'&/[+NN>)*(S`'830X1!)!O<XSSW>T9((UK`D"UG)L)ZNW%NC:;DTI2+]+Y M'?&N-%E'TZNM`#>8O)G2!=5#Y@AOH#3FM`03H%FUM".HVDI7`$H8HV"D4I)P M2[F)Z`U#FU/.[^V;\E#N<'!(O MZLHA@8DF=K(?FJI\=HX\.T*1WYK4"]I!?X.#KCRD\-0M_T]-KU^U48VY@F]=GI.3.^BN%1G5<]<87R[I M\OKXD;FW$^_)?-M;G8/RG2_\`4$L#!!0````(`'N!"T?!/*1#>P(``)$& M```/````>&PO=V]R:V)O;VLN>&ULE93!4MLP$(9?1:,3/;2V0QP@@SD$:,M, M"PQAZ%FQUG@'67(EF0!/S\HF12D>!DZ69.TG[;^_]M#-U\;>K8RY8P^-TFYN M"UY[W\Z3Q)4U-,)],RUH^E<9VPA/4WN;F*K"$DY,V36@?3))TUEB00F/1KL: M6\=?:.XC--=:$-+5`+Y1`ZP1J/G1H9M7J.`&K",P$VU[+AHH^(/B3`GG3R5Z MD`6?TM2L86O!=NVB0Q4F>9KS),`VJ5Y:5AH)`^RZ1O?GY0=G$BK1*7]-E]V< M6_!L,IU,9@,C;+M!6+L8&!:8*#W>P[58%3SE3'3>?$?EP9X(#S^LZ5K4M\3B MK$+K_#*DV^]L4&.#3^'>-'.U6?\T%I^,]D(M2VN4ZJ/"CSZ(3G#_5NB.'LNM MC5ZLKD(E"CY+"7B/#E>HT#\6O!\K")DD_Z72R_\Z8KH79U-B)K1DI]H3A9WI MH7@D3;@#;3Z3_<%VCC2P9S(;I(I!QT9+T`XDHY$S"B6I(ME"**%+8!%H$H$F MGP7M1J#="+3[8=#2TX=2CD#3"#3]+"B/0'D$RM^"SH7O+#!3L47G4(-SO>P+ MX=#1:@2:1:#96]#2F_*N-DJ2@=GIWXZJ%@7O1<%[(\&UH$O0H93#I7@,U7?L M*[MH^\<=.W[#KBUQ$)V(%J&Q3;-1OQZ_MRQL;/8L-FHXY]1U&V M$Z-BRV8CGMV29RRMV*I9_M(P7GL$M4DRJ`P=U/5P:D%E:*OT&629YAE5-LQ_ M4ZLM>.B'U/HZI8YI[4+_,J+O&@-YTTB/G@%02P,$%`````@`>X$+1VIU=*]# M`@``C@<``!@```!X;"]W;W)KM;F&3D2=A@;/[_?.<87^J1 MBS?9$J+`.Z.]7$:M4L-S',M=2QB63WP@O?YRX()AI;OB&,M!$+RW)D9CE"1% MS'#71TUMQUY$4_.3HEU/7@20)\:P^+?4.3/);SM],Y^=^&24F!T+)3ID06#=GLB&4 MFDB:_-<'_6`:X_7[)?IW6ZY.?XLEV7#ZI]NK5F>;1&!/#OA$U2L??Q!?0VX" M[CB5]@EV)ZDXNU@BP/"[:[O>MJ/[DD%O"QN0-Z#)@(J[AM0;TLD`,UNIR\S6 M]0TKW-2"CT`.V/QM^*SEP@31D8$N1NIYLC&%G:FF/C=)'9]-F!L%LHJU4\!) M$>O800"*0G9D[>AKP,8ITL>`]!;@!E>IM6>/[=FM/7/VS-KS4'Y.L7:*XC$@ M#P)R:U_<`GJKR!W`*6"6E5DZ8YZ+(*:P0X24S5DL51%1^KN\@O"1_C(!)D&&'=83BSC_W&I3,XL`PQV_- M1:B8PG.\IIQ!06&*VY^PNC-E7H.2&90T3'';&,&OYVQST:`JJTKX>2''5\>!<$9U$ M\J23:?7E.'4H.2CSNC!9NNO"=10?+K??=`4W_P%02P,$%`````@`>X$+1^G. M;BKG`P``K1$``!@```!X;"]W;W)KEQ)$W:<N_#P?OQ^)'VYR&Q]5A',\/93D\'WQ;#Y^[LS^%;_9=W]9C..U? MRN'<^WHW![5-"8SILJV/I]5F/5_[VF_6W>O8'$_^:U\,KVU;]_]L?=-='E=\ MM5SX=GPYC-.%/-U_YIIDRA9'_QJ0_QYP"WQ\OV7^=RPWRG^K! M5UWSUW$W'H):MBIV?E^_-N.W[O*;QQK4E/"Y:X;Y?_'\.HQ=NX2LBK;^$3^/ MI_GS$K^Q#,/H`,``N`9PF0P0&"#^$U!&97-=O]1CO5GWW:48SO7TM/E#P/LI M2CQ?91XFA$3BXB(T%)98V]S%7)2:FWN0I3<<:$Y??U*%*/BDE,0D]$C!8FH;K"1):YC'NC22T:4R2T1$1I MR?2[9_!_-<@IHZ0T]_484H^)>A+/8!L1'M3(A!JDP/*,>V/)=6#CY&/WXQU9 MBXOQ/%%+1!SCTB6P"C'!K,I8E9R1%",,V3-PA!*9F2.D,3;:4<#3`Q MU!89[2QW.O%P*P0-`VM9CB9)+@LNT;PS,M`&R*-QB90#(L,-<)MR'>1"4R0, M9"BB;9!'\Q(I'T1&&1;^4HI([K8BV@AY-#"1$Z&>I M?F"+S*>P=%3.I+-L^ENA4RG<;ZW/]XO^H^Y?C M:2B>NC'LT>>M]+[K1A\2L<^AR(.O=]>3QN_'Z=!,U<=?$^+)V)V7'T>NO]!L M_@502P,$%`````@`>X$+1Q$B.F45`@``"0<``!@```!X;"]W;W)KGYSFV$&+8`\&.#.\0W=,"] M?%-3UB$AA^P$^,`PJK2I(\"',`8=:GNWR/7<,RMR>A:D[?$S<_BYZQ#[M\>$ MCCO7<^>)E_;4"#4!BAQ]N?T[[I4_&DK MT4A:Z#H5KM&9B!P& M?S+X5X,7KAJ"R1!\,`!#INOZA@0J5LJ9"I')CBR&R^^D,YG^ M4D5^*:(@!Q>54B4V1EBDQ, MLL)D)+Z?A5GJ92M(LS"-D^!&N$@46XEB0Y2N$,6/$L5?)$JL1(DALBXT[:'D MH3UD4RVRI%:65$?$*SMC;R3>YUMH0;A(E%F),D/T0$4>M`;H:9G@?T@`-X?6 M@$[X%V*GMN?.@0IY_NECJJ948)D!-[*D1MY+UP'!M5#=1-5J3FHS$'28+Y[K M[5?\!U!+`P04````"`![@0M'9VU"?YX#``"]#P``&````'AL+W=O(E/XWA^3I)A M=Y)M-3RIL^ST-P?5M]6H'_MC,IQ[6>TGH[9)"$(\::NZB]>K:>UKOUZIR]C4 MG?S:1\.E;:O^WXULU/4EQO&\\*T^GD:SD*Q7R6*WKUO9#;7JHEX>7N+/^'E+ MD$$FXN]:7H>;^\@D_ZK4=_/PY_XE1B8'VL?TFI(C<.=:H;I,]I= MAE&ULTDR)9]SCK[2<%H=\6WUKN9P3Q,EC?;GS9,I!7X`]1LX"3ID&4H M8I[R6(@0CZ?20AQY"KB=P]W\&O=58;,!B`?-<'Z.>3C*#NN/HKN-I)3.8S#"$Y M81GVG8\S20G3KS&>DZ]\]XD%%[[^/9.(IBD/Z>#8W>2P[4THP$/FKC8R/TU0X M1#MUZ49XW5Y6E\GS,S&SS2_K&_Q<8,=ZJ2=5F"O?W:]7Y^HH_ZKZ8]T-T:L: M]40U#3X'I4:ITT5/6LQ)S]++0R,/H[D51B5,E_`PJO,\+"\3^_H_4$L#!!0` M```(`'N!"T=A-WOQV0,``+H0```8````>&PO=V]R:W-H965T&ULC5C;;N,V$/T5P>]><887B8%C('91M`\%%OO0/BLV?<'JXDIRO/W[4AK2 M219,CQZM;UWX>3,6/VHZG;X7EQ&L?+4YX/NY-IJN%+=S&M M_>;0]4TUVM?^F`^7WE3[V:BIWYP4L_,"W\_$T3@/Y>I7?[?;GQK3#N6NSWAR>%R_PM.4S9$;\?3:W MX<-S-I%_[;KOT\N?^^<%FSB8VNS&R45E/][,UM3UY,G._*]S^C[G9/CQV7O_ M?0[7TG^M!K/MZG_.^_%DV;)%MC>'ZEJ/W[K;'\;%(">'NZX>YO_9[CJ,7>-- M%EE3_:#/?+879"_(7GRFV,Z0@H(@R!)5*5#] M&K=U.*V@X`E\9#`>27P2\J&"\2BR#_*4%`]!0&K.BU_#M@X&LL3R,9LBR*8@ M-I%I-@3A"IC""!N"*2RX%(_9E,'C(1AGB`P? MLP$6I#,/6SZQ[#K,4MA%Y!%"'L<9Z(3\`(09.471,4;@ME,),=S6X9#Q`A)6 M'##,B/1%L!@C=+$#%"JRN%L/%""D2MCAP,.<2+-X-$N$68)4K(Q1\CA[3K,$ M1F$1!)(N`3%&A$&PA**51#B[`63"L0$R3(AD4`>7SAO;:PZW!*$+ MD:"KH(+B`:2'.B6HL!@":9B.DBW\NNL482C#$Y'0Z>`R^>R5KI8EQ`X!#].H M,&47AH432.]T\)3U]:4=(2QD9+=N/0YLA8%Z3`G#XHDD>%I&

/`M4L21Y M'`(O><*R(00K#$GQ=$I08;5#$B@=)4L88/27,%=8Q9"41\?4"=_526B5<*Y@ M6)^0-$7'S@N'6:KDN,+2@]+G)S:9TYY"2Y:TXN'+&KH[%@L*KZ]"!]*E9L%J M]9R4TT-NCZ<$G<.P2F'A.$5D:N-`7`BEB]AIX+T!E)98`JFPHF'I2,4DS8&X M$K(L@F7I+NH>*&U1IMQV4(?WJ[OLL01AY&$5XLRY2.E_PGS7EVJH_FKZH_G=LA> MN]$VK'-?>>BZT5A>[(NM@).I]O>7VAS&Z;&82H-::WH9NXO_I>#^<\7Z?U!+ M`P04````"`![@0M'OY/ZZJ8!``"Q`P``&````'AL+W=OHD(4M/5:O=AI:H/[;,#`UBU/:QM0O?O MZPNAR2I27_#,<,Z9,[Z4$YIWVP,X\J&DMCO:.S=L&;-U#XK;&QQ`^S\M&L6= M3TW'[&"`-Y&D)"NR[)8I+C2MREA[-E6)HY-"P[,A=E2*FW][D#CM:$Y/A1?1 M]2X46%6RA=<(!=H*U,1`NZ./^7:_#H@(>!4PV;.8!.\'Q/>0_&YV-`L60$+M M@@+WRQ&>0,H@Y!O_G36_6@;B>7Q2_QFG]>X/W,(3RC?1N-Z;S2AIH.6C="\X M_8)YA$T0K%':^"7U:!VJ$X42Q3_2*G1[-^[*AIXN!5>:SR[*YDQR!T@4G$_8Q9$,RK M7VU1T&OT(M*+[^FK2_HJ.5S-#N^_%UA?"JR3P'H6>+@V8L+L9TR>_=>$G>VI M`M/%JV-)C:-V:4N7ZG(['XMX)E_PJAQX!W^XZ82VY(#.GVP\@!;1@6^?W6PH MZ?W[61()K0OAG8]-NE(I<3B<'LCR2JM/4$L#!!0````(`'N!"T>L!^6/I`$` M`+$#```8````>&PO=V]R:W-H965T&ULC5/;;IPP$/T5RQ\0 M8@4Y:%]]L(`5FR&V&9)_SZ^`-FM5FI?\,QPSIDSOI0SZC?3 M`UCRH>1@]K2W=MPQ9NH>%#!)*2+$N2;TQQ,="J M#+47794X62D&>-'$3$IQ_><`$N<]3>E:>!5=;WV!527;>(U0,!B!`]'0[NE] MNCL4'A$`OP3,YBPFWOL1\)MX"2*BM5^!N.<$#2.F%7./W1?.KI2>> MQZOZ8YC6N3]R`P\H?XO&]LYL0DD#+9^D?<7Y)RPCW'K!&J4)7U)/QJ):*90H M_A%7,81UCG_R=*%=)V0+(=L(=TDP'AL%FS^XY56I<29FY/[LTIV#:R_BE(GS M9MS805.'P:OR5*5I6K*3%[K`1.)AP6P(YM2OMLCH-7H6Z-F_Z?DE/8\.\\7A M?P@4EP)%%"@6@?S:B!%S6#'%7TW8V9XJT%VX.H;4.`TV;NE6W6[G?1;.Y`M> ME2/OX)GK3@R&'-&ZDPT'T"):<.V3FUM*>O=^MD1":WWXW<4Z7JF86!S7![*] MTNH34$L#!!0````(`'N!"T>FJQ->I0$``+$#```8````>&PO=V]R:W-H965T M&ULA5/;;J,P$/T5RQ]0`R%M%1&DIJNJ^[!2U8?VV8$!K-H, M:YO0_?OU!6A21>H+GAG..7/&EV)"_6$Z`$L^E>S-GG;6#CO&3-6!XN8&!^C= MGP:UXM:ENF5FT,#K0%*294ERRQ07/2V+4'O198&CE:*'%TW,J!37_PX@<=K3 ME"Z%5]%VUA=86;"55PL%O1'8$PW-GCZDNT/N$0'P)F`R9S'QWH^('S[Y7>]I MXBV`A,IZ!>Z6$SR"E%[(-?X[:WZU],3S>%%_"M,Z]T=NX!'ENZAMY\PFE-30 M\%':5YR>81YAZP4KE"9\234:BVJA4*+X9UQ%']8I_LFSF7:=D,V$;"7<)\%X M;!1L_N*6EX7&B9B!^[-+=PZNO8A3)LZ;<6,'31T&+XM3F:;;@IV\T`4F$@\S M9D4PIWZU14:OT;-`SWZF;R[IF^AP,SN\_5D@OQ3(HT`^"]Q=&S%B#@OF_EL3 M=K:G"G0;KHXA%8Z]C5NZ5M?;^1`.D7W!RV+@+?SANA6](4>T[F3#`32(%ES[ MY&9+2>?>SYI(:*P/[URLXY6*B<5A>2#K*RW_`U!+`P04````"`![@0M'!6ES M<:0!``"Q`P``&````'AL+W=OEFQ2-E45?M0*552VP,=G!OWC-EF`,7M'8Z@_9\.C>+.IZ9G=C3`VTA2DA59]HDI M+C2MJUA[,G6%DY-"PY,A=E**FW]'D#@?:$[7PK/H!Q<*K*[8QFN%`FT%:F*@ M.]"'?'\L`R("?@N8[45,@O<3XDM(?K8'F@4+(*%Q08'[Y0R/(&40\HW_+IIO M+0/Q,E[5O\=IO?L3M_"(\H]HW>#-9I2TT/%)NF>?ZW8.0A=81+QN&`V!//J-UL4]!:]B/3B8_KNFKY+ M#G>I>Y%]+%!>"Y1)H%P$\ELC)LQQQ;QWR2[V5('IX]6QI,%)N[2E6W6[G0]% M/),W>%V-O(=?W/1"6W)"YT\V'D"'Z,"WS^[N*1G\^]D2"9T+X6<.>-+.6GS:GL`A]ZE4':/>^>&'2&V[D$R M>Z,'4/Y/JXUDSJ>F(W8PP)I(DH+0++LEDG&%JS+6GDU5ZM$)KN#9(#M*R]GB#E\(+[WH7"J0JRCUJ_ MAN1/L\=9L``":A<4F%].\`A"!"'?^&W6_&H9B.?QHOXK3NO='YF%1RW^\\;U MWFR&40,M&X5[T=-OF$?8!L%:"QN_J!ZMTW*A8"39>UJYBNN4_M!\IETGT)E` M5\)]%HVG1M'F$W.L*HV>D!U8.+O-SL--$/'*R'NS?NRH:>+@57FJ-C0OR2D( M76`2\3!C5@3QZE=;4'R-3B.=_DS/+^EYE@>R/I*JT]02P,$%`````@`>X$+ M1T,T!(VF`0``L0,``!D```!X;"]W;W)K&ULA5/+ M;MLP$/P5@A\0RK+2I(8L($Y0M(<"00[MF996$A&2JY"4E?Y]^9`4.S"0B[B[ MFIF=Y:.N6''F*U[4-S>X`#:_VG1*.Y\:CIF!P.\B20E M69YEWYCB0M.JC+5G4Y4X.BDT/!MB1Z6X^7<`B=.>;NA2>!%=[T*!525;>8U0 MH*U`30RT>_JPV1V*@(B`/P(F>Q:3X/V(^!J27\V>9L$"2*A=4.!^.<$C2!F$ M?..W6?.C92">QXOZCSBM=W_D%AY1_A6-Z[W9C)(&6CY*]X+33YA'N`V"-4H; MOZ0>K4.U4"A1_#VM0L=U2G_R8J9=)^0S(5\)]UDTGAI%FT_<\:HT.!$[\'!V MFYV'FR#BE8GW9OW84=/$P:OR5&WRNY*=@M`%)A$/,V9%,*]^M45.K]'S2,^_ MIF\OZ=OD<#L[++X6*"X%BB10S`+WUT9,F,."^?ZI"3O;4P6FBU?'DAI'[=*6 MKM7U=C[D\4P^X%4Y\`Y^<],);``MH@/?/KNYI:3W[V=-)+0NA'<^ M-NE*I<3AL#R0]956_P%02P,$%`````@`>X$+1WLT*IU^!```J!@``!D```!X M;"]W;W)K&ULE9G9;N)*$(9?Q>(!8O>.(X(T(0M$ M.M)H+N9<.]`L&B^,;<+,VQ_;74U(3MDIV#OYD M:5[=3?9U?;P-PVJ]MUE2W11'FS>_;(LR2^KFLMR%U;&TR:8+RM*01Y$.L^20 M3^:S[M[WR.;>#U=Y_]J:MN4_S7I+*+(OWWL*GW36FC2;"QV^24 MUC^*\])"'52;<%VD5?<>K$]5760^9!)DR1_W>SMSD3T2Q\ M:S-]T/!.<^\UK%^S=!HM^R4K2'-1A$TI\:+R"58,#L7@_1X+KQ']F@>O&2CK MH]>H?LV3U^A^S;/7F(&FLW>G(:(8PB&6G42(,1'S!RFJY")"># M.AEP$IB3;>;)) MO:#PGE1C>A+'D0&/"IUA%"Q6>ESSXCPR\W7SWH-(::Y(5CB0#(A4E)61Q7CK MQB-:ET=H.3BPIM#93L&ZZ$13T;TH9CB4'*!4Z(1GP`Q$$7G*XSB7'+A4Z*07 M@QN(;CC%"*>2`W"*,N=QB?8EEV/Z$E\A.="FT+V)A`I[D:$8X4ARC^1TR,B+ M2#7"@>0`I![873R"*#;4X8(3R8%(C6XP/`E.-(TDL:?P19(#N7I@C_'H18Q% MG%&F"8$C+@!QC5('''@1B0.!XRV`W*OG@8$<'.5`\!$<")Q'X5?)@07Y$42< M.LD(?)44P*U6`ST)(BZI7CC?`M#5FI)#X^VKQ[0O3J4PE/8U?MDFUAFG4G@J M*=.5P-=),6:=E#A$TD,TL#58@DA_6KF0!R)<.%`JG#CIB2/5#"=.CB%.XL1) M`G'/()(L$I+RQ"I['CB!.#.P'WP&D2*W+TZ M9AY`1-R72IPW.?VZ)Q^\B/B`(?%%4,9?6RV]Z(/5_Y]=4=G`"0,.N0+(S<"R MO%27Y=0,S/DK+Q/7LH$2X8`K`-Q0=MT*!UR-`5SA@"L/^,#IR\J+8J.CSW4. MK\XI,UONNH/Q*E@7I[QV1W^7NY?#]V_=$?6G^_?L]MD=H;^GF<^.R<[^DY2[ M0UX%KT5=%UEWUKDMBMHV18MNFG&RM\GFT`<@?I[J(NCOY_@"@0YM&=:&BT( M%Y6DK/3ORT62[A&'P_?>;*3R2:I7W0$8],:9T`?<&3/L"=%5!YSJ)SF` ML">-5)P:NU4MT8,"6GL29R2)HBWAM!>XR+WO616Y'`WK!3PKI$?.J?I[`B:G M`X[QXGCIV\XX!RERLO+JGH/0O11(07/`QWA?9@[A`;]ZF/2-C5SN9RE?W>9' M?<"12P$85,8I4+MLPMES)@XBM(O'\/*12K:QN\[1FX&Q$&U_N)J5,E1F-"\ MU;N^C6/B!OS.?[)O)ESQJTR1#[2%GU2UO=#H+(V]/G[*C90&;&;1TP:CSK[J M=<.@,<[<65N%BQXV1@[+LUW_'<4_4$L#!!0````(`'N!"T?[.\#/J@$``/@# M```9````>&PO=V]R:W-H965T?,&4]<]MJ\V!;` MH3M MMD5`1,!?#KT]BU'POM/Z)22_ZS6FP0((V+N@P/QR@BT($81\X==!\W_)0#R/ M1_6'V*UWOV,6MEK\X[5KO5F*40T-.PKWK/M'&%J8!\&]%C:^T?YHG98C!2/) MWM+*55S[]&6^'&C7"?E`R"="5GQ+F`V$V2<"2V8V'8V"Y;GMOO9[[4>DM]-?>P?%OMA M.-VG:?^\UTW5?VE/^FC^V;9=4PWFLMNE_:G3U68*:NH4")%I4QV.B]5R&OO> MK9;MRU`?COI[E_0O35-U_S[JNCT_+.C"#?PX[/;#.)"NENDE;G-H]+$_M,>D MT]N'Q5=Z7X(:(1/B[X,^]U>_DY'\4]O^'"_^W#PLR,A!U_IY&%-4YNM5%[JN MQTRF\B],^E9S#+S^[;)_F^0:^D]5KXNV_N>P&?:&+5DD&[VM7NKA1WO^0Z,& M,29\;NM^^DR>7_JA;5S((FFJW_;[<)R^S_8?EF&8/P`P`"X!ESK^`(8!["V` M!P,X!O#8"@(#Q(<*J=4^S=RZ&JK5LFO/27^JQOU$[PV\&Y.8S(F9KMZLQ)2S MF]9BM7Q=T0R6Z>N8Z!T&)LRCQ4A^&[+&-!=$:@AX6<#"5P&F\`"'PB*D"'"8 M35+^+\E-FNP]368GB^%DL?D$_'T";A-P3/!A*H\31MFY0(PB@@MU&U<@CH/, M2'8;M[8X1G-&*+F-*RT.%)7`Y+Q`X14H4*#P%;*!A<4H0X=[^5C8&F%"\A"L MQ(J04R$B]I_TTI9(6]XN]&@Q>4:DR`/J+"S+I8``;.TJ`@,9P)46!RR3BJMY M>19S1X4*$B\<+L\S20,"$6?4$0C4+1&72R`2Y@5F7H$9"O3> M!R@PNP@$"&W/[")0LD"^=>8$9N86#`C,G$"J6(1QY%Z!.0KTK@P:1QXI,(\4 MF$<*S#\GD!*OPFGXID0LA:#X6M1?R[:KT/VP1@R3]'I?>BAA=P3%!(]@!'Y& MMC71/.2("+J#;&:6L!,2IF@,)>:GA-TN#]WE"&*4*AG:(XCCE`L9LV[^]DFQ MY^7>!<%^AR"@DEPU:@\EETS&]`WJ[W<4VT\>(^I#[\%#!76M(":%W]^I,WCO MN0)O>P?B@@,-`$L$@E)42!)!RN_)U)ERR(L0)#@A/.!%I4M&6):)+(*3WT:I M\]'`7BT0E$M%5.CD@3C@S+2X"$[@-SYPQA=PHP)!=Z8WD]#:.9PBDD'$*0[\ M!@GNL2"P)@6"#">9!3RB=#ASHC4M)X*3WR(!YGM@@:!Y3O!)3GZ/!!;BY&JQ M3];RFQ_PV:95(D8*+EF$\X/?U,"96FCW.Y`R=V0>4Y1(LBVF-QM]\MR^'`?[Q'@9O;P]^0KC\_F' M\4=Z7U#/^)K>E_;=R%OZU?)4[?1?5;<['/ODJ1V&MID>WK=M.VC#F'PQHO>Z MVEPN:KT=QI]JG`W[AL1>#.W)O?"YO'5:_0=02P,$%`````@`>X$+1YNKTV:] M&````%8``!0```!X;"]S:&%R9613=')I;F=S+GAM;.U<6V_C1I9^GOX5A88' MTPW0:MUM!9D`LBUW*[$EQY*[)PCV@2++$A.*5%BDW1[,P_R'?=J_-[]DSZ6* M=]+NS@YV%\A#.K)8EU/G^IU3A_I6J5A\WON!^NOK71P?OGGW3CD[N;=5)SS( M`)[CN'/:/M.'2)INVHG9;SWW_6[W?&[O>T%KT42>+\E\CQ,@OBOKWN3 MX>OOOE7>=]_&WUV$3K*702SLP!6S(/;B)S$/>$TO#,2Q4#L[DNK;=_%WW[[# M.3QO+*[#(-XIF.-*M_ST^R3HB$'7$OUN;U1^.$VV'='KU3]\AI[R<#WB5FX] M%4UD>M3S$WM[[N[S]+,[#Z-"PR#EL&]D^;.?*S^('^50A'`ASB;A+ MW]Z6G][;OJKL?)Y$$4WPE`-+_R3M"#DF+NRX,O;XN-<_'O0:.;)^.E3F]+K' M/S9.N)&1%[J-^QDAO?K3GUHED:?]$KZLZ$)YI-ZW=NR/_0;N7WJ^C,0YT+D- MHPKK5WO;Q^>W\A!&L1=L09#[@QU4!AI9AOL]:.\J#IU?+;$B%1;+)%8QZ!5, MK\@I!*$'2KHP,U"A[[E`B"O.;-\.'`D+@$4I\>8NL!/7@R=OP3#N5A?BS='; M"C>D`VQE]1XVZ<-4*5BP\M16.U)\!S_(WQ+OP?9A>&7@U''0E)6(I"-AT,:O M2/FPA\3`3L1)J0G`.*V1*!C"LF%N]`/`W+ M`"]AC\C;[F)5._N3W`A7/D@_I!V$$ZJ&D2OI)!%*V`5-4%[E.1^KC9KU-8GGRK,WGN_%7I5O*>L/]A/R'10!O(9;X7_-N$CZI%4'&WA:,SY* M9+.\;H$]02+9'9M%J[IW+^$$+FQ%H^NYTW(Z,IA=Z+LR4G\1,Q!YE5)M6XIM MZZC3[?;P2`)T-9&6&'6[5I?_T[%#V$F\"R-PP"Y81=^:#"?6:6]"6@5_GHY/ MK`'\J0=[2B$?\&&8&:P%1U('Z<0>:$F%)%!V??`FJGJM1`5A^^ZU;!*/=H0A MIZHB+O@("%;`:C3!8R\X=NR#!ZRO7^< M)L-XB7S90*[FT[/YU7P]GZW$='$A5NOE^0\?EE<7L]L5S/SQ;K[^Z?=[T31`[TJD?B70/D6,6P&KF'\!["10!K>AAMT`T@5/EYND$,X,3_T::Q MF5*TZW5%2UXTG-7G14-;U"M39QW`&FFN*/ZS9#?-J*>\:70+\0U*D$I/H?B6 M$%=(DU\85`_%JL/T]N9F/WM M9K9850:]OUVN5N)Z>OM^OJ@$R)O9[70]7[PWDRO!9[XX7U[/Q)LK6.2MN+Q= M7@L]:;FH#%ZN/\QNA9FBEZRP;1[$$L05"X^84&_I+URJ0-W9['()?+BY77Z< MKX`^`7^:)=;3OU4/]_*1*(3"9A6P,)N__[">78CIQ]GM^YE8W%V?P0&6ERR< ME5C>K5=K\%G`[/+/+]3Y\^GJ M@[B\6GY:%90!-&AZOIY_)-?\385H&0L_5$I`RB3`KXH#@?%JB/HE43&3%H<( M(T/PIH!2`C,?OL7/A$0/4?C@@=V)S9-XD^`QO>"M"-F&`8O;&)8)3U3HN9"0 MDH*?)@^-4=7>(X#_>VT8XW!(L??`SD&'8SR,DM&#YU3#POG.#K;HP(+*YF4, M5B=AXC)IYP6HU-E/()L5?)@OWM8R_#DAS1+Z>+\F6/.07@4^.&83BX$5G(V@B$D M:QI>2W:>9WHQY-BA&*#HNR9<5BONNI,T>(+;V70U0X[1(@B*Z`-BH8_3J]FB M)I]H&@A6?S:#*+'`C<%S@:;-EQ4/U#9]!E\W3ES=W=QK^6*V8B2+,6!%O(-@@2Q"?E3F+MC.WH*4\5S-.N'NEPY1ZYKNP'F,824,D!ZR_BT8MW7B`. MNR<%N88=\-,#G)4BRB.D\QL;CW.`G`2+=Y#,@[+X"0)&,?/A!%$8>([XP.>\ MA?@3N;S*#:\"N#Z"C$7!J0,(+;;O/U%J$V!VAMS186- M7`_B74RL--Q)IUAB9>\/OKR^Z*2?!)P,(4&.ES`7\'N(%4^'S^TI8"2'"!<+ MG=XF07]/2XB','%VD,_AXW=@E4YX#/$._I<##%\1F2\!A09'!W_LJQ""'--GH^6DU&?WKG_\%?)?J MUS@\=/(66!%5R:Y4[,5Z`+)%T!Y@-H%-!L8@1&CRL"*/!1 MJ1!Q#IR8UH)P%!GE!#MBVV,APP)NE&RU_)2)8\=@D@'.-Y*CU6-#NRH9.6G] M/4C,Y6H.FZ\Q0?CL[7&F+`ZRP%)`623&65WD0!].9B9`X8.\861;:X60":DD M'BBY!Y<+!A)IWFU"^"=3_M3>6&>K-@'!/`BDST`5,"'HQST6+H!Z_XDB?!*0 M"F@>`BG[D/[22AB%;N+$VB^QCV*%=/(0_#ZM$Z@,C!ML#'8KF0W*^PQ$0(:I M\3*8#2::`C)+F5YD<,$*4DR0/_!U(V6`GK$[+-#P)9*V:!C,)1EM$/%]`+43)A)JB6Y+`OV M#=+-@'T@45'(QX=D+NA6[VTO`@:'293CS4'74*C*EOBE[DE7F+G#Q1`2X89$!R&"5L9@*!P1?0,!Z35YL2'7`XPS/'(SV1\=])\%<04[CWP*RXQ4KW$?!2H MN`\,`866-I$$*ZA_16^V:<=M=9=5YDM5;QM6X$J`%O M!^=.#=0C;7#)W3U(PS*S*:$YNA=P8IE9UGWB\ZDSW0,#\2$.>?C` M#SH!BS")%#R?ESF[=(,/]G'G.8A&?!T'O5S&/+;ZHY0`8++X#0C%^(\#I0WSS,K& M@^JQCV!*5-&)7(:O*G_+(,!C50R$(HNMKRV(#=G\[`%H1($M%M>D75SRJ#>V M!B>CVNVN;4C=S5XC+N8PJ:S:FN7`OREHII^%DY;=!K0;'36;3F:6[H%*JK"P MY::L`Z)0G>FXEW(3%44O*>G5B-46^LY&)QH*4PQ/A3#!WH*]ZP(+9!T4D,`W M2?9!;`]YV6JCG12NGVI4*F.%K0K7/<8UYP6<9X;F$R%"S/[,EGZ^C10BG(B7G9@/"128\*BQ9`G?Q5`=8^;,'T$>"'">= MDS_C#L4]+:(-7H-)&]=-!BD_R\CQ M%$59]N0E6;"=DO+CTQ&Y#8UC4Q(J-F[U0%9];)O*8GK>R$>TC?LIL\-H&NSRMB10&"A085^(QJ3_QF2F=^9C,0>'&"*=$N<+4+<*GN9 M-G:Z,M!\YHJ-W8Y"**$,V!?_ED@58]6<%@4^+0U:C1@W"[8@=QS?4>7>7+^%TM^>YVLDA9\]&`-<:X!P;6-AB0N M$PI(=IS=CR59(2DK'F4>'@*-(3&[/T^O[+%0@IDH)P$Y6G?2)]XP%202DJM& M,R3)<>;'24&?6S--M+CT$.%W4[R]I#(J2JC2A*!'G;6/*G;>Y:]C"KQH0$'% MH^H`I*NR?#(#-30C"_(G1T>J@4QZ#*-?J1RLQ09['T+%I:Y7.=Q/%8NJTJ6J MXYJ6IM3L]7D2I.3>&"C:PEIZ%(V>V3-%6^_EZ[',`1IJQ^41[A`P$OX M50@5$"L[D.HC-]W$P:]9Z*[G M)SFI`X>+2YZD*_*(_RWQ5I)]0DYGQ+L;]GM*'%.M&@+XEXUNJRE0>\_9%*_& M;Z8_7>O+UN5-;1,.E1<&7%ZHFX@/]%0=M#)\P,!@+^-=2/JJ2W:<'1/O6%&* M>>"G')./$!%V!]Q'>=0#J#SN]1C#Y`H-)N\QI9\7E+>+O996VK>*58]B7P9$ M0'"4:%)$\C&3##X/&([Z[Y1+'JA.7AI]5$I=\Q9XS4CE*D+)[-C)!CD5!&C# MO0^D>,;):3` ML[VF4O?IP/?`<)J*6:J2I&*`4?Y'*ZP5>Z4*:IR5>0$S("B5@5/3==PZN*VO MN`*$M&7VKG-.&)BG!4W5VH?0 M?\A4X#[$6UP4D@]IK6\@"5]*0:1:85V>.):&*H^NM5%X?K:AO;513_"-!3MI4VM]\$(`G.>SI67(H*+V!=T0.S$,3Z+8/)H1:`VRIZ"8UV!' ML'/`=]R<.5`63C?.>,6U7P1%%*3]`8WX4('9)[I@B9Q3@7 M2_(1PV]@A2?OLVLFA^1#U0"N0YA)-L;S]$*E-/Y`O?V4X1483\,J3,LB)6%E`(*$2+7JXMK\3X*DX,EKJ[.N8WDXE8L9(R@B+_\ M6A-1"L9XY3-O(BK!`X2!O:UT1P0^"=W/AQA8[G7:&<>^J8F4M#:#L+K`DM\H MM?'KC%6(B@((H12=-9R9K17U44A)NEKB&D[YAT,@K[0GR4XV1X.UL MH.LV"&=]"2J5E4@I1.]-2ZI',L-J$/X?3]Y.L*D9Y0"[PMIBUT!V*EP\2NP" M4"E)&,3],&T!)^HWIJN.(4K)^P,E%&&TBFM6Y/A6-4[R7ZT6^A7FF#?#A7P4 MWT..@`&F2"TL7$.M+M&L=,^PF*;2VP`1F+O$.:_$&H."1#*I:@3FH`C^$FK/ M:[AI*F+]40`\==744&([#$JU*T3!FJN+1*6%BYQAE.S`M/^`;T%RP`/XMKXC MSVEAW3F^5C.;U))[6OY/*6?&9/)K6AESEW@ZG@6F@D?X#8):D.I5ZM(=F^^# MF2=3JNOUF`!+.![%=DPVZ&4JZ6('B?@%QBN@(-85!9P`DH2U4V>9 M=A!0H,;)D026IX6P?"-!$[.(K:A26PS9!-QBO@K2W#*T5[**6YG>5+0\:LD8 M;F>K]71-G=&E1_B2_3?J8#ORKZ^ICR%ZD*\Y:1A1TI";RFDX[>>6.JG*+1,1 M=[X1K'TBX^0\7]G7,O2(> M)`].&MJB'+\0<8,8?6XP,>I:SO$:>GCX=#)PS*;]=F-&5)X M)UI<)^XE,CS*MB$S3?MPF.GUK]F4WBS3J63#P-SK."V-/'65$NXGTCVJ<$*+ MVKN53@+5-Z_6M$[S?*R:$[#SGUYE+S)FU%V!`Q1S^`-[R"-F!SUU7^FWV3+9 MF?>">]:P/[9.NZ?X:32T^KUA=?!YR$UU*QO+"T?B!"CJ#;OP:837<,/3ZI1E M^I:/N4<5IY.Q->I/Q&1\8G5/NM4Y5_0"$N8CN6ZI(_&F-YE8I^.>>(M_C/K6 MI#L4;QNF;^1]R/7S]!4#L\1X<)HN,3[MU2V1O@;5.&75*N%_AX3ZUDEO;/4' M8_QTTK-&XQK6E274L_H3&#KJT>?NX-0Z';U,2GUK<#JV3H8G\&DXF%C=?LV\ M)DE-QGVK.^XSSTZZ8VO0'W^IJ";CGG4R&)@U1M9D4KM&7E8-3 MQH7`\Z8+176O_>,)!STX[LF8CSM&28^[+6?B4`20(3(1T#!1N/QJ(M MNKY9(PVJ\K[BRME!RN9+!@5-@;H^SO[A,?_PF']XS/]G'O/5'QZSV6/6]3*_ MN9"`]GW5\M)W[YD?.O#3WQ:J_I=QT3!FQ\O![O'MKFGF-@+WI)XORRU8> MYI>M/,PO6]F3KFAW(;%'-RC]O):?$]MO__F.G,[5]C557BZ&[#]\@N!"]^_Z MMZ!:?K&E=(M>X4;-+?I+WF>NODC[;'/QS]>4?U79D;44Y_O%ZVG)G:S])TK: M%M6MU]5K]F2C\*8`B)T]Y$D6_Q"_XX"+A/+.[&:HT-3;\(M06/]*WQ&?/KL' M1@O336,;W6KXW9G-DE-N1FTB]1,W`Y4; M2^M_V$%WD];>L.J.79B(]_/VMD+2I'/2_7/+U+9W\IM>NO^4MC)]K&/9K'"H MR@^4$"Q`F9\M#\^T'9ZMS%5.Q-:#K#.=VWHJW%^F4% M*JISV1M_6Z5Z9UJO`1Y\4YOD%&>)JZ56U#:.*N\LCZA!V[9@:%-WT*=4_-U_`U!+`0(4`Q0````(`'N!"T?Y:$2P=`$``&`, M```3``````````````"``0````!;0V]N=&5N=%]4>7!E&UL4$L!`A0# M%`````@`>X$+1TAU!>[%````*P(```L``````````````(`!I0$``%]R96QS M+RYR96QS4$L!`A0#%`````@`>X$+1ZFB.H@;`0``F@H``!H````````````` M`(`!DP(``'AL+U]R96QS+W=OX$+1ZHW8^H-`@``,`8``!```````````````(`!Y@,``&1O8U!R;W!S+V%P M<"YX;6Q02P$"%`,4````"`![@0M'9/O),#X!``!I`P``$0`````````````` M@`$A!@``9&]C4')O<',O8V]R92YX;6Q02P$"%`,4````"`![@0M'F5R<(Q`& M``"<)P``$P``````````````@`&.!P``>&PO=&AE;64O=&AE;64Q+GAM;%!+ M`0(4`Q0````(`'N!"T=*CI5`1P(``.`)```-``````````````"``<\-``!X M;"]S='EL97,N>&UL4$L!`A0#%`````@`>X$+1\$\I$-[`@``D08```\````` M`````````(`!01```'AL+W=OD2``!X;"]W;W)K&PO=V]R:W-H965T&UL4$L!`A0#%`````@` M>X$+1Q$B.F45`@``"0<``!@``````````````(`!?QD``'AL+W=O'P``>&PO=V]R M:W-H965T&UL4$L!`A0#%`````@`>X$+1[^3^NJF`0``L0,` M`!@``````````````(`!K2,``'AL+W=OL!^6/I`$``+$#```8``````````````"``8DE``!X M;"]W;W)K&PO=V]R:W-H965T&UL4$L!`A0#%`````@`>X$+1P5ID M6T#HI`$``+$#```9``````````````"``1@K``!X;"]W;W)K&UL4$L!`A0#%`````@`>X$+1T,T!(VF`0``L0,``!D````````` M`````(`!\RP``'AL+W=OS0JG7X$``"H&```&0``````````````@`'0+@``>&PO=V]R:W-H M965T&UL4$L! M`A0#%`````@`>X$+1_L[P,^J`0``^`,``!D``````````````(`!A34``'AL M+W=O&PO=V]R:W-H965T;J]-FO1@```!6```4``````````````"` M`;$[``!X;"]S:&%R9613=')I;F=S+GAM;%!+!08`````&``8`%H&``"@5``` "```` ` end XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 R9.htm IDEA: XBRL DOCUMENT v3.2.0.727
Commitments and Contingencies
 6 Months Ended
Jun. 30, 2015
Commitments and Contingencies [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 4 – COMMITMENTS AND CONTINGENCIES

 

Litigation

 

The company is currently involved in the following legal proceedings.

 

In September 2014, we initiated litigation against Shadron Stastney, the Company’s previous CEO, in the U.S. District Court in the Eastern District of Michigan as a result of a dispute related to his separation agreement. Mr. Stastney alleged damages related to the non-registration of shares that he was granted as part of his separation agreement signed in September 2013. Under the terms of the contract we are not obligated to register the shares and we deny any obligation to do so. We have requested declarative relief from the court and also requested an injunction from the court preventing Mr. Stastney from continuing to pursue his claims. Mr. Stastney has filed a counterclaim requesting damages of $450,000 related to the nonregistration of his shares. The parties are currently in the discovery process.

 

In March 2015, we initiated litigation against LDM Group, LLC and PDR Network, LLC in the U.S. District Court in the Eastern District of Missouri related to the breach by LDM, and PDR as successor, of the settlement agreement signed February 28, 2014 related to previous litigation with LDM. LDM has failed to live up to its obligations under the settlement agreement including, but not limited to, not allowing us to distribute our eCoupon programs in the LDM network, not allowing us to distribute the LDM patient education programs, and not providing other information required under the settlement agreement. We are seeking enforcement of the settlement agreement and we are seeking damages in an amount at least equal to the amounts paid to date to LDM under the settlement agreement, which approximates $1.0 million, as well as damages for lost income and business value as a result of LDM’s breach of the agreement.

 

In March 2015, we also initiated litigation against PDR Network, LLC in the U.S. District Court in the District of New Jersey as a result of PDR’s breach of the Master Services Agreement between the parties requiring PDR to exclusively use our eCoupon solution. We assert that PDR’s acquisition of LDM and the use of the LDM network to distribute coupons by PDR violates the agreement between the parties and we are seeking damages in an amount at least equal the amounts paid to date by us to LDM under the settlement agreement, which approximates $1.0 million, as well as damages for lost income and business value as a result of PDR’s actions.

 

In May 2015, we filed an amended complaint in the Missouri case to consolidate the two cases and withdrew the case against PDR Networks in the U.S. District Court in the District of New Jersey, without prejudice.

 

In July, 2015, the U.S. District Court for the Eastern District of Missouri dismissed the case, citing lack of Federal jurisdiction in the matter. We are in the process of refiling the consolidated case against PDR Network and LDM group in State court in Missouri.
XML 14 R8.htm IDEA: XBRL DOCUMENT v3.2.0.727
Share Based Payments - Options
 6 Months Ended
Jun. 30, 2015
Share Based Payments - Options [Abstract]  
SHARE BASED PAYMENTS - OPTIONS

NOTE 3 – SHARE BASED PAYMENTS – OPTIONS

 

We use the fair value method to account for stock based compensation. We recorded $110,039 and $170,611 in compensation expense in the periods ended June 30, 2015 and 2014, respectively, related to options issued under our stock-based incentive compensation plan. This includes expense related to options issued in prior years for which the requisite service period for those options includes the current year, options granted in the current year and options repriced in the current year. The fair value of these instruments was calculated using the Black-Scholes option pricing model. Information related to the assumptions used in this model is set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014.
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.2.0.727
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Jun. 30, 2015
Dec. 31, 2014
Current Assets    
Cash and cash equivalents $ 3,645,878 $ 3,446,973
Accounts receivable 1,918,419 2,100,381
Prepaid expenses 76,376 28,093
Total Current Assets 5,640,673 5,575,447
Property and equipment, net 10,674 12,813
Other Assets    
Patent rights, net 901,491 930,854
Web development costs, net 424,075 504,643
Security deposit 5,049 5,049
Total Other Assets 1,330,615 1,440,546
TOTAL ASSETS 6,981,962 7,028,806
Current Liabilities    
Accounts payable - trade 172,183 200,372
Accounts payable - related party 570,000 570,000
Accrued expenses 9,851 25,459
Revenue share payable 1,190,995 1,502,761
Deferred revenue 336,213 120,130
Total Liabilities 2,279,242 2,418,722
Stockholders' Equity    
Common stock, $.001 par value, 500,000,000 shares authorized, 22,949,819 and 22,867,319 shares issued and outstanding, respectively $ 22,950 $ 22,867
Preferred stock, $.001 par value, 10,000,000 shares authorized, no shares issued and outstanding    
Stock warrants $ 2,153,295 $ 2,153,295
Additional paid-in-capital 27,806,253 27,595,609
Stock payable 1,132,148 $ 963,063
Deferred stock compensation (18,750)  
Accumulated deficit (26,393,176) $ (26,124,750)
Total Stockholders' Equity 4,702,720 4,610,084
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 6,981,962 $ 7,028,806
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.2.0.727
Nature of Business and Basis of Presentation
 6 Months Ended
Jun. 30, 2015
Nature of Business and Basis of Presentation [Abstract]  
NATURE OF BUSINESS AND BASIS OF PRESENTATION

NOTE 1 – NATURE OF BUSINESS AND BASIS OF PRESENTATION

 

OptimizeRx Corporation is a technology solution company focused on the health care industry. Its objective is to bring better access to better care by leveraging its proprietary technology to provide on demand savings and support within physicians and patients web based platforms, including Electronic Health Records and Patient Portals. Initially defined as a marketing and advertising company through its consumer website, OptimizeRx.com, the Company has matured as a technology solutions provider through its direct to physician solution, SampleMD. SampleMD allows physicians to automatically display and distribute sample vouchers and/or co-pay coupons electronically within the ePrescription platform to pharmacies on behalf of their patients. The SampleMD solution is integrated into the ePrescribing or Electronic Medical Records applications, but can also sit on a prescriber’s desktop.

 

OptimizeRx solutions provide health care institutions with an alternative option to the traditional hassles and issues associated with storing and managing physical drug samples and pre-printed coupons and it provides better access and affordability to patients to improve affordability, adherence and outcomes. In turn, OptimizeRx provides pharmaceutical manufacturers with both direct to consumer and direct to physician channels for more efficiently communicating and promoting their products and savings.

 

The consolidated financial statements for the three and six month periods ended June 30, 2015 and 2014 have been prepared by us without audit pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of management, all adjustments necessary to present fairly our financial position, results of operations, and cash flows as of June 30, 2015 and 2014, and for the periods then ended, have been made. Those adjustments consist of normal and recurring adjustments. The consolidated balance sheet as of December 31, 2014, has been derived from the audited consolidated balance sheet as of that date.

 

Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014, as filed with the U.S. Securities and Exchange Commission.

 

The results of operations for the three and six month periods ended June 30, 2015, are not necessarily indicative of the results to be expected for the full year. Certain reclassifications have been made in the prior period’s consolidated financial statements to conform to the current period’s presentation.
XML 17 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 18 R7.htm IDEA: XBRL DOCUMENT v3.2.0.727
Stockholders Equity
 6 Months Ended
Jun. 30, 2015
Stockholders Equity [Abstract]  
STOCKHOLDERS EQUITY

NOTE 2 – STOCKHOLDERS EQUITY

 

In January 2015, we issued 12,500 shares of common stock to outside Directors in connection with our Director Compensation plan, which calls for issuance of 6,250 shares per quarter for each Director. Those shares were recorded as stock payable at December 31, 2014. In addition, we recorded an additional 12,500 shares, valued at $16,375 as stock payable at March 31, 2015 for shares to be issued in April 2015 and 12,500 shares, valued at $13,375 were issued in June 2015 for the second quarter payment.

 

In February 2015, we entered into a capital markets advisory agreement covering a one year period, which called for 90,000 shares of common stock to be issued as compensation. These shares were valued at $112,500 and are being amortized to expense over the period of service. 45,000 of these shares were issued in March 2015, with the balance to be issued in August 2015. The agreement was terminated in July 2015, effective in August, and the remaining 45,000 shares will not be issued. The total expense to be recognized will be $56,250 and is being amortized over the period the agreement is in effect.

 

In March 2014, we entered into a securities purchase agreement, pursuant to which we sold 8,333,333 shares of our common stock for $1.20 per share, or gross proceeds of $10,000,000.

 

Placement agents in the offering received commissions equal to approximately 9.7% of gross proceeds, for an aggregate commission of approximately $970,000, including reimbursements for their reasonable out of pocket expenses. Placement agents also received warrants to purchase up to 804,139 shares of our common stock with an exercise price of $1.20 per share and a term of 5 years. The warrants were valued at $1,110,211, have been recorded as equity issuance costs, and were registered on a registration statement that went effective May 28, 2014. In addition to the warrants to placement agents, we also paid cash bonuses of $240,000 to three executive officers, agreed to issue 200,000 shares to three executive officers, and issued 150,000 shares to a consultant, in connection with the equity raise. The stock was valued based on the fair market value on the grant date, which was $630,000 in total. These amounts have been recorded as equity issuance costs, resulting in total equity issuance costs of $2.95 million. The 200,000 shares for the three executive officers have not been issued, but are recorded as stock payable and can be requested by the executive officers at any time.

 

We used the net proceeds of the offering to exercise the securities redemption option agreement, as amended, with Vicis Capital Master Fund that provided us with an option to purchase all of the outstanding shares and derivative securities held by Vicis for total payment of $6,000,000. The shares and derivative securities included the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Common Stock, and warrants to purchase shares of common stock held by Vicis in the Company. The balance of the net proceeds were used for working capital purposes.

 

In January 2014, an executive officer exercised 500,000 stock warrants using the cashless exercise feature included in the warrants. In exchange for the 500,000 warrants, 410,348 shares of common stock were issued.

 

In June 2015, we agreed to grant 197,605 fully vested shares of our common stock to two executive officers as bonuses. These shares have not been issued, but are recorded as stock payable and can be requested by the officers at any time.

 

In February 2014, we agreed to grant 337,500 shares of our common stock, half of which vested immediately and half of which vested in August 2014, to two executive officers as bonuses based on their efforts to recapitalize the company to secure approximately $3 million in working capital while reducing fully diluted shares by approximately 7 million shares. These shares have not been issued, but are recorded as stock payable and can be requested by the officers at any time.
XML 19 R3.htm IDEA: XBRL DOCUMENT v3.2.0.727
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Jun. 30, 2015
Dec. 31, 2014
Statement of Financial Position [Abstract]    
Common stock par value $ 0.001 $ 0.001
Common stock, shares authorized 500,000,000 500,000,000
Common stock, shares issued 22,949,819 22,867,319
Common stock, shares outstanding 22,949,819 22,867,319
Preferred Stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, shares issued    
Preferred stock, shares outstanding    
XML 20 R1.htm IDEA: XBRL DOCUMENT v3.2.0.727
Document and Entity Information - shares
 6 Months Ended
Jun. 30, 2015
Aug. 11, 2015
Document and Entity Information    
Entity Registrant Name OptimizeRx Corp  
Entity Central Index Key 0001448431  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Type 10-Q  
Document Period End Date Jun. 30, 2015  
Document Fiscal Year Focus 2015  
Document Fiscal Period Focus Q2  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   22,949,819
XML 21 R4.htm IDEA: XBRL DOCUMENT v3.2.0.727
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Income Statement [Abstract]        
NET REVENUE $ 1,705,457 $ 1,426,808 $ 3,193,010 $ 2,716,236
REVENUE SHARE EXPENSE 882,327 730,140 1,638,768 1,291,551
GROSS MARGIN 823,130 696,668 1,554,242 1,424,685
OPERATING EXPENSES 980,659 896,529 1,823,269 2,386,747
INCOME (LOSS) FROM OPERATIONS (157,529) (199,861) (269,027) (962,062)
OTHER INCOME (EXPENSE)        
Interest income 304 223 601 329
TOTAL OTHER INCOME (EXPENSE) 304 223 601 329
INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES $ (157,225) $ (199,638) $ (268,426) $ (961,733)
PROVISION FOR INCOME TAXES        
NET INCOME (LOSS) $ (157,225) $ (199,638) $ (268,426) $ (961,733)
WEIGHTED AVERGE NUMBER OF SHARES OUTSTANDING        
BASIC 22,924,819 23,241,707 22,917,678 20,355,651
DILUTED        
NET INCOME (LOSS) PER SHARE        
BASIC $ (0.01) $ (0.01) $ (0.01) $ (0.05)
DILUTED        
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.2.0.727
Stockholders Equity (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Jul. 31, 2015
Feb. 28, 2015
Jan. 31, 2015
Mar. 31, 2014
Feb. 28, 2014
Jan. 31, 2014
Jun. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Sharehoders equity [Texual]                  
Common stock issued for equity issuance costs               $ 630,000  
Employee bonus, Share         $ 337,500        
Additional working capital         $ 3,000,000        
Fully diluted shares         7,000,000        
Equity issuance cost               2,950,000  
Capital markets advisory agreement [Member]                  
Sharehoders equity [Texual]                  
Called for issuance of shares   90,000              
Additional shares issued                 45,000
Called for issuance of shares, values   $ 112,500              
Subsequent Event [Member] | Capital markets advisory agreement [Member]                  
Sharehoders equity [Texual]                  
Number of shares not be issued 45,000                
Called for issuance of shares, values $ 56,250                
Securities Purchase Agreement [Member]                  
Sharehoders equity [Texual]                  
Sale of comman stock shares       8,333,333          
Sale of common stock value       $ 10,000,000          
Sale of stock price per share       $ 1.20          
Placement Agents [Member]                  
Sharehoders equity [Texual]                  
Warrant exercise price period       5 years          
Commissions percentage       9.70%          
Commissions       $ 970,000          
Purchase of warrants       804,139          
Warrants, Value       $ 1,110,211          
Exercise price       $ 1.20          
Three Officers [Member]                  
Sharehoders equity [Texual]                  
Additional shares issued       200,000          
Employee Bonus       $ 240,000          
Consultant [Member]                  
Sharehoders equity [Texual]                  
Additional shares issued       150,000          
Vicis [Member]                  
Sharehoders equity [Texual]                  
Debt redemption, amount             $ 6,000,000 $ 6,000,000  
Officer [Member]                  
Sharehoders equity [Texual]                  
Additional shares issued           410,348      
Warrants exercised, number of shares           500,000      
Outside director [Member]                  
Sharehoders equity [Texual]                  
Called for issuance of shares     6,250            
Additional shares issued     12,500            
Additional shares issued             12,500 12,500  
Additional shares issued, value             $ 16,375 $ 13,375  
Two Officers [Member]                  
Sharehoders equity [Texual]                  
Employee bonus, Share               $ 197,605  
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.2.0.727
Restatement (Tables)
 6 Months Ended
Jun. 30, 2015
Restatement [Abstract]  
Schedule of restatement

Three months ended June 30, 2014         Previously  
Financial Statement   Line Item   Corrected     Stated  
Income statement   Revenue     1,426,808       1,454,214  
Income statement   Cost of Sales   $ 730,140     $ 540,048  
Income statement   Operating expenses     896,529       967,070  
Income statement   Loss from operations   $ (199,861 )   $ (52,904 )
Income statement   Loss before income taxes   $ (199,638 )   $ (52,681 )
Income statement   Net loss   $ (199,638 )   $ (52,681 )

  

Six months ended June 30, 2014         Previously  
Financial Statement   Line Item   Corrected     Stated  
Income statement   Revenue     2,716,236       2,771,560  
Income statement   Cost of Sales   $ 1,291,551     $ 1,038,858  
Income statement   Operating expenses     2,386,747       2,439,028  
Income statement   Loss from operations   $ (962,062 )   $ (706,326 )
Income statement   Loss before income taxes   $ (961,733 )   $ (705,996 )
Income statement   Net loss   $ (961,733 )   $ (705,996 )
Statement of cash flows   Net loss   $ (961,733 )   $ (705,996 )
Statement of cash flows   Stock and options issued for services   $ 627,344     $ 654,634  
Statement of cash flows   Increase in accounts payable   $ 203,714     $ 173,889  
Statement of cash flows   Decrease in revenue share payable   $ (311,776 )   $ (686,760 )
Statement of cash flows   Increase in deferred revenue   $ 19,651     $ 38,656  
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.2.0.727
Restatement (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Class of Stock [Line Items]        
Revenues $ 1,705,457 $ 1,426,808 $ 3,193,010 $ 2,716,236
COST OF SALES   730,140 756,440 1,291,551
Operating expenses 980,659 896,529 1,823,269 2,386,747
Loss from operations (157,529) (199,861) (269,027) (962,062)
Loss before income taxes (157,225) (199,638) (268,426) (961,733)
Net loss $ (157,225) (199,638) (268,426) (961,733)
Net loss       (961,733)
Stock and options issued for services     361,062 627,354
Increase in accounts payable     (28,189) 203,714
Decrease in revenue share payable     311,766 414,563
Increase in deferred revenue     $ 216,083 19,651
Previously Stated        
Class of Stock [Line Items]        
Revenues   1,454,214   2,771,560
COST OF SALES   540,048   1,038,858
Operating expenses   967,070   2,439,028
Loss from operations   (52,904)   (706,326)
Loss before income taxes   (52,681)   (705,996)
Net loss   $ (52,681)   (705,996)
Net loss       (705,996)
Stock and options issued for services       654,634
Increase in accounts payable       173,889
Decrease in revenue share payable       (686,760)
Increase in deferred revenue       $ 38,656
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.2.0.727
Share Based Payments - Options (Details) - USD ($)
 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Share based payments options [Textual]    
Stock-based compensation expense $ 110,039 $ 170,611
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.2.0.727
Commitments and Contingencies (Details) - USD ($)
Jun. 30, 2015
Sep. 30, 2014
Commitment and contingencies [Textual]    
Claims pertaining to damages to nonregistration of shares   $ 450,000
Damage related to LDM' s breach of the agreement. $ 1,000,000  
XML 27 R5.htm IDEA: XBRL DOCUMENT v3.2.0.727
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss for the period $ (268,426) $ (961,733)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation and amortization 159,337 115,828
Stock and options issued for services 361,062 627,354
Changes in:    
Accounts receivable 181,962 302,202
Prepaid expenses (48,283) (30,198)
Accounts payable (28,189) 203,714
Revenue share payable (311,766) (414,563)
Accrued expenses (15,608) (12,000)
Deferred revenue 216,083 19,651
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES $ 246,172 (149,745)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of property and equipment   (1,592)
Patent rights $ (4,517) (92,624)
Website site development costs (42,750) (119,616)
NET CASH USED IN INVESTING ACTIVITIES $ (47,267) (213,832)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Issuance of common stock   10,000,000
Equity issuance costs   (1,204,968)
Purchase of common and preferred stock and warrants   (6,000,000)
NET CASH PROVIDED BY FINANCING ACTIVITIES   2,795,032
NET INCREASE IN CASH AND CASH EQUIVALENTS $ 198,905 2,431,455
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD 3,446,973 1,118,243
CASH AND CASH EQUIVALENTS - END OF PERIOD $ 3,645,878 $ 3,549,698
SUPPLEMENTAL CASH FLOW INFORMATION:    
Cash paid for interest    
Cash paid for income taxes    
XML 28 R10.htm IDEA: XBRL DOCUMENT v3.2.0.727
Restatement
 6 Months Ended
Jun. 30, 2015
Restatement [Abstract]  
RESTATEMENT

NOTE 5 – RESTATEMENT

 

We restated our financial statements to correct the way we accounted for certain items related to stock based compensation, revenue share expense, and revenue recognition. The full impact of the restatement was reflected in the December 31, 2014 financial statements at the end of the year. The table below reflects the impact on the 2014 period reflected in this report.

 

The restated Consolidated Statement of Operations and Consolidated Statement of Cash Flows for the three and six months ended June 30, 2014, as applicable, is as follows:

 

Three months ended June 30, 2014         Previously  
Financial Statement   Line Item   Corrected     Stated  
Income statement   Revenue     1,426,808       1,454,214  
Income statement   Cost of Sales   $ 730,140     $ 540,048  
Income statement   Operating expenses     896,529       967,070  
Income statement   Loss from operations   $ (199,861 )   $ (52,904 )
Income statement   Loss before income taxes   $ (199,638 )   $ (52,681 )
Income statement   Net loss   $ (199,638 )   $ (52,681 )

  

Six months ended June 30, 2014         Previously  
Financial Statement   Line Item   Corrected     Stated  
Income statement   Revenue     2,716,236       2,771,560  
Income statement   Cost of Sales   $ 1,291,551     $ 1,038,858  
Income statement   Operating expenses     2,386,747       2,439,028  
Income statement   Loss from operations   $ (962,062 )   $ (706,326 )
Income statement   Loss before income taxes   $ (961,733 )   $ (705,996 )
Income statement   Net loss   $ (961,733 )   $ (705,996 )
Statement of cash flows   Net loss   $ (961,733 )   $ (705,996 )
Statement of cash flows   Stock and options issued for services   $ 627,344     $ 654,634  
Statement of cash flows   Increase in accounts payable   $ 203,714     $ 173,889  
Statement of cash flows   Decrease in revenue share payable   $ (311,776 )   $ (686,760 )
Statement of cash flows   Increase in deferred revenue   $ 19,651     $ 38,656  
XML 29 FilingSummary.xml IDEA: XBRL DOCUMENT 3.2.0.727 html 31 111 1 false 11 0 false 4 false false R1.htm 001 - Document - Document and Entity Information Sheet http://OPRX/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://OPRX/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://OPRX/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://OPRX/role/CondensedConsolidatedStatementsOfOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://OPRX/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 006 - Disclosure - Nature of Business and Basis of Presentation Sheet http://OPRX/role/NatureOfBusinessAndBasisOfPresentation Nature of Business and Basis of Presentation Notes 6 false false R7.htm 007 - Disclosure - Stockholders Equity Sheet http://OPRX/role/StockholdersEquity Stockholders Equity Notes 7 false false R8.htm 008 - Disclosure - Share Based Payments - Options Sheet http://OPRX/role/ShareBasedPaymentsOptions Share Based Payments - Options Notes 8 false false R9.htm 009 - Disclosure - Commitments and Contingencies Sheet http://OPRX/role/CommitmentsAndContingencies Commitments and Contingencies Notes 9 false false R10.htm 010 - Disclosure - Restatement Sheet http://OPRX/role/Restatement Restatement Notes 10 false false R11.htm 011 - Disclosure - Restatement (Tables) Sheet http://OPRX/role/RestatementTables Restatement (Tables) Tables http://OPRX/role/Restatement 11 false false R12.htm 012 - Disclosure - Stockholders Equity (Details) Sheet http://OPRX/role/StockholdersEquityDetails Stockholders Equity (Details) Details http://OPRX/role/StockholdersEquity 12 false false R13.htm 013 - Disclosure - Share Based Payments - Options (Details) Sheet http://OPRX/role/Sharebasedpaymentsoptionsdetails Share Based Payments - Options (Details) Details http://OPRX/role/ShareBasedPaymentsOptions 13 false false R14.htm 014 - Disclosure - Commitments and Contingencies (Details) Sheet http://OPRX/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://OPRX/role/CommitmentsAndContingencies 14 false false R15.htm 015 - Disclosure - Restatement (Details) Sheet http://OPRX/role/RestatementDetails Restatement (Details) Details http://OPRX/role/RestatementTables 15 false false All Reports Book All Reports In ''Condensed Consolidated Balance Sheets (Unaudited)'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''Condensed Consolidated Statements of Cash Flows (Unaudited)'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression. oprx-20150630.xml oprx-20150630_cal.xml oprx-20150630_def.xml oprx-20150630_lab.xml oprx-20150630_pre.xml oprx-20150630.xsd true true ZIP 30 0001213900-15-005930-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-15-005930-xbrl.zip M4$L#!!0````(`&B!"T<6E""ENBX``+KR`0`1`!P`;W!R>"TR,#$U,#8S,"YX M;6Q55`D``^-6RE7C5LI5=7@+``$$)0X```0Y`0``[%WY4^/&MOX]5?D?=+E5 M]_Z"L?8%AKGE89F0S``!)DN]]XH24MONC"PIW1+@O*KWM[_3+_*>*?V7;'<5I:O* MBB')YKXB[QNZU/O\/U*G4U3UP:50#93A%:A[RC2-/SF.O'2$PD3Z#%#Z&/(^ MX&3(6CSQ<1(1Z9>\386WJ;*J?D5^B*COCG>E7CI(:2(IZJ[$42CJON;LRRJ@ MR!MZO",!WF=_2Z"!D.Y',7D\W!DF2;S?[5Y<7OW&\%[%<9PN3YUDI;@N M(U2J='_[_.G:&Z*1V\$A3=S0JV#!2[#/YLI-S3A:H%N.*26JT:F5:3(JL7I6%"QM6\%'E[@^B^FR>R M3M8ZLM+1E$FQE!!P@47E\E164*\6]!&N+P,)-=G1HS>LS\]2N/55"^#P'M&D MODB65B--Z&*/UI?A2:R(4BU"L5=?`!+JLB MAWE"C>B0PHR!UI;A*36%'H,E]OO;IY)3I0E9F-7I0NH.HPSFAON4.]@5ZDO< M+?==XI$H0,N=MQN3*$8DP8"S1!.\`H;^<(?B41Q,G@T)ZA_N,$;J%"2T]TC] MG6Y!GT=1F*#'1+I&7L)8L$)J7IZ(_<.=/.-MC]Y>]&\UY?88>;?,2FYD^3;[ M_^:B]OG.M$+@89R,I[]CGST!5B825T=5^J+WC\Y^VGDO`R_INJUKRKON;&%6 M8;>^!5`6COQ2BYR?$GC`+5Q1H9NGI:>IQ9-I^6Y%)RLJZ4N=2]Y?2)'OV9`F5[F*:*\'75OCU%=_/F4/?\Y1(B*$GMJ':3 M3O,ZM31O?>JZUE=5K%CK`]+Y[)):,II_WAL0A)CW<1*"@3\EF`44ERGQAA!/ M3-)?-C&QH&:_(LO.>_[L28G:&'NT9N.*U7N[?NBY#%POT]L`_J(ONZ>?&()X MI]<*]-;1MSRM<.=EZ'5-R=[ M(='OBS:'FX/\`N;T M-W"9DAAM1/7-=&II;2@-ZM>&YIY?IW<4_9F"`"?W\-?-.,ZW':K/,QW\/2>! M"U10VJBHT\42,WG%T\]Y5K?6976KP3/G"LRNTL&\:=<]?]&L;G>43:?U[+\G M%?5J=W)G-Y*V84KVMM>7$,^]ZL6>?__=V?\I_WWZR^4/Z!$=&Z9E_WZ%_L3O MSX9?T?W)5TP>'ZQWGJ[KGF$8WLW_#M]_/-2-,^OPHP+_&HK]X]F^Q1,+]$5:\3NKHZ;& M+]?'<]7E;Y7N0]KZM=V"'F^O&91)O7R41.]+F<_9ZZ0NS#,V;'JN/'MXC,)H M!#Q84^VJ"JI4T:VB7RYYG)8$KC;+DI[2(S.DDX!3Z,IG^CH-W($@`'TWH"AKNU)]T>81?^TX.<74]9Y*P@;EDAC,-17%5G7M77_[BX_@8)B$4MZ7HTG`\`V!# M;,)H>55L%\D0D$-=O-=:$J-Y2YX/C&C@"4`LS.TM5;&U; MU%JL ML![+UH"%Q5:VH:R(EQ^5N$+W*$P17X'+>Z1%]2J&K%HF`'X"RY9PA3&*XLB. M8ZP$=W*:#_41//3SW&TJERUMEARO'LEV6(6MXFFF6IX_/HWUF?A`5VQ++0V% MRZG@>3A`52U'U5<&65J(;VT!6E5ML[3B,@MA4WCB-.@8\FKP+DENJHTK\)'B M_1`'ASL)<'IV`^Z&(+90TQ(0O[J$[5337NA?X<$P67&G2>#BLZ&I3FF:L0R0 M".#"K&U3X#W?Q^R8@AMU,(V=-1RN=$4`$["-J& M\7544U'U"ORG@8D30U0/@!B:HRGE_:;UQ.!&/HP"'Q':J!%7%V9-19;MTFK^ M/(S-00I;/;9@KJ;*JX(LQ9PPC#V/7N>6^9X")4J`QI8&UQ&@%+5>NN2"7"?, MZ'EP>(D(G[8VT@FETZ+"NU4?4B?`+%V;A+FA67`LRY#S/[52S,(2@'ZS3F@>_1FE:8MZY[-?K7S<9`&B+4$+5??T#-\V MH!N=$VZN[D5G#S>$W[;B%\"O+@N\R$%@-8ABA6I\*-A6J&<;$)0Y1ET.3(P( M0KU%M`A-#PTKK^JU0_IKPFF%SIO!U)B>\CV+^K,#:]^+O/R\AVK:LEV>[&9- M-P9G@QM-EPM@Z*JB;R'`VA?=+E\D5$Q5,UN$(UB?JF4IABD+,XBM3V#(AFY8 MPO2Y[2:CXFBR\H1VCB*:7/0_1I%/KV%FW;P36X!)K\QA*@":QB;8`@U=EG5; MF#1"W5M1'<4PE&<#)YH\9VI?\/45[3JCR2B]))$_05KQ$*]S71, MTRSIK-3X.IC$VJ6NZJ9M;`U**'?;JE8Y/2)$4=N.)P:$"^6##0M`7<3LS72( M__*W3%H(Q6S'--32%'T.0O/X!-.+8UJR)0N52&RPIMFF57YMYQD`B@[?=,V1 M5;M!*]KZ=*%L&F*M7"Q!`&NIYMH`ST(O&J%/P"7-$T5'<1S;5&H@3E&T`5*P MZ7:`_61=N%1"&:/CF*I0Y1U=(YIGH0&\(4ZF]:N;^%PA1JFEJ9MQK4 MYK9G`J9FEWVV->E>LU+%!Z:FK7SSO2`ZD%8L37M3ZK,'_@9PS#??#<(G*JIJ M?/-*%3VQLG7UI5@J5)<''Q]0B)K:=EAR0F`=&-L2MR`8V_I8(]H0"N,<)6VO M`U;"PTK[S0)K.,3:0I)FPY06@34]U`NS%M'#I3`=BQYR%@([1C&!DKRW8%#I MC=@]JW_Q7UO8^U4,N[SCLP2,.,Q;;\,ZFF:MC'GZ]B"[Z1J&]NP,XVE$KA&Y MQUX;FX6F:FGLNK2GL;2(6#!'F(9N:NW*N/7=K0K?CUD-<2E>`+U1=(RR?\_" M^C>L-G"RNXLN+8RP2H`A(,?MNW M*H']-5'@9ZY6:N$,AJQ9BKZ*\=2\.-X.?M&'[BS-MIUGE'CKL,A6UL;/^7D^ M9\T%2,V;G*[HQN2:A)4P/8,$HJ-_TS8M=JS[&87>^NRU8IGFNA(LM=*9F\U: M&/(5M?)BT2JH&I!B^QF;*2\=+]>58N:RKA8F38YI*,LDF$'4/GS!!*#9IF$^ MH\!;7W`$%KGREF#`[I89+=7=5\KSBJJ1;S MWN58Q$'>-NPW%&M+Q+^B.XH3\*%[%$3\DOHV5JL<4S$7`9]')!C]UO>?\PN. MU@#/O\[XA&=D6TUM$Y&J:+;VM-O6@%N!B#83:=NX1+?4\IV0FTD$V3V$?+XA MR%:1W-!#%_W2A0DM.$G-&^A/@!(M@9"-L>FJ'%^..TX):#W[]AF_QV"R2,>Z MJ8VW]V3=,2NWT:V`JPE!A&X[UG?WS`T2_#<$*?S77N@7-T2VP#3F:M:\*N)6 M91>]05Q'2/EGG]OE?]5R#'D%_J\!UYA(0I5=_^FSS&EGIP\MJ%O7%-VH?#IE M=7@-BK7M1IYC.[(`J8HC.>PBU?8/L:S5=C,G5Q!]'M'7;5ZH]!=DX(;Y/B\T M1Z,`^\4>,+`V!=OAOU[T`5W(U!-_>(N`.6%4,E,8'9!$:) M2\9E5%`NSH(HAL-'T'&^1-U[=N.PQ'].8[;:"ZI*ACB4XN&88F#$,$N-LR4? M*H&>I#N7B1,';L)ZC>Z"&%Z0\NNL3@*0@$0A]J0?,CFOD`>=E-62+QQ)E]`0 M#/$@-5`YL&XP!D1]=@FRY#)M@B%]1?Q3TJR4ZX.`":;9=5F93I,AB=+!D$L, MK$S3$6CD(5LAV96F/;4'!7:YVO./4DM#:&'D)L#K>6,U74<+79%*0SXF(!U7 M9:&=29%=Z1J<*4"?C_YG"/H\ZL#-ES0?E8;(A/^MPY` M_XA^3:)X[XVLWJB],6J?XX`9P@9QDSP#\S>)&R]($+J452=$GI'A/-EZ0S<, M44"AIXDTBJ`_4)_=D`_H`\:*HU$:E=A$DN=D$W(@%'#4.X1"1@2QRP(:"`?3S+?`1R'2\!D5I(0M7"8% M)Y&TX`^"!NP[$YS+L@A`RC\5B_,<)X_,Y08\>AH!:4'6S.F'C.EPR*@.2G*N MXF+MLI@'Z()U9"9FB!CS\&@TX@,["P#[+B;@L5%*2KKA'Z?EH13D2H.$@XHF M[UOM6P'O\[#*Y1GJE9-E+E1IHW"Y:S)T$XDEOU'9&Y4)UM81S+QS@Y\\*`(/]#"/A*:.#)[BLS/(/IN"1",,^O.Y9])5^)@"9P;@8<"0 MR.60H,P?:>AQH;-8CR?Q.4Y&E[45%?KA?`,ZC^9TTLMTDIVO8E.>4S8Y4^3. M3Q/*ZH-N(F3%ONQ=[ZU"XF^V_\84XH.>VG%[TT`' MS!L"?'"D20B!.;WX/,)G4ZW,!XM&^U5[(J_8BI@)6NM#"+*B.O*?$26F+1*ULD5S?7!S] M],/%I^.3JVOIY._RA;LCOG2443^O[UK M?4[<6/;?4Y7_@>/K4Y53)=N`$(^]-ZGR8CO7I]9KU]K)5CYM"1A8W0B)U6-M MG[_^=O?,Z(4``0*$=U*5Q(`TZN[IZ>G';UJ^<.(-MJ:WC%R M'W=G>D"M>)9!]`M2^38J1`[RNX1=T(Z#ZR5/T^EIQ&I\.VWIT3-P(_09^NF1 MZ&83((PD/%PCWN(24LDW-E>7:LO-8#QPC5]*I5*VR:CX*0Y2BY=L:JI M/(!5948D\38)<`T,S<1Y8Z0WD5-#*GQ^!/Z\UC*(/NZ79YX66P1N>H3,9-PJ M\UISUB><@&K1U3S'%HON&7@$<4_!QPVDK;'E9+#Q6);2Y2`\)<@CABF$`.2%F)1>DN*'" MJB!;V4)E"P\MYELG%EZT8EM:_.4SB__.V#T_SC_-0K@5H:*1IFNI@@39N/Q! M?7P-3%?3=1W_C:U>?`6ZK)-S1G=HF`NI#37HN#E"2\BZ7WRLA+!`/&MG;3([CL`,3C7U.!$Z`,2Y:SX19 MY=,D9AS$+J:(HPP%:!(+QL*/YK_+'R8H):I^2H<9ASAMZYPL7'CHO4D'&-PQ M;!VRWH3S##,!+!WI#.9=R85_WC-J4W`)I=N=E6PZ'3XO7DX;=T.9(^3,D7+F M\BP"E<<=[IU^"YD?<$0`R7O^,:"4A*0$&ZVV0+4%EBRMSPE/CM#/J(4."U)> M6&I/I"!3V'F1)Y)>)%A8-N7`.H&O2[B3".*="E`'V9<_+1BCUA?!]YV))KIV M$U+P9T;0N%&2OH0'*K:<&,<7N[`0YDFB$V_P%#%J03U7YE-ZY#3 M1*#>&J\:,*LHUONL05!JM071(L48U'4U>]7[Y M5?P8K_Q$6UW>7KX@!Y%F57@]`GG-.9.!OA!D2B-H4R5E02&!NOY-D&\QD?#L MF8O.AUI^REB5'>S^_%.R[$#PL?D],[)/HYHA]W3AM8@E$OH";$I.F8V0V\BF MC1F=.DB!09*>'KF!3&(UI)<@'R2OTFHM<%KU5G?1$DQDV]1*42NE])425W1X M&!*%$=P3;_0Z6KMN$.SBM?:=.Z&QJLZ%>!AG/+NY_JDO@YI,]GH7_K'RBM7R MV<_R25:-6KE+2-<[F4)W=M5@PH*?VN(AKUAFUG3*1A9/^*"RYU^4+*H``446 M8"H6AT"D0[A'"?KK&P^K75[6'R[_NKC\^/:8NN'_`@^N/JO:G:G\'S]U@ M%![G77G"=4KO+:(,+\?A<]00F4R^/Z01!Y\3MO44,^UUO4@*#D[XTEU^Q4_V80&0#08[]0O$]6A@\>Y<20IQ#'D,F+^!%-<9W'J&22>R%/R"1F.`)NX"E7+^1E M(4RG#TU[&'*NXPCWO6V"&!^'L#.AER).FL/3\(*I.V(V1K3QL9&$W`CZ`#*; M"BI#7U((`J=;$0_A,U*QX&NYQR:*;--K[KBI!DI8A>.GPK!3D4OG59B#!^YW M"Z-6>\-ZVW,KM?OV[^_N;I_XKHQ=9?KW'Y]N/_Y^_;%_>ZWVY&/;DW\^R8C%WLE8.N M@\TF6.WA1:&J=VA0S;R.5#%OG=HCGBHFUS!*Q5G4CPJ]5#NRIS5S8J)#7`,' M<.11;=3T`X>]IOI*90_TT2L4:OWK>TUJ.!W-O:(63\,`;@O!AQ4_75.-VHE_ M!4_\#@('H,#A3:HX!(5P7=0R"GM$)1SJK^0NSTS/3%?'SVMWX.9+@K&"S29P MQ\B#E7,J5L6Q!_P)3R2B%CV_YH/*\$6>DK9^ M7OO#&0D\-**V(C@`^L.>.0PH,2K.?[H#&^>"$RI!5QPC$-?)X7K0L5?*QHD; M1`%_Y-9\E^)1R@3&N;P1G@/U>&T=1&&Q<=Q]84CS0[`RCFR3-YF8MXR.A6>N MQXEG_(1Z2O!TV="5+Q$6I72$7:'D@`IKZF?FZFMTN!L!52$B;.DZ20H.(^<1 M$00M`<2:G]/LE-)DQ8E2FD0Z*^ZQE(&F^_&,/R+77[E%]I4U5M9X)]8X=2QD MA27^<'57^]USPYE6^_"ASUL+7GVJ?60!UA/XEYM:7=^':ZSL,AIX=+QO\(K/ MUJ(G8LT@I-9:+B9GQ@*X%`2VQ&MF#&%<_1'@S^2#HFTCP3+AD>"9Y\0T&063 MK`)<;Z/AXJA:B]I'2JOGBVS70FHB$#"O@Z"1M:VIQ>G0Z+,I_;&0ZCR)WH28 MBF%]ZC>&1@&V@VF$]4$B'3D-RX>1EXOV8S6L^8CLFQA4DZTT!&:+&F]@3XU4 M.Q)*K'E1AF\1S[0!H(GS&:.2$\,Q!*YVV&_9;\B"1,A-FN M3U/L3GD1:X!).\2B\#1?QJ$`2E+.BU!U(9)8?A6V8\KNOQF[3][64N._@:5/ M6OB/(.1_,\]'=SB]$&#@)0M!X$BC=P]?1@9B`,1@93E(^%+<**&M0'()V@H6 MUZ'!K(4F4->0Q".'-H0>::1QAQG;7#&Y,HFD;"- M(5FPV=BFZ%.4,'AY_&QJ!!=90-ZHKE)V<%[8M)56V>Y59ATKJ[>VU4L<&Q=A MGB-Q[)0Q@UC/B0Q8Y)8.37X".=&!B,?0SR[])E8J.(TC#^0JD*@LSWCZ&QM. M+>HP"1[K_X$?.518.;5*=I&AWUQ&],V/)*ID,4,P,\`*?0*WBP`);G06+7M9 M1E\:&H-#@>=,Q>$3-"]:;6A10@H?B-?>L!$V;P3Q>I8/]B$0<#^\`39P&#L* MQZ)>:Y1=PIL]!@8QPM$G6ZTM,F5D]-"3F&!2@+*-`3\1*VR9I'U19X7$&X;6 M*M\G"_^747?*/D'X\?YKSW.]ONMY_/SC,6#TWO[J6(D,,%+(@$_7CT^73]<( M#3B6\I^*AX]450DS1R?'1YGFV-G>DA[OCD\EF5<*S;CY$8?GAK)O+]R4JO,L MPNLA=(Z_;)L?J!=H-TWTO.8_B:8W443&:P9=NV(`/??4J?9]@6AG].R,^3PJ-C_$/3 MEKHS<(/`G?YW\MJ1O%8,A4\+TAHWI/9=RLK"FF+.KW'N^$1:<7.Q/+!`DMR"_+XT861778B)\5&1R28 MXY5H:ZY#`Q-^PGGA"I!J6)40M(>XOG=(SL@SQK\G7ADQI:J]G6 MNO5N91GJ[60Z>ON:CLZZTV&TM.8:'G79#&UMBBA:7=<9VXGI*7=SFANH[_+W M#CZ:-O,/1%0!\9UN-.)2+>U`W-=HU4LGM;2I.2YQ&M@*ME7<`E=AE:_A7::W>T>F>O%O8P M&W^423]VF_`!&[_3$;+XK8K5I78'N]@OC5Y/Z[8;I=/ZKQ]+C$93Z]4WRZBO M)T7E`VR]W@=L[/)NL4AU8+Y4V1/8U9IOZ^6[KC_>FF]W]V$Y572_.:4?68"G M5=0*5RO\6%;X!<$XXL\;H6#R*AQEPYDXTN8L<&?B0O$%-T3BN\H"DO':@?S# MRM'.N-/3(.?716!EA<$Y!`8G3]WW@;%YS,.]%4'8Y!$LY!&M'TY/<<.9,^9F MP)D]$;<7A@O!8,HCK@3TR[YT&9^]'KIE7WIQ2-#*,?.X"1;EB-=Z-9`EA[(= MZ^9VUH:01%S@[YL%?TG80?&I7H$36437:NC(5N0LP$ZL/\XBL`>-U-0ZC;;6 MU-M[)*BWD3CRL0L;B&,!V$**H]/0C/:RHLIV!.TRN;+;1;:>Z2SRT%7@B(V, M=3P+RT+T!?/?T)H]F']C61"^@0X>@I&ZWM6ZQK*T^K-:JEYCHG^^:<\[_TVDVMWFZN_:R\5/,!R._4VYK>7.:-%25?&>L"*ERL-GL0-6YH'5T_7C4V MM%ZO$FI\)/[R9F0L*3!)>::_2WLJ;W&KI+KT` M-/6&-O'N.'J7GN@M6PG-:#<[FMXJ6ARL;$:C;;2TMEXJ&\I,%_5U/&;RUSF* MYE2^?+=N)52C6=>U3N'R=V4UO-'1M6YWV3F)2J0RWIQ^7[%8O].]TZJDY+_H M#?!/.F5L\`5=[\QLC]B8>?AJ#6]AT?(`]JZGM8^_TJ)W@8OU M5V51HYU%9\Z_XW:M=K7)/K>?X@:/3^X#ON_X+V9Z/+,1W:#ZVQZNVZ#"=JK^ M:JJ_6G6YV*N(5'\UU5]-]5=3_=4./7@U4+`'-W2JOYKJK[;P.:J_VIJC[G@Z M5'^U(I;S"$Y@J_YJT9"JOUJIXE3]U:JTS@M0^K;[JQ577-5=37574]W5*(>A MNJNI[FIEB%%U5SN>]:ZZJZG>2R6M>=5=[4`K/M-,6/574VO\#:UQU5]-]5=3 M&)QJ]J12_=4JWG-)]5=3_=54?S757TWU5\O2J?JKJ?YJ^>.H_FH[2J_L=I&M M9SI5?[4#,Z+ZJY4T!<7)4/W55'^U-4RTZJY6MM53W=64J5;=U0Y._IMO]5,1 M)5;]J=ZFTOX8_1^4]KY-[?T16O+,=5?[^2?57VW';*C^:@=2=M5?3?57>\OZ MK?JK[8-\U5_M@&9;]5?;&1<'[Z]6J$U:LJ\:.:^?V(C!/:-[KV_:-AM=A1[H MT`.#^T>/:/S\W,YJ_="'1;6XN5KN]U9@L_OQK0.D6Z/0M"]?+/_+E858$=>[ M8],!\TYJH6/Q1Y'I]4]`9X?6U+3]7T]N/]Z<_-9N&O68Z8(\E,_V#1O,L]WL MYGP?89UN'3_P0IP?8KQOSJS`M!_#VM!7/<6C7']^,QA$%%IKA^\ENK4==;W01G"3(W(__.]'+)S_D^ MEWSJ:%:9CTS/P?G`@;T0SLPBZM8PRB;AWT;BP88BUU,PAP#\]_O:-FW MC&)38J+TR"A\#'%D^)"X]-9Y0FRW25TW5UBZXGH7,4.,/K(AF)_`8OY#Z`V_ M@@>R#K-@"+HZ_9-@=@VF%@@#%X$U$L7*3VS(K.]@+BLFC3\>KS*B:/"S$_5< M6:SF"87ASKR7=Y]-#[X-KE^8-[1\!E["D/'MH32V\Q?N@VT.N3`F\!]?L/S; M@_'7_URLH&S!3,HK2`/*LIQ;S=F7&?.^$#G)V6O"[)TW\VI[:)FMPMFZD\+Y%]`)=M2(PO1'#'7=Z=3 MR_[W4$;[DD)[7R_V!!9"S230:]6:CD8D)MN!PSD4B>W5P MA2YJ9R.*DWQ<3V>V^\K8)V8CP/Z#90XLFVS\7M;KTE!B?DJ;K?1B74G]6H$N MS7YEXMP\AC9S>-0WY_'!?$5#X(OH`6\#`\+P^$2^-[+V M^R^6.OQZ>B]:1DW1F2&%?0\NV@A<3X3*4PS[NX>HS$+[4FO!OM0JQA-.1H%U MM8K67;%;DGH^/;O"Y5CI1G)CT^NTZP65=(54R`^_'(TL_-:T/[O>WW"_V.&6 MN%IY,[G^#)^U88I3<>HB4B):;T+;?KVR[!#@\'4DE MP\!ZG\O_K`6^:"^3#IXC(IMF\F4V9U5V:7_U!=)O(RGH.5KGHIXY[2X@[-8" M81>T2XU.O9V*Y'+I*(72+7<%B#GK&'`7IU0&+:\WKO>',S.M4=\VK2F^#DK\ M08T_<&^YYL>G/C%TA)G\N4`2[)'-/3BQG.G?(`0 MQKB/3A'M?H6=]=J-3K*XL)JH`[#PI>\Q&NX*PGT>2@Z98\+N&_<7D3I6P/D\ MZ]2-7J^]+M-D)\4Q=UK?0KL+A`U;SE)'ATNEIMAM'6^]VVMWEY$D]_I>?.N=8]F_G@1>R$XNRJ:PA*6S M8PI+T/^]RK!L"J]-SX$G^[).OA,;OZRL=%8_KR=,82X]FQ&\G3>RE&!C)P1O MYY\<7,*5(5@LKQUK\1J+:AE!Y6EI2025IX4[D=".")+Y]B?W75P\/S^?OPP\^]SU)A?->EV_ MP)\O\,(3'/IB;FSZ%F^QWN%_X>/_`U!+`P04````"`!H@0M'9.&QN,@'``#` M7```%0`<`&]P-6RE5U>`L` M`00E#@``!#D!``#=7%MOVSH,?C_`_H-/]CHW27NVLQ;KAO1V4*!=@Z3=]C:H M-M,(N%=R(73W7WG[':Z[^6' M@[W]@\ZNT[MT7%=-%&#RZQ9Q<*1@A!^VQD),#]KM^7R^L[AEP0YE=^W=3F>O MO29LK2@/%APGJ.=[:]IN^\?EQ=`;PP2YF'"!B/?`I8;)X^ON[^^WHU\E*<<' M/.*_H!X2D:E*Y7(**=0W=TWFJDMN=]?=Z^XLN-]2-F`T@`&,G&CZ`[&EZO^X$=;76Q7&::M)/90X(5!9)H+*5]"$\<(\:6E[Z%#TQY'@VEL`/P M0`I^&\!7$`9^IV.S'S"]UC%.NS;AU&?F0*](PAV;,) MDBLQ!K922@/$8ZKVYSKE.\-$`G*!9^"?$YF"W&'IYRM)I+=K1"YAE%ILRX5R M3)YVH#*MS8)PO7?1*18HP']4(C*9A@+8D([$'#'0XU3":#=.95J;!>$Z<1J" M%S(LEBX9L@W2+UU7%OTFV+3%^V.ID!5I/(F@W:V7*NN_!S`#$@(P[%,MF-G*;9X&8?5]BY5 M-[;V/_:LAA,8@13.CZ4N7PH%#%;C4J9L#,M[>V`9"NK]&M-`RL55OBB6N@U@ MEKCFF@*=3"B)Q"@MPJ=)M^@XQ4;.E`\R"MJ7F/19[-U&..11-P**7#7MRS*^ M(\:0>BQ#_(&2@%^%0CV950^>-;!HV1J!CUYQ^_:(/=_'*QGZ"/OG)*X4ZI+! M`HY&P%.H[B93DX)$,)(R3HF*4K\$C=46S5')OCQBG?&HHC<0'FE>FD]HF*Q& MQ$3I&*(/Q1"Y=6,T`($P`?\4,2*#))>[M7`21KMIJ0GVM,5_`^9&8&9BA!B[ M?^U97H^V'O)^5REI+V6U8T>E52L-HJ;`4)8H-TW5/$K#++2=:B;[_.:OAW^; M[HT;"OF_>MC`KT974V#1K,]HDBL;[T6[Y\S.M)&Z,=4=3>- MQ(4.W;/,>Y*M=NODF#)[AUCKLMG.-H.J9=P?9%*N7)/::LUBWNFZGW*HM]D-42Q\VKD3B-E76[K7)/86(Q#N:9L!08Z.ADNB M3B2^4D*3.A4'IW*>>F4_)P(8<-4#$34.K&31"%[`L$5_*C5_VJN*=+9OC3^L MD#.IMDR[I(ZA5/,AT3J"$66PHKM&"^"7F%#5R_5(R>0HJ\SX$L28RE]FDB3* MWK20UR?%%OUH"\8NC'>/0Z/ENS4+S*:)`/8]A?@*PBAQ2M)M,[[F"9R-J35Z M@:V!6JH5.]X1$-!O08LXF@%TCJ:FB9FFU/*2A19U-.LLH/,-U5ERAJNMS)(S M=\U;0'562@HA-T104\?8`S':3N+>Y38_06ZPO5 M(Q/*!/X3?=4^.ROF:CAF6H-L]A2C[@'R530R M/^<\!/^,LB&P&?9R5[\!4T,Q,3&'C:<8Y:)G@#BCM4G,N7L#86T MFHG*VS6V4*W-BIX\8%L)V13KJT,U;9KRYA$K$$VU_3]IL3[T][PR3#/&*6\W MVW1C+FA2%4Q3WEWB2WK+W66H^H23+,W%-MJ)HK1_6AW,I0Z MH%`)V33OJX,U8YP8TWV;,"U0?%52?&:U(F^0FL\8H&54%[JF/>]WB&7T+#K; MK-&NPB#;+5!6!#)S4J&"L-!>D"5EYI!WDA56;?E%^4,+52(2,S+'1 MA_^FD'R'6RZU/I$A+J!%"\F8]16!DV>8\@)'_>T9^6J?88*(]\SPGS=([:_M M\`#\Z(&9*CBI5Q=>C1X=CM-%_5)>^[Q5`UO.2S[*3+/))XFZ`FE4"CP)F92[ M#PQ3/SHD=U\@5(IJ:Z4F_(W$JJ*)+.S^RO>RY)'(U3=0;Q557V6>L3Z25WEU M&@_<2'?8E%'M.].8_X;0E:>G]U4:IZ@TS!9=X"GJYCR0--ZP6MXD]8+FR$W? M+'^#U0N:(S?(&(:#PM:43_=OV):7_@=02P,$%`````@`:($+1TV@.(M&"P`` M(8P``!4`'`!O<')X+3(P,34P-C,P7V1E9BYX;6Q55`D``^-6RE7C5LI5=7@+ M``$$)0X```0Y`0``[5UM<^*V%OY^9^Y_X-*O)6#(;C>9YG8())W,)"5#LB_? M-,86H+NV124[@?[Z*PEL7FQ9(LBQO>UT9DO@2#K/.4=OC^6C7W];^E[C!1** M<'#5M,XZS08,'.RB8';5_/Q\V_K4_.V___[7K_]IM;Y=C^\;0^Q$/@S"Q@.3 MF2+H-EY1.&_<_-6Z<5&(2>/+NJZ&==8[ZYQU&^SC5^@&D+KVZN=&/YI%-&Q8 MW9\;W8[U@7VX[%U<=KJ-_D.CU>(->2CX/K$I;##%`GK5G(?AXK+=?GU]/5M. MB'>&R:S=[71Z[5BPN9:\7%*T)_W:BV6M]K>'^R=G#GV[A0(:VH&S+<6KR2IG M75Q=+:F;Z,5DW#!I M9K>"#^WUCTUN+ILX!'MP#*>-S!5 MDR)_X<'XNSF!4RG$N'VN^0>N\T^\MO8)VK#/,.!1TW+AU(Z\T*!NZ;H-:8I] M&P7%*+JN^B0]114M'_H32$PJN5?O*1K.F3+$B2:PE0`WJ&=6[:=H&^"P;[3+ M;"H4.L4*J2K'"[)L\6&S\['7$;4\A=CY/L>>RP;=FS\C%*Z&,+211YN-0VBC MQ_&WML`B+W2B-@/L^RCDLP/M!^X`!R&;1=AL@B#54$NC](GZC2$;^T/(F]#0 M)T-:M,^&$10@/@G#U'.4!,@-C9J]3C4PXFF7$F8FQJ MTXD(M(BV9K:]:'/0;>B%-/Y&F*'5L39SS$^;K\'`LRD=384^#`R\8W!IW)!G M3Z`GF@>Y\J"SMLL[ZLWG/:.0 MM[2MALFR;QG&[.:?[(:VK"!">OA5TV&(J*0#TC\5YM;04P&EPX;X]B0<>.)!MDH!F?\P_9W#S,- MKYHAB>"[][$TZB7*&QLRY4&WB$C*63JD(ZL>H9(=YC*;2B.K]"#A1AQ#3X"C M<[1XQC=L'F<3W-YJ62=\\FL"O2("2[:Z3T>5U#.:CE2B^\?%H`>&NSNVPER] MO^5\?U\G,`WX/+WHY=^`1\]VQ%#5G_$1[&%O6[CC*KDP."_$"UG;5`T/J+O/ MOF]R<15G]F?V*]-[BAQ(\FV>E@0?:F_P3%"QM2WSYF9[1LKZD1V$^<8^E`,? M:V_J#$BQH;OF#?T%.4@QB.R(@%]J;]Y]-+%E>Z5/SJJQ)5,.?*JS/V208J>< ME^Z4(=L6.*QNI5?V!<'%C^"6%*;8+Q\*F%Y?\28*%(-12A!8G3H;6PXJMO9' M\];NS]AL+I9/V41`6@A8A1!)/_SV/]N2!2Z[@L,6`5PNZH-^$2^^09 M<:MQ<:O]-UNQY'WN*>9\A[WK$W0BPNP!Z6-$G#GKBHD:^:.^LB"PBF&1\F[3)WFI(IRN67>9G`4+<9MR*YHI#ZPRB;'\ M_J'EI"V,RCCF%@5VX"#;NPO85!#E[*<4)8!5"*WVMYDC<\Q:'7[OF5F0,FC< M+D^0O""'66TTS="=EXQ#)\EX?6V7&S+5*=Y1&VW/A66[;$0/= M8HCU8GUS`*#`QQ4B#-8M)<[':./\@>U`'A;2<4VG,.B6Q@P?[X'C8%6(`+3Y M?DXH_D?$+<+^V`FBNT#,S0SSSAXTJ^<<40WHEG&,[=2>=23`ZFQ?=S3G!Y00 M4TMLSB%#>''NUA=#^B6<7+.G(_U$)HX[B(97K_:G+@);Y:0.(C"1X(< MN)Y>96.JO`3HED$AGC*0YF,Q<9K%>-^*=12(];K17A'0+>.$GKD>DP)CXA2, M^=6?MIMD94"WC)-[!M>%*32QHWXQ/XH-X23D6P5?U'B/@UD(B<^_[?LX"J3[ M7E4YT"V#KCAE1--!%#OB4Q&GLGT?49Z!P:A/ MTJ.5:4G0JQ%/D(,AL6]%^+=^X,;J'>RHV2KPB^U%;%6X>>!X**\BYDZH&O1J MQ$F8!)V$1P4H"VX(L8I1K=^$$.C5D6[84S\Q?OEL`E^Q;)^Y/+,U3(X3TL*@ M5T->(!M&XI3R7W:Y\1<>7D$H7E^`[CVR)\@3)U;52PEE6="K$7MP%*K$@Q4@ M$E0/5<0(?01SD!Z_:A=%5C8#U3 M&`T"997@O$;\C@FP21@4\8ZKZZ)U75\Q^<[TVAS)D]%M,GEP7B,:1HDDL7@! M64)N(\];#9$7L5V0]-B:1!*S]YKIETNAJ)@]^YJ]VS^6Q/CWN-Y+KR M0B5DV$TIH\IJFUV@A$RRN6:4#!12Y>N=PM7<^_CEIW&5NTBR#)4BJ<[)<*.O M5I><$#7'WMH.JE[R4\,NJLB;;29]5;V7U,R\^EYFNM/.XN?4JYN,?D<+&SD#CP;^6)!O?[@_B^B M`M;-DA,W<`SYFXPP_EEVIM)L`Z5D:CW>K9)5IBD35&:HO8XHZPV\@_@3%`@N M+S%-N/<>0X)=?2K@[966DFC65'2B M%:!6%)[)=F<&CLHL2S9;TB11QU,\2E&NK3HMMT;QLNF6+//+'H)HH?E[.:\B M1(QI+U:0C'%@8!.$'PE\03BBWBK>TZAY&4714BD:W5XEFPN5T"KCP3%\@4&4 MFW(F%BF5J#ER.;*C7KJ8`\E2;[`YTO)IU:N3DF2T M$-NK8+8A8/*B/B5;ZCTW1SHA2_GJY`U)M+L+'.S#^_SC=1G2I5YQ\U97[*E? MG>MLMFK=,JAK.B+B2?(6&RJ"7L,I)G`M]VPO(7U``28H7-VQ/1N!E/,A^[6L M#YH\P'".V2\O<,UZYCGY';4H]2*>(X/G?PG?\!0:VS8DROWUI\C/9O2 MO#I)3=1!=U)'+NC:H+(ZX.[=/07D.1&*CD1UF[>K;S%99S*5'[C-+534O3X% MI/94P3"1UL18GV&;?0J'5UFVG(MLWMYCU&A,Y$F1 M=)AT^YN]X/K%=ZDW]`L7='U-`1U(&XZ1%"A%]:0X^_]&]Z-ZTD'9HNZ1>:>> ME(%&E5PEX\E@F["TR,#$U,#8S,%]L86(N>&UL550)``/C5LI5XU;*575X"P`!!"4. M```$.0$``-5=;7/;.)+^?E7W'W#9JYJD2D[L))--IG;G2K;E1#.RI)7D9*92 M6U,T"=OEP&ZQW'B M1^'?7YR\/GZ!<.A&GA_>_OW%U>+BZ..+__OYO__K;_]S=/3;Z6R$SB-WO<1A MBBY)FQL?>^C!3^_0X#]'`\]/HQA]S?I")Z_?O3Y^_1:1C]^P%^+$H?XF.CNB#`C_\\]I),"(#"Y._O[A+T]5/ M;]X\/#R\?KR.@]=1?/OF[?'QNS=%PQ=9RY\>$W^G]<.[HNW)F]\N1W/W#B^= M(S],4B=TMU2TFSJZDT^?/KUAOY*FB?]3PNA'D>ND;*JDXT+<%O2OHZ+9$?WJ MZ.3MT;N3UX^)]X+.01P%>(9O$'O\3^G3"O_]1>(O5P$=-OON+L8W]6,(XO@- MI7\3XELGQ1[M_Q/M_^0#[?\O^=34;F6LL6QIM5Q:D_D=@:IIJ:?1^3Y.R/#CRD./>P58Z.4`FW).F9:EBG_R-WI M+*#J-HIW<4:K^/&(6H_C#^^.&1+ZS1^%9>J'1.Q3/WT:AC=1O&3JNG^=I+'C MID5';.BL^S^^7'Q\^\O)+V\_?_KP[@_UCM[\7,S`SH!CG$3KV,5:Z+.7L#LR MY_J/7[XR@A1B?)OV0@V M@/KQ[DMP8K<8'?DH092W>.-&Q,BNTJ,=<#=QM&PTZ\6XHD8S]$:9U7*8#&*" MW=>WT?T;#_L$ZLE[^H&RX?NCXY/<>/^%?/5']MP9OO7IX\)T["QQ'=^]__'# M+Q_?TW\^?/KUEY/WGXX__L&E[X+=/OSUX^CX`_WGX\GEZ-V'D[?'_`%5N2QG MK&T[1!N",)?6U.[SE-8T=,%*9X2?8R<8$JWZ^"M^DNDP/F'7.DL$@<,]>4/$ M6B+2%%PY2=]#K3*2O81#<4R?*#^/*L"+P+G5T3J[A)#J9A_"/J=L?D>T@57Z MI7;VI8JE;NH/Q1]GZSBF3_(3UPE^QTY,5DCGQ.=442I<6@B](@"RSS!Y4Y2U M1;0Q\8(\1)OOLT]C`/_6Z4CZV9>JB)KIOW0G+$)(*FJQWI""-W(@\!EDJPA5RF":!3A M>^"J$]%+.#3';'78!?DF,5$K^UW8H&&JL+A\5+9,K+&5FH?SGI254/U+ZH:[ M,K[F\A=/B*K$D'JI#HJ,IW(5!<=5ZE.KJJ-X+^6PT80+/\#Q&=&*MU%<&TL0 M!T]VR>'#4OMP.'$%U@P5[:Q22X+7HAB3JGLG!PY)10USU9 MIW1?E6X;:\2G1+T`!JO$X'B1*T:%&%D/982H1&F%TE)_>[*HEOS5Z7+@C9-< M,X3KY.C6<5:4#7]\@X,T*;YAFSXE?LR__F.>$MZG&G5R<^&'3NCZ1*U&B2_; M^:F32*T^H=2?)O!]CMV0H>@&;0A108F^%[3_M$91FKQJH?8T>,_=,70_27": MJ&Y:SP>+.;@.%S-(K[_?:=<[^;2`I(M%9>^N,A)#7E*R"B-&ZDYDS)[GKAQ[]9_#OM7_O M!&0T23\]<^+XB3A:7YU@+0U-ZG4&9314H58XD1"P8RWL0XFTAYP4%=2(D5MA M:1H#=>D'O"5M'=6JBAG,8NU\407+QI;Y\;H\"8 M:MZ,G"N[$[=IC%>.[PT>5SA,L$#.ZG11/3&4T\*#LL]LM>VL\$8T$2"<-83? M@5'B)J$Q$K$2T+*XT7(8WKSL01$N?UOG_K1T@Z7=<;,;+N@Y+7G-E[H`UB`B M_G?Z-"53S@[M$[]P1<.QQ$*I&P5!'W"V00BLJF#YS2VQ%$9XV)(5%VU[**S" M`;0=:5E:M3C10V&IA!/RE M9&?XS-6=C%SXH9_BD7^/O6&8DJGWR5HH&Y.&O9'T`F5QI.#VV2TC.&(4:$N2 M,R!;ZUMA>K2!39V4NFJQ?WM'<=AD<]0X4&AUE-BORTV*E4\<9/\_V#N+EJMU MBN-Y=),^.#'FR)1(RTAZ@[9&4K#5L/V&`!44J""!$;%6\7W#U\C#]SB(F..# MW"B!%+D&K*5CRY2XM,/S3]A=QW[Z=(Y7].2*JAW;)X,R7-7A5PXL[;:PPBJI MCYH(2.VPP8P0AU^$5J>>64"6-PV6->`&9!>&8!EC48!,/.8L//98?]T.!HNAH,Y._DR7TS. M?OTR&9T/9O,?V!&8Q>_6V0Q=!EY4E(FM,FYS3A.9.RF;=GQN;.D_T2,TB=CS1<1:5DSYU74$;.C%,WKFJ MFM96F3,S5&B5-4='**44UEDM!9[4.C'&9T@P.9OA@&5*=>*2$E!>)ZGT!;:* M4@/*9C]8&!7K8TXQW-&VX7LUC%X>3X8EJ2X?1#]V]N8 MY15';G$=[IY>M$%.0N__IW<873L!K8E`<&*<(H^VS7\)MM*!;J*8V-R:&6$E M(/P012%&3S3WTTO2DE*'-/5R@.@I.0*./-A]R;Z<,:8?4-;<.G/2TEZ;1;MKI61I>BD[]NG`LG-4`53VG';2W[%6/31, M$K+";M^NE"HKM09@&A=^5D*;61$K59_W))OW_WU]?'Q"`Z+9$J^'?CP^[AUG M_V5KM@0YZ_0NBNG9U1YZ^[;WZ?VGWL>33^RB%OGSXX>_]MZ1/_/&/GN#[,=H MF^&O1WS19(7=U+_'@3VA5YZ M7)JQFU4:.7^5^H#R;B3`*E=>!,VM\!HT\3"60@\YD37&7(7=A(9=@=J;9D*V:_!ABG30?GFB=(6Z0X!R*;HWI#KM>KT0%N&ZBM@];':L[VI,UQ+ M-A#K&)B_95C#O=UO$M*;JSA,V&O)`F2F&X4U/4$;)"%([@Y;N34G/&K%GJ$> M*K;N0FZ)ICU0NX7+K0(%;G'E@J:U-\J5LNY4QPRGCA]B;^#$(?&BD[Y+5/N: MG4LDH_1=];OG"CU!+0>50%9/"LF(K%@:&F$K-4)>VV`4%4B78,"6O.KB)5SX M*LL6Y/9R\VUEA!?;MR8BI!R\YA/-,]Y89[ MR=9=N#8XJ%3?CP7'EG@`!8>8V'[`@3SV1L>85+%D>0BLO2IMQ$HJQDJ1'T$. M:Q"U/(E9@3"/;;E,<K:+I4NH8V9&NSZTP="*JL6T$U0YDO.S<:E=49. M@W/5LIPILRV(=&9U)_N;K6*#4U65+BPX8%4#2R!U^ZVM6&6:H"E.!U1.`%AC M[A183_6@$8?O`,4H.V_3P+#M=&.1,=N#)SZVF#4^V.FCEBR7&J1=>?)K$=ED MLNKX4-=,U3`AH$P9G(^QJB*V(C`UD;+MD(P9J%VA$AS,L\=*Z1Z;L:JR]^ZY MM[;68XJ]0ELQ9?#<(Y?/9V'6'&NA<.Q=G^DQL\&Y4&M6:;O#,EVH27H!K/HF M!B<61RM7;.:8[%^WJ3&CK%:UL,I^CR_[L\W!LP1D[\\&"F!E>JMZTLR*JF-O81M<07 ML\DERJ5B,FY1H!NX.XK#)U\C*E-%&NLHM*&@H=K@A^.SR>4`O:3OX)7L)8#Y M10)1%OI'?#GNN"YM]OQ^Z!7:T#0T*^D-W(.2@:TM:,LEL,LST<:V^#*8H4+" M\C:\ANO&5E ME[.V%C@$^B#\EH?>X#IY6X,',Z-B>1!:4J$P="?1XRB,=FVZ9IA?WA&T"15! MK&S]E-KF0DX,3=:\8F@.[(.VA2F[YZIF.]M2`POKD(%[!5))4W((9&+6]=$( MN@*X(!-P%H5D2&LRJLEFS7:*;Z(89^T6SB-.+OTPBOWTJ:3[=GO)+B!?XO0N M(K_ M*Y0H'J@O=2FXLG!@;=W-O'P;##]_60S.4?_K8/9Y@,97 MEZ>#&9I<9&>`YVARM9@O^N/SX?BS5?[=@::@_WF@@!S<$6RH-Y0G["3IV`ED32A5U@_IT=Y!RCK@5:5 MS_HHYX/)%:8%3FM3V*?]^?#,"A>V%20L!>GY<'1%E)@UGIB15(H+11F()+@6 MRI6ETJUDD<+7[1[:<].?CH:Z*>_9(B>M^11`RG2;S*CC=9@Q.MR*3;0DJ].+ M7'HH'T(`2+Z(@EL>-812"6&@*5GV,,_?"L=`$PH[O,U%`.8$R(1%:.\ED@(< MI&DE!`-NIGG0E,,G%ME;52Q2G]F^N(;J&@;<,Q"*BGG4`5SD<_?#U,@7Y+;8 M^"T<%4&'<:V;X;!M.2QA*"U#N,M-75:'RA/;3&[.G.3N(H@>C'GE`(Q$IO3':F\2\6:2](7V>F9`CJ(:1S=^Q[V3I^N$NP-P\T% MM+Z;^O=9$1O-99M!SX"G$_0GH68W6K,3*Y9-K6`_Z\^_H(O1Y-ON?=CQ9]0_ M6PR_LK)//UEC6'^"=#?U%U((^$)=K M/\`8H.W?@2:V4N/S`(^Q:BW7_3QF":[R!Z&P.+Q%OJ6?7>J:K/)GH>LG]')- M'H?\\!7:7F!R-H^$T7&=2YN.MW-`<>^RLOR*\(C/SF3W0Z^_C.+4_T]M-C:> MT1%U`>7WB&%5*Y1S6UOAR9BC82>:'`$>,%=%@?&$/HF0#-9RD#6ED5&.4%>;PL1$E306&%O&T"CLA+E\+*, M[>RD.:Y+W7Q73A^7F&%1B6RHI@94N0D:.4\L8S,9;#$TEG"I MLC#QHW3C,DT?`W@CM^'TU-S,:M*C%4Y/^[-R=D?^HM4X0GLB-BV)ANPR9@MR M`:DN^JX;K.#6!V#\DK!;2J!X.%G@T24?GJ%ZM554XD)IU&N.5XWN"G$UJ5FNO M'WMQ1U+F)8[C-[&8?36,=TOITE1B`-"MZ+(7UEZ%.Y;[3ZP MWNUK[=RUU->EM?*PSR^LM^1/0&6*D31:L@KRE'G)M&"BR360VIG M]TP.ZEP"Q*)8$4>N-(-%]4)EXQ4%7:.NT3.T:=>:!/.K"5:9^6:8!PO$KB6P M9*7G@W-T^CMZ>34G'X;C5[4W%&PJ/``,'=P5TA=ZM;S^NA(/KN:R',Z'N(DE MZMFRFUCB25!4=X).K'!&6L&^?Q-K./XZF#^WFU@*/&]R$TO.\-U)^S0[39HL MHK[[[[4?8S)8HH32IREYG32K.\WCOJ)-=)T:C9ZAG1JM2:CLV>;$]*I.3HX* M^AYB/?38J=9-)Q9MES5#3L9Y1Y=5T0V]F\3H&%+DD(>^C!3^_8!HU#^Z))VZ.0R5Z..F:=6K`I8_`NTRT` M<`](0\SXVR]*,M:F&OB&KPE+X'-\CX-(RSM1[@_TLI<:8!4MD1.B$J4%[D<# MD*5?D1LE$)JO940F:O`A?ZW$%?'6+ON63H9%M[_,YJ)@5_8_3_:J82]_:6@E M^14P=95D8R2H_0C0,XC\-(KXV%$KI@'2(K:;AW-K`SS@WHTY)[<4U[%%9B_\ MT`G=5O+F&#P!.KYC-"F*LBWHY#EL8NG-P7Y4]V(X[H_/;(CJMLRQ+>SER`6B MPRAO'+D8>ZPP)[U@3@:&)S=GT7(9A>SRN:H!EW<$9;=5(%:OVV0T667C@HJE M@F1TB!%:L2EC`J\,R,T`)>T":G`[ZI"`P/P,93D3NA>J0M8T90Y+-7'.SD)/ MV>'GKS3GR"8!!55J6F$5Y4[A$^FH0:_/4,):H8P89=2(D9>S[-`>+(I,-`#] M=9.()JO=DB=E<1(B@F%"+%Y6(IIE:6%A#/JAO'1/4EH#AGQB-M"B$$6#2WAW#.AF\.KHL<\BQ?][H$S$98Y+;K28^#1:(J. MC4&4PP5/GE'0I#Y8DJ73+\A9SMJK(F?MIA,$%A$]'/2Z4Z]U@1)KW`5SMF\Y M/M*YH--Q$45#_Z$>W;T3T#V8S*_9OX"@ZB9H]0GE%&@"Y]1@FPWZ\P%Z>3[( M/KVB^P",]6F))O9A\(^KX=?^:#!>M'^JW<3PMXF[4[#ZVSM04,'\&!-A%GHM M!I+<84F?]6H5L/(M3E"4;QF&9.V]S)(LFU;W4>P6VCM1AU\)XJA16K5YTP#M MU70Z&EP20>V/T&;[A@CTQ61VV5\,)V/[]FLT65NMV)$67W=Y"3DEBYXDG3J^ MN=W^;(7EEXR7+598[C4:OO3SQM;8MCHVD5R?K?!(IS?K MHR5>.(\XX?&U)/W`#CFTK:G"J;E@7FYAE>V0CWZ?]VE[E%("ZTP#A[-4DU#4 ML%5W4C&);YTP+WIQ%H5)%/A>41!C2KBBV-B9W.1+8R?8UB?4O6O9SL.@C$M; M4U59U#CI.F9!VM-UXH"=-5GG64_E.@JN08'DML.JYZS\PBZ3L(>%5B-\_W!UYZ[N8L"CT@?RH]> M6&B=ZU^"N$!XW1OHLB[X=F*SH8RC%+=@"-4[AK9P.E-0X\669P#(P.W&-K,JU@578]S.RS^N1D#.PQ*H8V8]F14 MV'TRIA?5!^.S@R1;-;98E@-KL@G9`K3+R^$BL\#L%)H(*K@E-I-7)3ML)*S= M::J\VA(94UZ_ER:$B^,H/HOB&+-,-=I+4JT^H6RP)O!JC9:D""C;:'!-7JO0 MWAJ\4[N8V-C:ZG4.;6QUIX)3?HY>]2@*>K-X>]=<`.!L7;/JRQOEH,*S2[.MS:89PVG__) M35'CI1Q<[M-;H+=LS-_\]&X8>OZ][ZV=8/#H!FN/*)EJ&(KNVT?$>\"I'S/* M4QSB&S]-3I\6?DJ?M.V&M"7?$HSUCU^8%`)^!HB@/8MG,$5B3;$IP%0F1*6! M9]D[M\_LH[VTOLN-,.`E1`Z-$+M`P%??2V3T9#?R)0^(/*M#7, M+1V_DBI)II9TNXL*;QRE+\+004$P8MHP!D+\BMAQ1O?Q3&?+;@IP&K(05/OU<*IIL,G MC5#>"I@]=&961<6(WTH#1J&'UM=!ZH2IAO:H$($HCIJA5\\G%$TLTQ:\:>F54`5,I)Y0WX/(- MX-ZC!8-O;^(;<$#_EJP?V%J3$TKE^BN[E*!.WSZ(RKF1XG?( MT*GB1"J[?G7SWP8C\*.<%1;>IP%1`]6!"UX_9`A2.GU2^:^?[R:5&["[CEFV MU"+G].81!HM`>6^PM1H4P%:V:#B]5(4F_XAOM,E/E=8+_ MO28#&-S33J;@#QRJ(4H'TXUTV31$K&FV2:]95N!DKWG2MZ>8X%/\ZL"X42_85D]LB:[CV]Q]CK-FW:;T4G24 M')`1W>0=&H9)&J]UEW^R;J#5&Q_>/JMMTW]MF]JV1E1\:4IZ3?S&.CQR$SMA MB1MCN-[GY9N*.7#V@XOH;HWJ?]);:5ZD&>"'1MK=^)4Y"&Q9]5\2/81 M'U1KGW>ZK$NR\E,GH$G+HS@U7."K=0:M^650J\F*67N4$R@L[0%W<$S!+9WX M3TP/A'OW?A+%3\BQ-X"AQ;-J5YP5&+9#60R/J=MD6LL3T&1?A:Q*D^!.^D26`V2Y"SS8^SP(_T?+1F M(1:EOF"#LE*@M;G4,HHB?6=&([CJ#J"U6T"'\^2D&9$]2EJ'0Q5BS$KLV7$: MTQGVJ)WP)O&9$P38*]>H90-6CS@K=@<6E5&&6U_`NB!%K$XU)=ZM9MW+;J<= MH"*C]HU>6TN-<<:!*BVT[SL*89!6BM0/R95KHI MD%H[D/3R*O`6V#/5<3O!IFZQ$V:5BJTZ2"89?]_S?'HUA[@3.R7JK3&^(D%0 MS[VX*P5-'-5-&?>M=HC\7#N<.2ZF>D/I,(E:3R!'3%1!UEO(C+!D%0EI;A11 M00QH'1LA'*_I,GIK"U$8I>@:.RBP&5Z1!C3Z&>Y#)%.[ M]$.:HICZ/"YU!F@GK\']`'V!Y!\UTI'&#JV_0R]3LK%EG$?^**FS8<@"M8Y; MQQY2A:K3-[CWH#<1/"O-.NBAK13G:BE767Z(2OW8Y(2T`[_LI$`Z\ZVQI98? MH,_O(().+[GY'H[SW/`N]N_)BD0FZ;7K(ZU.P1;DFM`ELKW3!RHZ0=%A1=ND MJ&I;P*E41X54WSO!&H-;YD9L+5ZG&_!T`W?_FT/SSJ2#1QR[?H*GL>_B+!Z@ M%9(6=`,:C1;"V^>WO#$J6B/6/`][6;'F-<>$"TPKAFEU&$Q2=[X#4#!NNXED M*$?4I=(%8L>+83`GP\!D[]);8)WW`4D,\48[9$ZV;297%4UF5C<2E+G--AK8 M6GY3M:5US`83Y):*C6J0L'OY48U"2EFOO"CM;;FNWKFS)#;>+BCX9:B,);5C MSZ8BQO%,S_%U2O>KEJRFVB@*;VFH=1&M$3>ADD:ET]?!V7T%H2 M4U:5+7XX65&P&B6M6B[])*%9]8A2<>F;O%6VEX(>0->C/%"U-;>R=FC;T`++ M:(QB=3@4YJM.52!N+1#+5II"@9$O,D72TFEQE9CX$M1S3[8C.EO',9:;?+5. M`&L`":$)I,>"LU8MCAYL,:G$7++"1%+.:I+K-;^4/[G)0SYZ&5QJR$&M72V< M2LK7(@W#Y`85S6PQ='H`B+OW<"@`YC;.&(-EYHTO&W+;QA6,CD\A]T.O&,#> M40P_\K[2.,$TSI/S[[=7#K`V?0[HN>5F$\39)TAZZ"M`8,D.D+"'EUM@>/FI MYN;FRVS#`= M9HG%U^GVGO0"QTM5\U5#"660:D'41C.WK7J(MK/`T"@-OFZL8/:"SS-""\!E MF.ZX?;!8?0%D`%95)1.CRJ@67?9D_J#68DK>F[57/0NPIC<]K5HV MF0`5WO/L95OS]L0G]9BWV77/,N=V+)[515IVC&"2WNGGKU'H$=I8*H%6O&I6 MNH#=0XS6ID66"=#GJC`LNG4Q5<(63J\B$'8&:3`E$'5%DA#"2 MV!8\G@#V;+MKH97,H0+GVF$(MV6XR_6S/\=1HK=' M9]"]C493/!T&II1U>'1->]PI4]]#K%/+C:S>=&R"1='$!K1.,ES'M*8=BR6N7=NAH8O;5!-Q&_T%8N+555IMA*-\-2TJ7P[;YQVYJ4%IVZI8O/?)3MUS1Z?@@ MDBR@QCV-TGGTC'O`11)#RDXA%9$BVLJ*;`0J0Q_4A+G`C9F4?>1'D@SC5^(T M/4EQ4M$H.T^)VH:D/#M@>*>:-\EX[$O`HS;^(D<-6T,)INN.M3ZP^*,%A7$**=& M.3E<&8CVD6:!JU6!-,J1?L_IX0NH&/&N(.NL'N-V?`^C$BK2CMK6]P(>D^6! MJXVXYM%4M]34@K5B:UB(N:*?N\_/U0ZJDH(L-R5^42TJ^"BP4+#4+Z[PI*H[ M%3&*DN0L"E,_O,6AZ^-DX5P'RD>'.=10JT@NF'V&HPW13DMBG6A;>-ND]F*$ M2S/A6P%DK9&H=)Q(W`0]05LA(4@5MAL!%Y8SG'<=52=]?4T3**6L)'#H[3*] MP1)$O3>0-8@.V-I4)8P6$>(]+K1O$=(25">D?M*NGK=J%:+-O_QEB"[S=F@) M\BM33Q=1?!6N'-\["QQ_2>L2YQ^\?ZT3-O3!_*AY0FT*9+=Z:_3=4(\%NK$+*]I M#26:#:O0K^E.`8,-0,UD;@V>`+78:C0I^U)5=(9*O?6V3DJZ6Q"DM[E5_72X M.]7Z1V9;G9%SIE)0<8V<:);1^>4/*$'7,7;<.ZI7Z&[[IBIZ94L=9#/4KBD` M6[PW5QC"!7YC;6&UZM3U\TP>`>W4F4U+:UK3(D>MG9FHJHKI^>P'XL>R"D+V M^5X-Q$+)T3*7B0YWI]P[[*TWQ2M.GXB/E^C%GT5=@-TC$L*J;'WDK3.2%?HH0U*#:":XK!D*85H M"_2=MK$OX,Q[+4HZC_-.NCR'>>.L@_2"*-S0]9U@GI*1L/,`=$B7F!Z,4M5L M2GW!G=94`EHY[URT1QL"=$%L3WB;,^5YM'3\T!Z-I_-")8BF`+GU6%F^*R_J!UI`+@2LKH3=.,9^TY#:C[%M4.):B]P@[M M=)2DDYO/4>0E\RBH/1!<)[C[9%"*LCK\ZEY5PDKHL#:(-K(@D*4P[,E\@287 M:-X?#>;6Z&L.MPA54K)7B+("VE*B+2GJIVGL7Z]3NK)@H0`'($#<.OPQ3I'/"*TZ MY&>,)3C(379Z^0P>![A7H*Y5E/P"59623<.(]/LS^4S^H2=5R0__#U!+`P04 M````"`!H@0M'A>Z//<07``#R=@$`%0`<`&]P-6RE5U>`L``00E#@``!#D!``#M75ESXSB2?M^(_0]:S^NX M;%GNHRJF9L)GAV-=ML)V=?4\,6@2DC!-$6J0=%G]ZQ?@H8LX*4@ILCIU'O#=$$D_CS4?_#Z5$/Q0$)<3S^?/3UY?;XYZ-__?._ M_^L?_W-\_-OETWWOF@39%,5I[PLK,\(H['W'Z:1W\^?Q38A30GN_%G7U^A\& M'TX_G/78C]]0&*,D].=_[UUDXRQ)>_VSO_?.3OL_L!\^#3Y^.CWK77SI'1_S M+XIP_/NKGZ`>:UB.3L]/3P4E5\*@H^>D] MP6NEOP^JLOV3W[[41.@)C7KYUW]*YS/T^2C! MTUG$FYU_-J%H]/F(S.C[,=?CZ8^#4R[]MXJ>BSB\B5.[1>,?AT^_G?`/3Y1R)]NUZ8K$(8H3%+(?$A+AT$]1>.E'G(;G"4)I\C7V M,V8]*%0UT:::_;5XZ%.FM@E*<>!'CIJ_7NT:PY6?3&XC\MT1!$%U6R)X\-.,HL?1999@-A8FK)]=^@EFWS6D*&'?JNVA MAC5LV<[GE`2_3T@4LE'\YH^,#02J-@E*;_O]$V;[#!?O!/."C5EN2\IF2(6V MMKOI%*=YC4S=S%I2-BVRZ1$C97M48ENVZ`DEE9VJ6K!:S-TWOOBOD1IYO;!S M>[Q&J8\CM3U(A5Q8)Y^TPUEI:*0PM-"@43K9W=FJ@V\PF69INT>H5^3VU^X6D?M2HQ2N2>VKK`VJFVX7OMM%;D4H-LE)JMK,CN63/6&HC>4\36GV'51%Z![8XLWRB38*W> MB&]-"=6-P_P33U7YQ6N24C](JXHB#BROWC.6]4Z+X=JHC27T7*T)"CZ,R=M) MB#!3;_^<_\#;?WY\VB]WR']C'WG%-S^A,>9?&*5;M^-@@J,%P2-*IO;ZJ]I"M$AZA+*5SN1 M/Y:H?ZV,-VBCVC?D'4X%24_@2Q, M;W&$Z!7KJ6-"UQS;2(`92$?`SS,Z`3*\S> MR!$B9T;%8+WMG2"2'_GSDR_V#S\R?/.C_"PLO?(IG;/Q^5<_RD1['2MY(->+ MED`QWZ:0.L'_11"0C,%[0@%B4%\C](#24E6J_JP0`_+Q-&1;@T3NWFP3RT.* M9CX.;]YG?+VCIU=8'LB'U)!7&02Y`[5-A*XIPW3>!7)#->V8&TV7>UHMB4M7 M#ZCWW0_)#-%T/F1[C'P[Q>:7&5]:LC%'V1WE8D`.+=M%E`9"-X;9QW2"J/$F M1U`:R!EF2Z:XY=T86=D6CVWX[_$;"N\8`_$8LR5!@57=2=6"0/XU#6-B>K5( M.K'RO?)GF$T$^$_N_YG.LA319S)*OS-]JHE6"T)YZAHQK8?2C8'Y&049S>_# MSKCC1N4Y6R_I]6%]3U9L"MK>C3%Y10MF\ZG7AW4M6=&VT>XNK'.U7%5P#\$Q M9.H!Y*WM`CGWV'_%$4XQXG?>ZX\&#):NIE5X?5A?T':N>QN4W9@G5Q";^_;E M0EX?UF5D1:#6!@3@.K$0KCR@0W_.W9\OU`\-7(0**:\/ZVC2<*;V`TOP=)'I M)Q3YQ;/;%5694RX4]_JP_B@7W$N!=6.09VAIQAI:TY2:>K&,UX=U637E6XX& M>LLD>;KRA-Y0G*'\`DUIIW+:-!)>']8;946:`19GJW+0?GE=MK3$JN^48@'O M#-8!U:A'RJ'(+WVWB5NKP58P+IW!NJ$:<2J&(;\]WIX==*,]LV+[<0;KK7*P M35*#Z\:Z:>4:J_96U$91[PS6T:6A1W(X(`#1B6W0L&JJ$9>"TMX9M%NK`9T2 M',[Z9KKZ1GV_A'[S*7\7S$>O)SR>I)HK]R9BWAFLZZH1Q3I`T%L;1_O7,,1% MLX<^#N_B\A!3M7L52WAGL'ZJ1APKL$!O@R0[UQQFN6F3[557RWAGL"XD*UJ$ MK7>V9P$<4ZL=&;\7@.(D)Z&*C*;=D=:%O#-8/U&COJ:&L_U.1AQ+:;\\/_$P M4S$*;WP:LVDBN0B";)KE#E`&'P?*VQ)Z8>\,UM74B'#Q'-#RS,'$4RZ5:_?C7#UPFO4NV5^T663@CE=VO- M#&!3"OAYK#/B!;@ZYQ`N,-XE26;'=B$!_#[6,=,+3-UP-UG&\S`1`WXAZYCO M=6#03JA='!$TF-C-*@!^4KN=(1A#[,81_CI+0C\*->E"0B@.3OM/SCJ MM7.]7`CXR:Y[RA>PNN$2$T$TF_0UDL#/>]T3OX[-F0,M@O*:Z/+Y[-D0[^*` M3-&B409.$HD$@%^DO,FG>@16%0'V<,AU)CT>6+0;V'-A<%>X#(!BP*V4`O8B6'>C]:;OS.^^1\K**2,>EY:H?*V\ M61;8*6!-GPA`-S;_"V2%3NZ9F9H0N2P-O*UO3N4:!'>W6`![)'];7Z#B08=* M2S4-SB,5!-ZTVQ.L0].-??I=S.9KE/#X4BN(E3SRW369&+,6-8EQOQ2S0B%!7E M7OQWE'S!,:%Y0/*%Z:_74MSK^(+2"6%_>6-%\MV]=@>]EU8`QP2SGD7VJQIG MOD1PDV::*'OJ)8J1>C\GD8".*M;05H0XG+D)0=<:#R@UVAZLE8,.)V9-8ZWU M\MP:[>F5U;7>ZHB2YQ,/V,ATC:,L1<7BZ1HG0422C!KM%AK6"!VFS-H4+%DL*#H3;VT373E$6?!:2D!'57/`[`J2G8W&<)=%>+*@VXA\/XB, M<8O&V+VJJ8D!W!KAN7=8,X:4O&%&R^7\:\*#T"\.J"Z"%+\5#[CTV.PK.YRW M-B(RY'MT>YB=&%^;^6!@]]S-V#+QSKC+2`>X$+H(_Y.5/N`7\H0"$@J\QO/C_F32GOO-\2^HSH&PZ$=[WT0M`Y]?9"N9$:NC$F,+U1 MY"?H&A7_,DUQ!]=2747&B7@U]C!3M]G-[FUJ!KZQY')2VEX3W7B86M=#/9>I ME4'5Q8%O0CE@VM2$A-BWGH4.(MP+36JE8FLBP)?I-JC>=1P;S]=':9M M;*1":#1^5)'PP*\W[7OP6`*'GF$D"]AZTP6!]64+62/A`[BHY)9U.^C;/X`X MV&%A(V.&[P*357FY-%`71B2Z=CO1WL#B\ER[A7;I:2BLJ@,VPZ74IJ<$+[.ET% M?2,!0F'^*)6?3_/HZ4QYRV"GJA6D3A8Z)V=#8B4+1Q.T!WR!([]]<)U1AGN( M*"9%O-+%G02N*.5=#@-YZ'R=3OBV1@R]FMSE0+`1[#;_#?$$"_Q7MEFJ4J]9 MCQ*F%4,G"=W#$&*CBFY,.N9*=;(Z@4Y#ZM2&[&!W84W+X;)NP/_AOIDW/^*; MOV)$WCQ24-B+337PF4Z;K&-M$7;7."Y8'Z%TSKJ#-F6QB3Q\5E1WYB"`YNQ, M=I:;&FLM33MM#0<3N]Z]-3B,B5=8PTT,M*!]SF:S*->3'U5ZNHM'A$[]U[``UXWP]E4L+IX_6'D]8UD,/'NK!4>R*Q?K:#KQ_G$ET)J6 MS+62X%E9'?!9`[3#(^V=/2Q_\-.,LJWO99;@&"7\,A$/@9#DF^%%[?M^2_Y( MQWY^^PYVLY>%5&/=&PM[]=^2ZKAY(BNQZJ'$= MP%VOIFS9.M@"3_LZ1QE#:WKR/R8&11MM,>_. M,;&S/OF$DFHQO>\^6+Z\9#J]FOA,L5S)-Y02>D68IH)\BC<)`V11#4`/-&F> M20>TJ@>X_UE2(NE^MHA;-Q^N]+T7_@AU[[/@7Z,'KJJ9#"DF]-_(+Y.XF/0\ M(_E.]#A3I*WK:?7]\35*?1SMO<>UR,T23%"816R;4[UO7=WN7/#;7./<4K[A M='(7A_@-AYD?W;P'4<9#=]?W+MR?Q[9'%*68YI)E7I'DK*H+`\<=IB)V,1E^NR8 M57'-YTXJOA28X-D+N6'K!381DJF/54$O+6L"CJ`J9=.0?"TX*+.0/;>,_*!( MQ##FW>8+X@DU9$\@A(6!(YF40;*V;UU&"ZO,7V1WM&04;SMZ?#C`839IR+-JN'3JT@ M5(!#J>(%_!B!:+=K[#E[3=`?&4-T\\9/NMCW:5RN$@GPF(,M''T-5`JVW=R9 M>6E]K%(9Z*B%*IJ,B5U"Z=3`H=WR",M#ARA4\V/$Z1)(N_EYB]F8ERE6 MWAH)Z*B$;9X(%"IMN9OKA:D]8:WDRBR293%5K[QB6@).N/82\9_TYW,.OP8Z M<*+*&"0'>([1MWM$N_)G./4C_D27T%2_;S&2@XZ'Z)QBL25I=="!#*U7D9\P M_>37X>YQC.Y2-%7-=\+RT`$1VSS;214*=@P@\X(4[Y&6%R9?T#M'+[^Y:"(& M'5M1KGZ1*T2/I0-#0JZ+)Q3RT2Y\I%=^%*%P-5YDK@:E=\2L!J@@B,9<2O8^ MYNBZ8`TYF"(ZJ(KRE6)0@0FWY74#`G12#6W4VZ71$5P:W94?(&Z.TM'81!@J M3&!#_NR`.?,E0O9)GZ]`_NH7#/,,4?Y#.D^&R*//3U0$4/=&;^N\.7:,NO":R)0$0#=]=8: MG&Y$4;PFG>EGL2CUGM4_[I MQ90_PI6-P3HY;P#C5]MF)#;!5)'X\R&1F,?V2!)^AY`97,#5/99FSQ86]@8P MOJQMZ)("J3CZV.*5<)FKF4\;R1+H54:Y-A4CJE+.&[32:Z7%M'1W'%*OK.Z< M/8X4.5DD);U!J_Q0"A0+;K;V14'[E5<2OVQX:ZI$1.MY8\R2\6Q;M3=HER%:;7:(<95F*\5=>ODO)`W:*TXGZKK16V!NTT[]E!&QA M`#">KIT:0&[E#?E?RGKGK?*.6>%:L`_C(G/#_B(X^VB!F:<&S2-B*XA7B7GG MK7*QF4):T-UF;YO*L)O1OY"2:+=UMO7Z)VWTD.W!=KEI9;NV4\Q+SHU M(&V5WGFK/(*@>?%LN" M+1BOG82MVRR*YMN=[TZ9*!?,<24-EB[\HCE]K:6'>66!,`BKEM39CB>%&$J77) M'51IFF!&V;]*=K%[MIM<:Y4N+X-8H!O9PJ38VAU2P%VT+-@4!7)Z)..C%$7G M^-PB/!5LL'\%1\:D@@?V/Z385,#Q[%3L&!$*'O=_1_/JO4&L#KD0<.8`VY%7 M">30XK0N%P^;:P?#;:=Q!<#9!=2L"/:4-L`ZL*FL[GG-;PG]&L]\'%Y%/I[F M2\KBA_`_69+KX^:=[[?0$^*!AE#U9]G;(;=?`)0-P=XB)&.#*R5TP.(NLX1U M0=XKIZ\XSIE<*#5=>]^\T)K^5F;S2H$2-+BRK*V`0PPNO^YQ.<]#F)GG/ZU)=2)1L1I?NS=_5Q3E MI%RS[J7QM&T6/9@LH$)6Q%0*,+2;OVLT\K,H7<0@?:[&R81#U.=),A`'=KN) M*)/=L3`"TV["GP,4^Q23(45OF&1)-*_V''HOG$84V"%G2I]LD-:":S?Q;J+I M`B=X:#1F2X"`.>?<\/F$WE"<*6.=5D6`G7%2`L1\K;2ZY3V.).GCZ!="PN29 M1*)+<)*2P$E`+?FJ-]Y9SP+T5SW.\MUO/"X][%?T?)%QP3BM/Y72W'']PM*)X3]Y0T5CGB5B>RQ%=")3"UM M;\^:<1;I%'!T>D"IT;BT5@XZA:JE6=3:[BS:Z8PD.,5O!SL<;36*0"5&W5GG M7TV<"A4$516ROKR.7#Q/O"6T2-PC?R*F%()*G&K)GAD09S%-H9-6RE5U>`L``00E#@``!#D!``#M&]MNV[CR?8']!QX_]0"5%<=-S\9H MNDAS601(FR!)+V\+6J)MHC2IDE1B[]?OD!(MR:9EJ.LV^M#+G/D/.D!SF MS>^S*4/W1"HJ^%&GU]WK(,(C$5,^/NI\O#L/?NO\_O;77][\)PB^O+NY1*$:_0><$:4Q.B!Z@DZ^RLXBZD6$GW*>*%>M]_=Z^XC^/Q,8DY4C.+_SR_O+6ZN-8,[V@WULB";#6Z\D`*.DPU40YLDBD7,MY MU:&*1-VQN`]SH)'6KTJ+4BEA5J^CRZ&&\%65,";43P,`#SJ911,_OH%XW$#Y M/5':3Y+!/-9P3"/EI[$@0]*KDB@:^0D`X$&'`.AY0I0W-!;BL47I1*X1`A"/ M%$E&:R?:ZQ"@11022:(-$Q/+R,[-$8YT0&8)PQQ#/IJ?P^^%YP3GZ=3/)-8R M-*:%@!0`%I$T6M!M)LH)3`;#G`N--23!MV]PDE`^$F;8K+.!4?$.")#Y^'AS M44U+U@"788]Y?,8UU?,+8""GEF$'4?!!+<9"5$Q&E%.K!J0R%!2IN_2)>8PR M'JC$Y$VXS,$Q316)K_A;^PU!4<##4IC\E%/E*#Z*@F$S_`BS*&7K!805G[9Q M\HG@,>'`"#Z48#0VL^L=9B9OWDX(T>HCQRE4-)/EC,_;$/A#L`]^OP5OD3P& M"XZHS!+E/%'&%+U8L/WOOU$I.?D:0\[6$Z(IJ-,Z1%5J?[SZV\8+O:B(>:[Q M6_A078VN$B*MX$;+:Q.E/VZOFL6M8([$"!7L_UUQ%;^?8#4Y9^*A=<`\A/YX M'7Q/O`QW9-D_KWA]P#J5Y&KT+E44SE0*M@#OL*+@[^N255F(&N+ZH_+:[!*H MBIA0P`1^9-R,[QT_NWFP',UHF>?/'X=;+:*O$\%B..V>?4MA_Y3YW#/N]^__ MEOU;ID09Z3-PXP0J)$PA4Y'G6>)(;!;.O;D6['?J;RM.-0R0Y8`<"QC.N?S\ M_CT1TRG5UFQ8_9!/->5C..M2HEP:7X_@]_'ALH]++&Q&J##Y^5U\`X?TO#)E M+BT/>%W8VUMV88GD63GL#@^9FXFKPW[G]6JW6]0CM"+G,=S<*\I'.8F-T[RLB&RFA%7O+P)R^_L?KLR]9S\7E./*O.[ M`9[?]Z]:E:_GY/I2'JVXVC/N=^U!;6;^21QI_C$K_H:,D&V=#,S][U%'T6G" M3,O%CDWLW;;I.P6NU?0GF-2=39E#,9QKFC@V),M>R`4[%OF5=WUK!YB(A$@- MLSETRG?"1[`''-[6GFJ,=LH:AH=MK0$2PG;.$)C7;0U96@J/:T[H6B#P531& M``"6"*D17VGQUG4TL^[PI8@LFQH2\RMP=($9"GK[0;_7G:DX4ZR%_(5%+>4[ MNG;R_5WBAI(=@1%YT$!8;:]VC4PKSTL8$J:5&PD*5DVMKNE]UNGB(0F2I3IW(]MU/!UIQOI429<_`H*-FTU6>EA-]%B062_MI@2JZWM)N(+ MJNPS*!BT56"Y5=Y$O*,Q']N(7FZ@-Y+MB.Q7.^F;WGTT249,R@J5R4B')@GV M7F^C0<-46)*NMY5<_[2@J39E+F<%DW;*U3Y":3(K'(WY:)<+ZA\^-'+#,M46 M@?$_UVBGA.`?OD>/^LG,F\\<$G8$$_`T@L.Q96R>*&^/^N;^AXHLM1WH3X)(W] M3(8*L$\A>DPDTVIR;83]%,RV"]2NS-/4E+1K*_X39BE9K%?SDF1Y330H. MN&:P<;'%?VP"^IY,AT26(^V'9Z9EKV4'L9ABRG_4;N!N(@FY&HT@I/8A\"JSJ[('MD.;'8YB^=O7- M:+GB+(W_G[?FL1[$%*2;O^*YV*CZJ?6@3WD'V2&'WY((DKJYI+Y.932!#>H M2[6[%K]BH(5]9]G>WL+/6$JH`6D4N2] M\#QM0,Y(LM$?%C"7V:Y&^1RKG'L\P!U:.L=Q;#O)F'T6\BLL]A.<4.W^%B0K M16M1_K')]6@G\_.4L?DI9:EY5F\]73+,!]PR-`N#'BVI*9>P/+FL#-NA.;7V MO3'42%U33AN1[$Y=+9X\+;^=6F]G"YH?:6B87;^__?67OP%02P$"'@,4```` M"`!H@0M'%I0@I;HN``"Z\@$`$0`8```````!````I($`````;W!R>"TR,#$U M,#8S,"YX;6Q55`4``^-6RE5U>`L``00E#@``!#D!``!02P$"'@,4````"`!H M@0M'9.&QN,@'``#`7```%0`8```````!````I($%+P``;W!R>"TR,#$U,#8S M,%]C86PN>&UL550%``/C5LI5=7@+``$$)0X```0Y`0``4$L!`AX#%`````@` M:($+1TV@.(M&"P``(8P``!4`&````````0```*2!'#<``&]P`Q0````( M`&B!"T=V?+/_RBD```)2`@`5`!@```````$```"D@;%"``!O<')X+3(P,34P M-C,P7VQA8BYX;6Q55`4``^-6RE5U>`L``00E#@``!#D!``!02P$"'@,4```` M"`!H@0M'A>Z//<07``#R=@$`%0`8```````!````I('*;```;W!R>"TR,#$U M,#8S,%]P&UL550%``/C5LI5=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`:($+1T]XW=U/"```VCX``!$`&````````0```*2!W80``&]P'-D550%``/C5LI5=7@+``$$)0X```0Y`0``4$L%!@`````&``8` *&@(``'>-```````` ` end